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I Summary 
Signaling by ErbB receptors requires the activation of their cytoplasmic tyrosine kinase 
domains which is initiated by ligand binding to the receptor ectodomains. Up to now, 
cytoplasmic factors contributing to the activation of ErbB receptors have been unknown. This 
thesis introduces members of the cytohesin family of guanine nucleotide exchange factors as 
the first cytoplasmic ErbB receptor activators.  
Chemical inhibition or knock-down of cytohesins decreased ErbB receptor 
autophosphorylation and signaling whereas cytohesin overexpression stimulated receptor 
activation. Crosslinking experiments and studies with a constitutively dimerized EGFR 
construct showed that cytohesins act on already dimerized receptors. Cell-free reconstitution 
of cytohesin-dependent receptor autophosphorylation as well as monitoring EGFR 
conformation by fluorescence anisotropy microscopy indicate that cytohesins facilitate 
conformational rearrangements in the intracellular domains of dimerized receptors. Thus 
cytohesins may represent an additional layer of regulation of ErbB receptor activation which 
would allow the cell to modulate the number of activated ligand-bound receptors according to 
cellular needs.  
Consistent with cytohesins playing a prominent role in ErbB receptor signaling, cytohesins 
were found to be overexpressed in human lung adenocarcinomas. Furthermore, the 
overexpression correlated with increased activation of the EGF signaling pathway. Inhibition 
of cytohesins by the cytohesin-specific small-molecule inhibitor SecinH3 resulted in reduced 
proliferation and induction of apoptosis in EGFR-dependent lung cancer cells in vitro, as well 
as in tumor xenografts in mice. These findings underline the functional importance of 
cytohesin-dependent EGFR activation for tumor growth. Furthermore, chemical inhibition of 
cytohesins led to a strong reduction of glioblastoma cell proliferation. 
In order to optimize the inhibitory potential of SecinH3 , new Secin chemotypes were 
analyzed. In addition, a new assay for the screening of small molecules that interfere with 
cytohesin-catalyzed guanine nucleotide exchange on ARFs was established.  
The work in hand establishes cytohesins as an unprecedented, pathophysiologically relevant 
class of cytoplasmic conformational ErbB receptor activators and opens up new, entirely 
unexplored avenues for fighting ErbB receptor-dependent cancers by targeting not the 
receptors themselves but their activators. 
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II Introduction 
II.1 The ErbB receptor family of  receptor tyrosine kinases  
II.1.1 Receptor tyrosine kinases (RTKs)  
Cells are continuously exposed to diverse extracellular stimuli. The correct interpretation of 
these signals is of great importance for the cell and the whole organism, in order to achieve 
the appropriate response. A large group of genes in all eukaryotes encodes for proteins that 
function as membrane spanning cell surface receptors. By binding of specific ligands they are 
able to perceive extracellular stimuli and to relay these signals to internal signal transduction 
pathways, enabling the cell to respond correctly to its environment. One large sub-class of cell 
surface receptors is characterized by their intrinsic tyrosine kinase activity. These receptor 
tyrosine kinases (RTKs) catalyze the transfer of the γ phosphate of ATP to hydroxyl groups of 
tyrosine residues on target proteins.  
 
 
Figure 1 Human receptor tyrosine kinases 
The prototypic receptor for each family is indicated above and the known members are listed below. EGFR, 
epidermal growth factor receptor; InsR, insulin receptor; PDGFR, platelet-derived growth factor receptor; 
VEGFR; vascular endothelial growth factor receptor; FGFR, fibroblast growth factor receptor; KLG/CCK, 
colon carcinoma kinase; NGFR, nerve growth factor receptor; HGFR, hepatocyte growth factor receptor, EphR, 
ephrin receptor; Axl, a Tyro3 PTK; TIE, tyrosine kinase receptor in endothelial cells; RYK, receptor related to 
tyrosine kinases; DDR, discoidin domain receptor; Ret, rearranged during transfection; ROS, RPTK expressed in 
some epithelial cell types; LTK, leukocyte tyrosine kinase; ROR, receptor orphan; MuSK, muscle-specific kinase; 
LMR, Lemur. AB, acidic box; CadhD, cadherin-like domain; CRD, cysteine-rich domain; DiscD, discoidin-like 
domain; EGFD, epidermal growth factor-like domain; FNIII, fibronectin type III-like domain; IgD, 
immunoglobulin-like domain; KrinD, kringle-like domain; LRD, leucine-rich domain. The symbols α  and β 
denote distinct RTK subunits. RTK members in bold and italic type are implicated in human malignancies. An 
asterisk indicates that the member is devoid of intrinsic kinase activity. [1] 
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Binding of ligands to the extracellular domain of these receptors leads to the activation of the 
intracellular kinase domain and subsequently to the phosphorylation of various target proteins 
[2]. Although all human RTKs display the common structure of an usually glycosylated 
extracellular ligand-binding domain, a single transmembrane-helix and a cytoplasmic domain 
harboring the tyrosine kinase unit, they can be further grouped into families, based on their 
primary structures. Figure 1 summarizes the families of human receptor tyrosine kinases.  
RTKs are important regulators of fundamental cellular processes like metabolism, 
proliferation and differentiation. Aberrant signaling of the normally tightly controlled RTKs 
results in deregulated activity of downstream kinases and is a common feature of malignant 
transformation [1].  
 
II.1.2 The ErbB family of RTKs 
ErbB proteins (named after v-erb-B, a transforming protein of avian erythroblastosis virus [3]) 
are typical receptor tyrosine kinases that constitute subclass I (EGFR family) of RTKs. They 
are key regulators of cell differentiation, survival, proliferation and migration. Aberrant ErbB 
receptor function is a hallmark of many human cancers [4]. The ErbB receptor family is 
comprised of four known members (Figure 2): epidermal growth factor receptor 1 (EGFR, 
also referred to as ErbB1), human epidermal growth factor 2 (p185, neu, HER2, ErbB2), 
HER3 (ErbB3) and HER4 (ErbB4) [5]. They all show the typical structure of RTKs: a 
glycosylated extracellular ligand binding domain which is connected to an intracellular domain 
by a single transmembrane helix. The cytoplasmic domain harbors the protein tyrosine kinase 
core and additional regulatory sequences.  
 
 
 
 
 
 
 
 
Figure 2 Receptors of the ErbB family of receptor tyrosine kinases and their ligands 
All four receptors share high homology in the extracellular domain and the kinase domain. However, HER3 lacks 
kinase activity. Although there is no known ligand for HER2 (p185), HER2 has been found to be the preferred 
dimerization partner for the other ErbB family members. Only few examples of possible receptor dimers are 
shown [6]. 
This figure is copyright protected!
Please refer to: 
http://www.ncbi.nlm.nih.gov/pubmed/17671639 
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Numerous ligands for the ErbB receptor family have been described. With respect to their 
binding affinities they can be divided into three groups: the first group, consisting of 
epidermal growth factor (EGF), transforming growth factor α (TGFα) and amphiregulin, 
shows high specificity for the EGFR; betacellulin, epiregulin and heparin-binding EGF, the 
second group, bind both EGFR and HER4. The third group, consisting of the neuregulins 
(NRGs), can be divided into the HER3 and HER4 binding NRG1 and NRG2 on one hand, 
and the HER4 specific NRG3 and NRG4 on the other hand [7]. With the exception of EGF, 
ErbB ligands exclusively act over short distances as autocrine or paracrine growth factors. No 
direct ligand for HER2 has yet been described. 
 
II.1.3 Signaling of ErbB receptors – An Overview 
Binding of the ligand to the extracellular domain of ErbB receptors favors receptor 
dimerization. The ligand-induced conformational change in the receptor ectodomains results 
in the association of the cytoplasmic tyrosine kinase domains of two receptor molecules, 
which has been considered to be sufficient for kinase activation. The activated kinase catalyzes 
the intermolecular autophosphorylation of tyrosine residues in the intracellular domain of an 
adjacent ErbB receptor molecule which in turn keeps the kinase active. Phosphorylated 
tyrosine residues in the cytoplasmic domain serve as docking sites for signaling proteins 
containing SH2 and PTB domains. These signaling proteins get activated by recruitment to 
the receptor and /or phosphorylation and are responsible for onward transmission of the 
signal [8]. The downstream signal transduction pathways are determined by the specific set of 
recruited signaling proteins which reflects the identity of the ligand and the receptor oligomer 
composition. Although there is no known ligand for HER2, this ErbB receptor can act as a 
co-receptor and is the preferred heterodimerization partner for all other ErbB family members 
[9]. HER3 is a distinct member of the EGFR family because its kinase domain lacks certain 
residues that are known to be essential for catalytic activity in other kinases. That is why 
HER3 shows only impaired kinase activity [10-11]. Nevertheless, HER3 functions as a 
signaling entity based on its ability to bind specific ligands and its tyrosine residues that can be 
transphosphorylated in a heterodimeric complex with another ErbB receptor. In this way 
HER3 is capable of providing specific docking sites for downstream signaling proteins, 
despite its impaired kinase activity. This feature makes HER3 an important player in the ErbB 
signaling. That is why the horizontal network of interactions is crucial for ErbB signaling [12].  
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II.1.4 Activation of ErbB receptors 
Crystallographic data obtained in the past few years have shed new light on the structural basis 
of receptor activation and have introduced a detailed two-step model of ErbB receptor 
activation, embodied by receptor dimerization and kinase activation.  
 
II.1.4.1 Ligand-induced dimerization of the extracellular domain 
Two models for the induction of receptor dimerization by ligand binding have been proposed. 
Gullick et al. postulated a ligand-mediated mechanism, in which the bivalency of the ligand 
mediates receptor dimerization, resulting in an 1:2 ligand:receptor complex [13]. On the other 
hand, the receptor-mediated mechanism for dimerization, hypothesized by Lemmon et al. 
[14], requires the binding of two molecules of monomeric ligands to two receptor molecules, 
resulting in a 2:2 ligand:receptor complex formed by stable intermediates of 1:1 
ligand:receptor complexes. Further studies confirmed the receptor-mediated mechanism for 
ErbB receptor dimerization [15-18]. Burgess et al. showed that binding of EGF to the 
monomeric EGFR leads to a dramatic conformational change and the exposition of a 
dimerization arm [19]. The extracellular part of the EGFR consists of four domains (I to IV) 
and exists in two distinct conformations (Figure 3). In the inactive conformation, the 
interaction of domains II and IV results in a tethered form of the receptor preventing 
domains I and III from forming the ligand binding site. This conformation is in equilibrium 
with a ligand stabilized, open active state of the receptor, in which domains I and III interact 
to form the ligand-binding pocket. Since domain II is no longer bound to domain IV it can 
form a dimerization loop for the interaction with the domain II of another EGFR molecule to 
form a receptor dimer.  
 
Figure 3 Model of ligand induced dimerization of the extracellular domain of EGFR 
A molecular surface model of the extracellular domain of monomeric EGFR in the tethered, inactive form (left 
part) and EGF stabilized, dimeric, active conformation (right part). Domains I and III are shown in red/pink, 
domain II in green and domain IV in grey/white [17]. 
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Studies of the structure of HER2 revealed a constitutively exposed dimerization arm, 
explaining its ability to dimerize with other members of the ErbB family despite the lack of 
ligand-binding activity [20-21].  
 
II.1.4.2 Activation of the kinase domain 
Dimerization of the extracellular domain of EGFRs also leads to the dimerization of the 
intracellular domains, which was thought to be sufficient for kinase activation [8, 22]. 
However, recent findings suggest an additional step of receptor activation: the formation of an 
asymmetric dimer between the intracellular kinase domains, in which one kinase domain (the 
activator) acts as an allosteric activator of the other (the receiver) kinase [23], similar to the 
activation mechanism of cyclin-dependent kinases [24]. The asymmetric dimer conformation 
enables the interaction of the carboxy-terminal lobe of one kinase domain with the amino-
terminal lobe of the other, required for the activation of the kinase [23].  
In this model, (ligand-independent) dimerization of the intracellular domain leads to the 
formation of an inactive symmetric kinase dimer, which shows an autoinhibited conformation 
of the kinase domains. In this conformation a catalytically critical helix of the N-terminal part 
of the kinase (helix αC) is rotated outward with respect to its conformation in the active state, 
enabling the centrally located activation loop to be tightly packed inside the active site in a way 
that blocks substrate binding [23]. Furthermore, parts of the juxtamembrane domain interact 
with the kinase domain, holding it in the inactive orientation. However, the precise orientation 
of the kinase domains in these (ligand-independent) preformed dimers is unknown (Figure 4) 
[25-26].  
Upon ligand-binding, the extracellular domains of EGFRs dimerize. The involved 
conformational changes in the extracellular domain lead to the approaching of the membrane-
near segments of the receptors at the junction with the transmembrane segments [19]. Ligand 
binding relieves the inhibitory association between the juxtamembrane region and the kinase 
domain, facilitating dimerization between the two juxtamembrane domains that stabilizes the 
kinase domain dimer (juxtamembrane latch). Furthermore, ligand binding results in the re-
orientation of the kinase domains relative to each other, with the carboxy-terminal lobe of one 
kinase domain facing the amino-terminal lobe of the other, the so called asymmetric dimer 
(Figure 4). At the same time, helix αC rotates toward the active site, resulting in an open 
conformation of the activation loop that is compatible with substrate binding [23]. 
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Figure 4 A schematic representation of the activation mechanism of EGFR [25] 
 
Recently, the described model for EGFR activation was extended to HER3 [11, 27], 
explaining its important role in ErbB receptor heterodimers despite its impaired kinase 
activity: Sequence comparisons between HER3 and EGFR suggested that although the kinase 
domain of HER3 cannot be activated it can serve as the activator in asymmetric dimers. The 
sequences of HER3 in the region spanning the helix αC (favors outward rotation) or the 
juxtamembrane segment (prevents juxtamembrane latch) are divergent from that of other 
EGFR family members. In addition residues that are important for docking the activator 
kinase are missing in HER3. In summary, the (C-lobe) kinase domain of HER3 acts as a 
constitutively active activator for other members of the ErbB family, although it shows no or 
only low kinase activity [27].  
 
II.1.4.3 MIG6 – a negative regulator of ErbB receptor activation 
The cytoplasmic protein MIG6 (mitogen-induced gene 6, also known as ERRFI1 or RALT) 
interacts with and is a feedback inhibitor of both EGFR and HER2 [28-29]. Deletion of the 
MIG6 gene leads to hyper-activation of EGFR and may indicate its role as a tumor-suppressor 
gene [30-32]. Crystal structures of complexes between EGFR and MIG6 show that a region 
spanning residues 323-372 of MIG6 is critical for EGFR binding (MIG6-EBR, EGFR binding 
region). However, only residues 337-361 (denoted as segment1) bind to the distal surface of 
the C-lobe of the kinase domain and stabilize the inactive, symmetric conformation of the 
receptor [33-35]. Furthermore, a second segment of MIG6 (residues 362-412, denoted as 
segment 2) binds to the activation loop of the activated kinase domain. Therefore, MIG6 uses 
a double-headed mechanism for inhibiting EGFR: first by the blockage of the asymmetric 
dimer interface and second by directly interacting with the active site of the kinase (Figure 5). 
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Figure 5 Schematic for EGFR inhibition by MIG6 involving both segment 1 and segment 2 [34] 
 
Recently obtained structural data have revealed an additional mechanism for MIG6 induced 
EGFR inhibition. A six residue motif in the juxtamembrane latch of EGFR is almost identical 
in sequence with six residues in MIG6, indicating that part of the function of MIG6 is to 
prevent formation of the juxtamembrane latch [25].  
 
II.1.5 Downstream signaling of ErbB receptors 
Activated ErbB receptors stimulate many intracellular signaling pathways and different ErbB 
receptors preferentially activate certain signaling pathways, owing to the ability of individual 
ErbB receptors to bind specific effector proteins (Figure 6).  
 
Figure 6 Schematic for the main phosphorylation sites of ErbB receptors and the corresponding adaptor 
proteins [7] 
 
Two of the main pathways activated by the receptors are the mitogen-activated protein kinase 
(MAPK) and the phosphatidylinositol 3-kinase (PI3K)–AKT pathway (Figure 7).  
The MAPK-pathway is initiated by binding of the adaptor protein Grb2 via its SH2-domain to 
phosphorylated tyrosine residues in the intracellular domain of the receptor or to the adaptor 
protein Shc. Grb2 itself recruits the guanine-nucleotide exchange factor Sos via its SH3-
domain (binds to prolin-rich sequences): Sos catalyzes the GDP/GTP exchange on the small 
GTPase Ras, which subsequently binds the serin-threonine-kinase Raf. The following 
activation cascade involves the mitogen activated protein kinase kinase (MEK) and leads to 
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the phosphorylation of the extracellular-signal-regulated kinases ERK1 and ERK2 (p44/42), 
important regulators of cell proliferation, differentiation and apoptosis [36].  
PI3-kinases (phosphatidylinositol-3-kinase) are heterodimeric molecules composed of a 
regulatory (p85) and a catalytic subunit (p110). The regulatory subunit (p85) interacts with 
phosphorylated tyrosine residues in the intracellular part of ErbB or on the adaptor proteins 
IRS (insulin receptor substrate 1) or Gab1, thereby recruiting the catalytic subunit (p110) to 
the membrane. Once both subunits are combined, the PI3-kinase catalyzes the 
phosphorylation of the inositol ring of the phospholipid phosphatidylinositol (4,5) 
bisphosphate (PIP2) at position 3 to phosphatidylinositol (3,4,5)-trisphosphate (PIP3). The 
pleckstrin homology domain of Akt binds directly to PIP3 resulting in the translocation of 
Akt to the plasma membrane. Likewise, the phosphoinositide-dependent protein kinase 1 
(PDK1) is recruited to the plasma membrane upon activation of PI3-kinase. The 
colocalization of activated PDK1 and Akt allows Akt to become phosphorylated by PDK1 on 
threonine 308, leading to partial activation of Akt. Full activation of Akt occurs upon 
phosphorylation of serine 473 by the TORC2 complex of the mTOR protein kinase. The 
PI3K-Akt signal has been shown to regulate various cellular functions, but is mainly involved 
in cell proliferation and survival [37].  
 
 
Figure 7 Downstream signaling of ErbB receptors 
 
Other important ErbB receptor signaling effectors are the signal transducer and activator of 
transcription proteins (STATs) [38], SRC tyrosine kinase [39], and mammalian target of 
rapamycin (mTOR), a serine/threonine kinase [40]. 
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II.2 ErbB receptors and cancer 
Deregulated or autonomous cell growth is the defining feature of all neoplasms. In contrast to 
benign neoplasms, malignant neoplasms have the capacity to invade normal tissues and 
metastasize to and grow at distant body sites, the other main defining criterion of cancer. 
Deregulated cell growth occurs as a result of perturbed signal transduction disturbing the 
critical balance between the rate of cell-proliferation/growth on one hand and programmed 
cell death on the other [41]. Receptor tyrosine kinases are important regulators of intracellular 
signal-transduction pathways, and hence often mutated in cancers. More than half of the 
known RTKs have been found to be associated with human malignancies [1]. 
One example is provided by the family of ErbB receptors. In many different cancer cell types, 
the ErbB receptor pathway becomes hyperactivated by a range of mechanisms, including 
overproduction of ligands, overexpression of receptors, or constitutive activation of receptors 
[8]. The ErbB receptors were first implicated in cancer in the early 1980s, when the avian 
erythroblastosis tumor virus was found to encode an aberrant form of the human EGFR [42-
43]. Activated EGFR provides signals that drive dysregulated proliferation, invasion, 
metastasis, angiogenesis as well as cell survival. Over the past several decades, the role of 
ErbB receptors in malignant processes has been the content of intensive studies. Today 
deregulated signaling of ErbB receptors is known to be involved in the initiation and 
progression of various human cancer types. Thus, the ErbB receptors are attractive candidates 
for targeted therapy, and, to date, several anti-ErbB monoclonal antibodies and small-
molecule tyrosine kinase inhibitors (TKIs) have been developed. 
 
II.2.1 Lung cancer 
Lung cancer is one of the leading causes for death, accounting for one third of all cancer-
related deaths [44]. Lung cancer can be broadly divided into Small Cell Lung Cancer (SCLC; 
representing (10–15% of lung cancers, commonly associated with smoking), Non-Small Cell 
Lung Cancer (NSCLC; representing 85–90% of lung cancers) and carcinoid tumors of the 
lung (less than 5% of lung cancers). While carcinoid tumors of the lung and SCLC generally 
respond well to surgery, chemotherapy and/or radiation therapy, NSCLC is largely refractory 
to these treatments, explaining the short overall survival time of patients with this disease. 
NSCLC can be further sub-classified into Squamous Cell Carcinoma (30% of NSCLC, often 
linked to a history of smoking), Adenocarcinoma (50% of NSCLC) and Large Cell Carcinoma 
(20% of NSCLC) [44]. 
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Among the potential therapeutic targets that could be exploited in the management of lung 
cancer, the ErbB proteins have emerged as key players. The EGFR was first found to be 
overexpressed in NSCLC nearly 25 years ago [45], identifying it as a new target for NSCLC 
therapy. However, more recent studies have shown that EGFR overexpression is found in 
60% of NSCLC, but only counts as a weak prognostic marker in NSCLC. On the other hand, 
overexpression of ErbB2 which is found in 40% of NSCLC correlates with poor overall 
survival. In addition to the overexpression of ErbB receptor family members, NSCLC often 
show autocrine expression of three EGFR ligands, namely TGFα, EGF and amphiregulin, 
leading to sustained activation of the downstream signaling of these receptors [45-46].  
Mutations in the intracellular domain of EGFR have been identified as the most common 
cause of aberrant EGFR activation. Whereas mutations in the extracellular part of the receptor 
(for example EGFRvIII, see glioblastoma chapter for more details) are rare, 25-40% of 
NSCLC show mutations in the tyrosine kinase domain of EGFR (Figure 8). These mutations 
involve exons 18-21 of EGFR and cluster around the ATP binding site of the kinase. 
Mutations in exon18 (commonly at position G719) count for 5% off all mutations and target 
the nucleotide binding loop of the receptor. 50% of all mutations are found within exon 19, 
mostly in frame deletions at position 747-750. Together with mutations in exon 21, these 
modifications cluster around the helix αC, thereby destabilizing the inactive conformation of 
the EGFR kinase [23, 47]. Exon 20 harbors 5% off all mutations (for example T790M), which 
render NSCLC tumors insensitive to EGFR kinase inhibitors. The remaining 40% of all 
mutations are found in the activation loop of the receptor (exon21, for example L858R, 
destabilizing the inactive conformation of the EGFR kinase [23]) [48].  
Interestingly, with exception of mutations in exon 20, kinase-mutated EGFR proteins 
expressed in NSCLC are generally more sensitive to tyrosine kinase inhibitors (TKIs) as the 
wild-type expressing tumors. This phenomenon may be explained by the weakened affinity for 
ATP of these receptors, as reported by some groups. On the other hand, it appears that tumor 
cells harboring oncogenic EGFR alleles acquire dependency on the survival signals transduced 
by the hyperactivated EGFR, such that inhibition of these signals leads to rapid cell death of 
the tumor cells. However, the precise mechanism underlying increased TKI sensitivity of these 
tumors has yet to be established [49].  
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Figure 8 EGFR mutations in lung cancer 
Schematic illustrating the EGFR and the relevant mutations located in the in Exons 18-21 (regions expanded). A 
detailed list of EGFR mutations located in these exons that are associated with sensitivity (magenta boxes) or 
resistance (yellow boxes) to gefitinib or erlotinib is shown. The main mutations in each class are shown in bold 
type. TM: transmembrane domain.[46] 
 
Based on the structure and function of EGFR, two therapeutic strategies have been developed 
(Figure 9) [50]. The first uses humanized monoclonal antibodies (mAbs) generated against the 
receptor’s ligand-binding extracellular domain. These mAbs block binding of receptor-
activating ligands, and, in some cases, can induce receptor endocytosis and downregulation. 
The second approach uses small molecules (TKI, tyrosine kinase inhibitors) that compete with 
adenosine triphosphate for binding to the receptor’s kinase pocket, thereby blocking receptor 
activation and the transduction of downstream signals.  
However, the acquisition of resistance to EGFR TKIs in NSCLC therapy remains an 
important limitation to the utility of such treatments [51]. Two molecular mechanisms for 
TKI resistance have been postulated. The first mechanism involves the acquisition of 
secondary mutations within the EGFR catalytic domain. One mutation T790M, also referred 
to as gate-keeper mutation, restores the ATP affinity of the catalytic domain which accounts 
for the reduced susceptibility to TKIs, is found in 50% in all cases of acquired resistance. The 
second mechanism of acquired EGFR TKI resistance in NSCLC is based on the amplification 
of the gene encoding for the MET receptor kinase. MET transduces signals to similar set of 
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effectors as EGFR and it appears that it restores EGFR signaling by providing redundant 
survival signals [49, 52]. 
 
 
Figure 9 EGFR inhibitors in development and in practice [50] 
 
Taken together, ErbB receptor signaling plays a major role in NSCLC, but, although it 
represents a promising target for cancer therapy, new approaches are needed to circumvent 
acquired TKI resistance.  
 
II.2.2 Breast cancer 
Breast cancer is the most common malignancy in women, accounting for 32% of all female 
cancers and is responsible for 15% of cancer deaths in women, making it the number-two 
cause of cancer death. Breast cancer can be classified based on its origin in the ducts or 
lobules. Approximately 80% of all breast cancers are described as infiltrating ductal carcinoma 
(IDC), 15% as medullary carcinoma (MC), 5% as infiltrating lobular carcinoma (ILC). In 
addition, breast cancer is categorized by the expression level of the surface receptors for 
estrogen and progesterone and the human epidermal growth factor receptor 2 (HER2) [53]. 
The first frontier in the treatment of breast cancer is surgery, followed by radiation therapy. 
Patients with estrogen receptor positive tumors will typically also receive hormone therapy. 
Typical hormonal treatments include Tamoxifen (antagonist of the estrogen receptor), 
aromatase inhibitors or GnRH (Gonadotropin-releasing hormone)-analogues [53]. 
The HER2 gene is amplified and overexpressed in about 25% of breast cancers, conferring a 
more aggressive biology [54] and it makes a compelling case that HER2 plays a dominant role 
in causing and maintaining the transformed phenotype. The association between HER2 
overexpression and a poor prognosis is supported by the significantly shorter overall survival 
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rate and time to relapse in patients with HER2-overexpressing breast cancer relative to 
patients with tumors without HER2 overexpression [54-55].  
The apparent dependency of HER2-overexpressing tumors on constitutive HER2 function 
has made HER2 an attractive target for anti-cancer drug development (Figure 9). Two drugs 
are currently FDA-approved for treatment of HER2-positive cancers. Trastuzumab 
(Herceptin) is a humanized monoclonal antibody that recognizes the external domain of 
HER2 [56]. Its mechanism of action is still not totally clear, but it seems to have its greatest 
effects in tumors with increased HER2 homodimers. Although it does not block 
autophosphorylation of HER2, it does inhibit HER2 downstream signaling [57]. Lapatinib 
(GW572016, Tykerb) is a dual tyrosine kinase inhibitor targeting EGFR and HER2, binding to 
the ATP-binding pocket with the consequence of blocking the downstream signaling 
pathways from these receptors [58-59]. In addition, Pertuzumab (2C4, Omnitarg) [60], a 
monoclonal antibody directed against extracellular domain II of HER2, sterically blocking 
dimerization of HER2 with EGFR and HER3, has entered clinical testing for the treatment of 
breast cancer. However first clinical trials have shown only limited activity [61].  
Despite these new therapeutic possibilities the problem of acquired resistance has still to be 
conquered. Mutations in the PTEN gene are found in 50% of patients with breast cancer and 
have been shown to be associated with resistance and poorer prognosis. In addition, 
mutations in the extracellular domain of HER2 prevent trastuzumab from binding to the 
domain, resulting in trastuzumab resistance. Also, increased signaling form other receptors 
activating the MAPK- or PI3K-pathway are known to render cells resistant to HER2 targeted 
therapy. Although the discovery of trastuzumab and lapatinib represents a real breakthrough 
in treating HER2 positive breast cancer, each has only a response rate around 30% as single 
agent in first-line treatment of HER2 positive breast cancer, meaning that around 70% of 
patients will not derive any benefit from treatment with either agent [62-63]. 
 
II.2.3 Glioblastoma 
Gliomas (glia cells = supporting cells of the nervous system including oligodendrocytes, 
astrocytes and Schwann cells) are the most common subtype of primary (a subtype which 
arises de novo) brain tumors and are responsible for about 2% off all deaths from cancer. 
Gliomas are classified according to their line of differentiation and are afterward graded 
according to their malignancy. Glioblastomas are the most frequent form of gliomas and 
represent grade IV astrocytomas. As all grade IV tumors glioblastomas are highly malignant, 
usually resistant to chemotherapy and infiltrate throughout the brain. This invasive nature 
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results in the inability of surgery and the very short median survival of 9-12 month of 
glioblastoma patients [64]. The epidermal growth factor receptor (EGFR) is a primary 
contributor to glioblastoma initiation and progression. EGFR amplification and 
overexpression is the most common genetic alteration in primary glioblastoma with a 
frequency of 40-70%, but is not observed in lower grade astrocytomas. Of the glioblastoma 
that overexpress EGFR ~75% are also found to have mutations in the EGFR gene, ranging 
from point mutations or deletions in the extracellular domain to deletions in the cytoplasmic 
part of the receptor [65-66]. A number of mutations in the extracellular domain of the EGFR 
are exclusively found in glioblastoma. They reside primarily at the interfaces of extracellular 
domain I/II or II/IV and are thought to prevent tethering of domain II and IV and therefore 
keep the receptor in an active conformation. The most abundant mutation, which is found in 
approximately 50-60% of glioblastoma that overexpress the EGFR but not in normal tissue, is 
the EGFR variant III (EGFRvIII). This mutant lacks domains I and II of the extracellular 
part of the EGFR as a result of the deletion of exons 2 to 7 of the EGFR gene. Although 
EGFRvIII is incapable of ligand binding it is constitutively tyrosine phosphorylated, even 
though to a lesser extent than the ligand-stimulated EGFR [67]. Loss of the domain II is 
thought to prevent the formation of the closed inactive conformation, favoring a shift in the 
equilibrium to the open active conformation of the receptor. Additionally the signaling 
potency of EGFRvIII is increased by its constitutive localization at the plasma membrane due 
to impaired endocytosis and degradation of the receptor [68]. EGFRvIII also influences 
signaling of the wild type receptor, as it can signal through EGFRvIII homodimers or through 
heterodimers with either EGFR or ErbB2. The glioblastoma cell line U87 stably transfected 
with EGFRvIII (U87 EGFRvIII) shows a significant growth advantage compared to the 
parental cell line (which expresses only wt EGFR) when grown as tumour xenografts and in 
vitro under serum starvation conditions [66]. The growth advantage is thought to result from 
an elevated proliferation rate coupled with a reduction in apoptosis. Although EGFRvIII is 
phosphorylated on the same tyrosine residues as the wild-type receptor, signaling in response 
to EGFRvIII is distinct from that in response to activation of the wild-type receptor. PI3K 
signaling is the dominant signaling pathway activated as a result of EGFRvIII expression. 
Upregulation of PI3K activity activates Akt-mTOR signaling which decreases the abundance 
of the cyclin-dependent kinase inhibitor p27 and consequently inhibits G1 arrest under 
conditions of serum starvation. Amplification of EGFRvIII also leads to activation of the 
Ras-Raf-MEK pathway but does not result in high phosphorylation of extracellular signal 
regulated kinase 1 and 2 (Erk1/2). Similarly, unlike wild-type EGFR, EGFRvIII does not 
appear to activate the STAT3 pathway. The reduced apoptotic rate of EGFRvIII expressing 
Introduction  
 
 
 - 26 - 
cells is due to an increase in apoptosis inhibitor Bcl-XL expression [65-66]. Nevertheless, 
forced expression of EGFRvIII alone was insufficient to form high-grade tumors in mouse 
models, which implies that although EGFRvIII is an important driver of transformation in 
primary glioblastoma, its transformation activity requires additional genetic aberrations [69]. 
The invasive nature and high malignancy of glioblastomas together with the resistance to 
classical chemo- and radiotherapy contribute to the very poor prognosis of glioblastoma 
patients. The high prevalence of EGFRvIII in glioblastomas and the lack of expression in 
normal tissue make it a very attractive therapeutic target. The absence of domains I and II give 
rise to a tumor specific epitope in EGFRvIII, against which monoclonal antibodies have been 
generated. The EGFRvIII-specific monoclonal antibody Y10 showed a high potency to 
inhibit the growth of subcutaneous glioblastoma xenografts but not of orthotopic tumors, due 
to its inability to cross the blood-brain barrier [70]. MAb806, another EGFRvIII-targeting 
monoclonal antibody, which was able to cross the blood brain barrier, led to tumor shrinkage 
in both, subcutaneous and orthotopic tumor models and is currently under investigation for 
clinical use [71]. Several EGFR specific tyrosine kinase inhibitors (TKI) have also been 
evaluated for their efficacy against gliomas but they appear relatively ineffective for tumors 
expressing EGFRvIII, although the EGFR specific TKI AG1478 showed an additive effect 
on tumor size shrinkage if combined with classical chemotherapeutics like temozolomide or 
cisplatin [72]. More recently, another novel small molecule inhibitor was reported to show a 
slightly selective inhibitory effect on the growth of several glioma cells expressing EGFRvIII 
compared to matched glioma cells negative for EGFRvIII [73]. However the target or 
mechanism of action for this small molecule is still unknown. 
 
II.3 Cytohesins and ARF-GTPases 
II.3.1 Adenosine diphosphate ribosylation factors (ARFs) 
Adenosine diphosphate ribosylation factors (ARFs) are small guanine nucleotide-binding 
proteins and belong to the Ras superfamily. Like all small GTPases, these proteins act as 
molecular switches that cycle between two conformations: the active guanosine triphosphate 
(GTP)-bound conformation and the inactive guanosine diphosphate (GDP)-bound state. 
They are controlled, on one hand, by factors that lead to the dissociation of GDP and the 
binding of GTP, the GEFs (guanine nucleotide exchange factors), and on the other hand by 
proteins that stimulate the intrinsic GTP hydrolase activity (GAPs, GTPase-activating 
proteins).  
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Guanine nucleotide exchange factors (GEFs) catalyze the dissociation of the nucleotide from 
the G protein by modifying the nucleotide-binding site in such a way, that the nucleotide 
affinity is decreased, which results in the release of the nucleotide. Since G proteins show a 
nanomolar to picomolar affinity for GDP and GTP, the GEF is subsequently replaced by a 
new nucleotide. Cytohesins, a class of ARF GEFs (see next chapter), bind to the binary 
complex between ARF and GDP, in which the GDP is sandwiched between two loops called 
switch 1 and switch 2 (residues 38–52 and 69–84 in ARF1), which are connected by an 
interswitch region comprising two ß-strands. Switch regions 1 and 2 interact with the 
phosphates of GDP and a coordinating magnesium ion, thereby stabilizing the GDP bound 
conformation of ARF. In the cytosolic full-length form of ARF-GDP the myristoylated 
amphipathic amino-terminal helix locks the interswitch in a retracted conformation that 
blocks nucleotide exchange. Its reversible binding to membrane releases the hasp and opens 
up the locked conformation of the interswitch to enable nucleotide exchange [74-76]. Binding 
of cytohesin displaces switch 1 to open up the nucleotide binding site and GDP is 
subsequently kicked out of the transiently formed ternary complex between cytohesin, ARF 
and GDP [77-78]. The detailed function of cytohesins in these mechanisms was described by 
Beraud-Dufour et al. [79]: A glutamic acid finger of the cytohesin Sec7 domain approaches the 
negatively charged phosphate of GDP and displaces the coordinated magnesium ion thereby 
perturbing the interaction surface in the phosphate-binding region, which leads to nucleotide 
release. In the course of the exchange reaction a new nucleotide displaces the GEF, since the 
nucleotide weakens the affinity of the G protein for the GEF. The affinity of G proteins for 
GDP or GTP is similar, that is why the ratio of concentration between GDP and GTP 
determines the exchange. Thus the resulting increase in GTP-bound over GDP-bound ARF 
in cells is due to the approximately ten times higher cellular concentration of GTP compared 
to GDP [77].  
ARF proteins control essential cellular functions including cytoskeletal dynamics, cell 
migration or vesicular trafficking [80]. There are six mammalian ARF proteins which can be 
categorized into three classes, based on amino-acid sequence identity. Class I ARF proteins 
(ARF1, ARF2 and ARF3) are involved in coat complex formation along the secretory pathway 
in ER and Golgi. The functions of the class II ARF proteins (ARF4 and ARF5) are still 
unclear, however, some studies have indicated that ARF5 might have a role in early Golgi 
transport. ARF6, which is the sole member of class III, is thought to regulate endosomal 
membrane traffic and structural organization at the cell surface [81-82]. 
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II.3.2 The cytohesin family of ARF-GEFs 
Cytohesins are guanine nucleotide exchange factors (GEFs) for ARFs. There are four known 
human cytohesins: cytohesin-1 [83], cytohesin-2 (ARNO) [84], cytohesin-3 (Grp1) [85] and 
cytohesin-4 [86]. They are proteins of approximately 47 kDa which share a conserved domain 
structure: the amino-terminal coiled-coil domain, which is used for interaction with cellular-
binding partners, the central Sec7 domain, which contains the GEF function, and the carboxy-
terminal pleckstrin homology (PH) domain, which can bind to inositol phospholipids and 
therefore regulate the protein’s membrane association.  
 
 
Figure 10 Domain structure of cytohesins 
 
Cytohesins have been shown to be involved in signal transduction in vertebrates and 
invertebrates. Kolanus et al. identified cytohesin-1 as a regulator of integrin β binding to 
ICAM-1 in immune cells. Interestingly, this effect is independent of the GEF activity of 
cytohesin-1 [87]. Kliche et al. have shown, that cytohesin-1 binds to the transmembrane 
protein kaposin A, which is known for its transforming potential in tumor cells by selective 
activation of the mitogen-associated protein (MAP)-signaling pathway [88]. Our group 
developed an aptamer that specifically binds to cytohesin-2, without disturbing the GEF 
activity toward ARF1. Transfected into HeLa cells this aptamer abrogated MAP-signaling and 
reporter gene transcription directed by serum response elements [89]. However, our discovery 
of the small molecule inhibitor of cytohesins (SecinH3) has opened up new possibilities to 
directly target cytohesins and to shed new light into their function [90]. 
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II.3.3 The small molecule SecinH3 
Until very recently, only one small molecule inhibitor of GDP/GTP exchange on ARF was 
available, the fungal macrolide Brefeldin A, which binds to Sec7 domains of large GEFs, but 
shows no inhibitory effect on small GEFs like the cytohesins [91]. By a similar mechanism, 
the small molecule LM11 targets the complexes of ARF1-GDP with the large GEF BIG1 as 
well as with BFA-insensitive ARNO (cytohesin-2). Both molecules have been shown to inhibit 
ARF-regulated traffic at the Golgi apparatus in cells [92].  
 
 
Figure 11 Known GEF inhibitors 
Brefeldin A (BFA) binds to the complex between large GEFs an ARF, whereas LM11 targets the complex 
between ARF1 and BIG1 or ARNO. The RNA aptamer M69 binds selectively to the cytohesin family of small 
GEFs and inhibits its GEF activity. SecinH3 is the first known small molecule inhibitor that specifically targets 
small GEFs. Modified from [93]. 
 
A novel Sec7 inhibitor for cytohesins has been recently identified by our group in an aptamer 
displacement screen using the cytohesin specific aptamer M69 [90, 94-95]. The small organic 
compound SecinH3 specifically inhibits GDP/GTP exchange catalyzed by the human 
cytohesins 1-3 and by the Drosophila melanogaster cytohesin homolog Steppke [90], while 
showing only weak affinity to large GEFs. Various studies have proven the potential of 
SecinH3 (Sec7-inhibitor H3) as an indirect inhibitor of ARF1 and ARF6 [90, 96-101]. 
With the help of this new tool the involvement of cytohesins in insulin signaling was 
demonstrated. SecinH3 blocks the transcription of insulin-dependent genes in human HepG2 
cells and in murine liver cells in vivo most likely by inhibiting the binding of adapter molecules 
like IRS-1 (insulin receptor substrate 1) to the activated insulin receptor (Figure 12) [90]. 
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Figure 12 Function of cytohesin in insulin signaling 
Cytohesins bind to the insulin-receptor and facilitate the binding and phosphorylation of further substrates of the 
receptor in an ARF-dependent mechanism. 
 
In parallel Fuss et al. described a Drosophila mutant in which expression of the only cytohesin 
homolog Steppke is strongly reduced [102]. These flies show a significantly smaller size and a 
drastic weight reduction of the larvae as compared with wild-type larvae. Biochemical studies 
revealed that PI3K signaling induced by the insulin receptor was strongly reduced in the 
Steppke mutants. Feeding wildtype larvae with SecinH3 led to the same phenotype as seen for 
the Steppke mutants, indicating that a cytohesin ARF-GEF is essential in an important and 
conserved signaling pathway as the insulin pathway. The modulation of insulin signaling 
describes a new ARF-dependent function of cytohesins. Recently these findings where 
substantiated by an additional study of Lim et al. showing that cytohesins interact with the 
Connector Enhancer of KSR1 (CNK1), thereby promoting insulin receptor signaling [96].  
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III Objectives 
Cytohesins have been shown to be involved in insulin receptor signaling [90]. Preliminary 
data, obtained in my diploma thesis, suggests a further involvement of cytohesins in ErbB 
receptor signaling.  
From this background, the aim of this thesis was to dissect the mechanism of cytohesin 
mediated ErbB receptor activation. 
As a first step towards this goal, the involvement of cyohesin in ErbB receptor signaling had 
to be confirmed. After establishing an appropiate cell culture system, the effect of cytohesin 
inhibition or overexpression had to be evaluated.  
In a second step, the underlying mechanism of cytohesin mediated ErbB receptor activation 
had to be dissected with respect to the direct impact of cytohesins on receptor trafficking, 
dimerization or on the conformation of the receptor. For this purpose, appropriate test 
systems to analyze the indicated steps of ErbB receptor activation had to be established.  
Furthermore, additional questions about the mechanism of cytohesin mediated ErbB receptor 
activation had to be answered: Do cytohesins directly bind to and activate the EGFR? Which 
domain of cytohesins is responsible for this effect? Is the GEF-activity of cytohesins required?  
As a further objective, a potential pathophysiological relevance of cytohesins in EGFR-
dependent human cancers were to be elucidated, and the impact of cytohesin inhibition on 
these cancers were to be evaluated.  
Another part of this thesis was focused on the optimization of the small molecule inhibitor 
specific for cytohesins, SecinH3 [90]. New Secin chemotypes obtained in structure activity 
relationship studies and virtual screening approaches had to be characterized in vitro and in 
cell culture for their potential to interfere with cytohesin mediated functions.  
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IV Results 
IV.1 Cytohesins are cytoplasmic ErbB receptor activators 
IV.1.1 Inhibition of cytohesins decreases ErbB receptor signaling 
IV.1.1.1 Chemical inhibition of cytohesins reduces EGFR phosphorylation 
and signaling 
It has recently been shown that cytohesins are important regulators of insulin signaling [90].  
To investigate whether cytohesins are also involved in EGFR signaling, I tested the effect of 
the cytohesin antagonist SecinH3 on the activation of the EGFR.  
I used a human lung adenocarcinoma-derived cell line, named H460, which expresses normal 
levels of wild-type EGFR [103]. Before stimulation with 50ng/ml EGF for 5min, the cells 
were starved overnight (basal medium without fetal bovine serum) in the presence of 15µM 
SecinH3 or solvent (0.4% DMSO). Cell lysates were analyzed by SDS-PAGE and western 
blotting. Phosphorylation of the indicated proteins was determined by immunodetection using 
the indicated (phosphospecific) antibodies. Heat shock cognate protein 70 (Hsc70) served as 
loading control.  
 
Figure 13 Chemical inhibition of cytohesins inhibits EGFR signaling 
Western blot analysis of H460 cells treated with SecinH3 or solvent and stimulated with EGF. Phosphorylation 
of the indicated proteins was determined by immunodetection using phosphospecific antibodies 
(pEGFR_Y1086, pIRS_Y612, pAkt_T308, pShc_Y239/240, pp44/42_T202/Y204). Heat shock cognate protein 
70 (Hsc70) served as loading control. The diagrams show relative phosphorylation levels after normalization for 
Hsc70 with the untreated ligand-stimulated cells set as 1 (n=6). Data represented as mean ± SEM, *: p<0.05 ***: 
p<0.001. 
SecinH3 treated cells showed an about 50% inhibition of EGFR activation, using 
autophosphorylation as readout (Figure 13). The inhibitory effect was also found on the levels 
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of the adaptor proteins IRS1 and Shc and of the downstream kinases p44/p42 (Erk1/Erk2). 
XH1009, a control compound which is structurally related to SecinH3 but does neither bind 
nor inhibit cytohesins, had no effect on EGFR activation and signaling (Figure 14).  
 
 
Figure 14 Secinh3 but not XH1009 inhibits EGFR signaling 
Representative western blot analysis of H460 cells treated with the control compound XH1009, SecinH3 or 
solvent and stimulated with EGF. Phosphorylation of the indicated proteins was determined by 
immunodetection using phosphospecific antibodies (pEGFR_Y1086, pIRS_Y612, pAkt_T308, pShc_Y239/240, 
pp44/42_T202/Y204). Heat shock cognate protein 70 (Hsc70) served as loading control.  
 
To obtain SecinH3-independent evidence, the cytohesin-specific aptamer M69 or cytohesin-
specific siRNAs were used. Inhibition of EGFR activation was observed in both experiments 
(data not shown, experiments done by Jin-Na Song [104]). 
These results show an involvement of cytohesins in EGFR signaling.  
 
IV.1.1.2 Chemical inhibition of cytohesins reduces HER3 phosphorylation 
and signaling 
In order to examine whether cytohesins also affect the signaling of other ErbB receptors, a 
HER2/HER3 expressing human breast adenocarcinoma derived cell line (SkBr3 cells) was 
used [105]. SkBr3 cells were starved overnight (basal medium without fetal bovine serum) in 
the presence of 15µM SecinH3 or solvent (0.4% DMSO) and stimulated with the HER3-
ligand heregulin (HRG, 5min, 25ng/ml) in order to induce formation of HER2/HER3 
heterodimers. Cell lysates were analyzed by SDS-PAGE and western blotting. 
Phosphorylation levels were analyzed as described.  
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Figure 15 Chemical inhibition of cytohesins inhibits HER3 signaling 
Western blot analysis of SkBr3 cells treated with SecinH3 or solvent and stimulated with heregulin (HRG). 
Phosphorylation of the indicated proteins was determined by immunodetection using phosphospecific antibodies 
(pHER3_Y1289, pIRS_Y612, pAkt_T308, pShc_Y239/240, pp44/42_T202/Y204). Heat shock cognate protein 
70 (Hsc70) served as loading control. The diagrams show relative phosphorylation levels after normalization for 
Hsc70 with the untreated ligand-stimulated cells set as 1 (n=6). Data represented as mean ±SEM, *: p<0.05 ***: 
p<0.001. 
Again, SecinH3 reduced the phosphorylation of HER3 by about 50%, which was also 
reflected in reduced activation of the adaptor protein IRS1 and the downstream kinases Akt 
and p44/p42 (Figure 15). The control compound XH1009 had no inhibitory effect (data not 
shown [104]). Once more the involvement of cytohesins in the activation of HER3 was 
confirmed by the aptamer M69 and by cytohesin specific siRNAs (data not shown, 
experiments done by Jin-Na Song [104]). 
Taken together, these results imply that cytohesins are involved in the regulation of ErbB 
receptor signaling. 
 
IV.1.2 Cytohesins enhance ErbB receptor activation 
IV.1.2.1 Overexpression of the cytohesin ARNO enhances both EGFR and 
HER3 phosphorylation 
Having shown that cytohesin inhibition reduces ErbB signaling one might ask whether 
overexpression of cytohesins leads to an enhancement of ErbB receptor activation. To 
examine this question, I transfected H460 and SkBr3 cells with increasing amounts of FLAG-
tagged wild-type ARNO or empty vector for 48h. All cells were transfected with equal total 
amounts of plasmid, i.e. empty vector was added to fill in. Before harvesting, cells were 
starved overnight in the absence of FBS and were stimulated with EGF or HRG, respectively. 
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Receptor activation was analyzed as previously described. I selected ARNO for this analysis 
since it showed the highest expression in both cell types (determined by quantitative PCR, 
data not shown).  
 
Figure 16 Overexpression of the cytohesin ARNO enhances EGFR autophosphorylation 
H460 cells were transfected with the indicated amounts of FLAG-tagged ARNO and were stimulated with EGF. 
Receptor autophosphorylation was analyzed as above and transfected ARNO was detected with an anti-FLAG 
antibody (n=3). The diagram shows relative phosphorylation levels (pEGFR_Y1086) after normalization for 
Hsc70. The phosphorylation level of empty-vector transfected, ligand-stimulated cells was set as 1. Data 
represented as mean ±SEM. 
 
Figure 17 Overexpression of the cytohesin ARNO enhances HER3 phosphorylation 
SkBr3 cells were transfected with the indicated increasing amounts of FLAG-tagged ARNO and were stimulated 
with HRG. HER3 phosphorylation was analyzed as above and transfected ARNO was detected with an anti-
FLAG antibody (n=3). The diagram shows relative phosphorylation levels (pHER3_Y1289) after normalization 
for Hsc70. The phosphorylation level of empty-vector transfected, ligand-stimulated cells was set as 1. Data 
represented as mean ±SEM. 
Overexpression of ARNO increased the phosphorylation of both EGFR (H460 cells, Figure 
16) and HER3 (SkBr3 cells, Figure 17) in an expression level dependent manner. 
These results show that overexpression of ARNO enhances the ligand-dependent activation 
of ErbB receptor family members. 
 
IV.1.2.2 The Sec7 domain of ARNO is sufficient for EGFR activation 
Cytohesins are multidomain proteins. They share a conserved domain structure consisting of 
the amino-terminal coiled-coil domain, which is used for interaction with cellular-binding 
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partners, the central Sec7 domain, which contains the GEF function and the carboxy-terminal 
pleckstrin homology (PH) domain, which can bind to inositol phospholipids and therefore 
regulate the protein’s membrane association [80].  
To determine which domain of ARNO is responsible for the enhancement of EGFR 
activation, I transfected H460 cells with either empty vector (mock) or the following FLAG-
tagged ARNO constructs: full length protein (FL), ARNO lacking the coiled-coil (∆cc) or the 
pleckstrin homology (∆PH) domain or the isolated Sec7 domain (Sec7). After stimulation with 
EGF the phosphorylation of the EGFR was analyzed as above.  
All ARNO constructs were expressed equally in the cells and stimulated EGFR 
autophosphorylation as efficient as the full-length protein (Figure 18). As the lowest common 
denominator, all tested constructs contained the Sec7 domain of ARNO, attributing the 
EGFR-activating capability of the cytohesins to this domain.  
 
 
Figure 18 The Sec7 domain of ARNO is sufficient to enhance EGFR activation 
Representative western blot of H460 cells transfected with full-length ARNO (FL), with ARNO lacking the 
coiled-coil (∆cc) or the pleckstrin homology (∆PH) domain or the isolated Sec7 domain (Sec7). 
Autophosphorylation of EGFR (pEGFR_Y1086) was determined as above. mock: empty vector 
 
IV.1.2.3 Activation of ErbB receptors by ARNO is independent of its GEF 
activity 
The known function of ARNO is to act as a GEF on ARF proteins. This activity resides in 
the Sec7 domain of cytohesins, which is in turn also sufficient to activate ErbB receptors. 
Hence, it is important to analyze whether the GEF activity of ARNO is also required for the 
activation of the EGFR.  
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Therefore, I transfected H460 cells and SkBr3 cells with either empty vector, ARNO wild-type 
or the GEF-inactive ARNO mutant ARNO-E156K and analyzed EGFR autophosphorylation 
as described above.  
 
Figure 19 ARNO enhances ErbB receptor autophosphorylation independently of its GEF activity 
Representative western blot analysis of H460 (A) or SkBr3 (B) cells transfected with FLAG-tagged wild-type 
ARNO or GEF-inactive ARNO-E156K. Cells were stimulated with EGF or heregulin (HRG), respectively. 
Receptor autophosphorylation (pEGFR_Y1086, pHER3_Y1289) and ARNO expression was analyzed as 
described. 
Unexpectedly, overexpressed wild-type ARNO and ARNO-E156K were equally potent in 
enhancing EGFR autophosphorylation in H460 cells (Figure 19A). ARNO-E156K also 
stimulated HER2/HER3 autophosphorylation in SkBr3 cells (Figure 19B), suggesting that the 
GEF activity is not required for the ARNO-mediated activation of ErbB receptors. 
One explanation for this observation could be that the effect of the E156K-mutation might 
be overcome due to high expression levels.  
To rule out this possibility, I transfected H460 cells with ARNO-specific siRNA (to knock 
down endogenous ARNO expression) and increasing amounts of plasmid encoding ARNO or 
ARNO-E156K. To exclude interference between ARNO knockdown and overexpression, a 
siRNA which bound to the untranslated region of endogenous ARNO mRNA (not included 
in the plasmid coding for ARNO or ARNOE156K) was used. EGF-induced EGFR 
autophosphorylation was analyzed as above. Knock-down of endogenous ARNO was 
controlled using an ARNO specific antibody (the lower band in the ARNO blot represents a 
non-specific cross-reactivity of the antibody, ARNO is the upper band). 
As Figure 20 shows, ARNO-E156K expressed at endogenous protein level rescued the 
inhibition of EGFR autophosphorylation induced by knockdown of endogenous ARNO, 
showing that the ability of ARNO-E156K to enhance EGFR activation was not due to its 
overexpression. 
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Figure 20 Re-expression of ARNO or the GEF-inactive ARNO-E156K rescues the effect of ARNO 
knockdown on EGFR autophosphorylation 
Representative western blot of H460 cells transfected with ARNO-specific siRNA and increasing amounts (+ or 
++) of plasmid encoding ARNO or ARNO-E156K. EGFR autophosphorylation was detected using a 
phosphospecific antibody (pEGFR_Y1086). Hsc70 served as loading control. Empty: empty vector, ns: non-
silencing siRNA.  
Furthermore, knockdown of ARF1 or ARF6 had no influence on the activation of the EGFR 
or HER2/Her3 (data not shown, experiments done by Jin-Na Song [104]).  
These results indicate that the cytohesin-mediated activation of ErbB receptors does not 
involve ARF1 or ARF6, nor does it require the GEF function of the Sec7 domain, and thus 
implicate a hitherto unknown GEF-independent function of cytohesins.  
 
IV.1.3 Cytohesins facilitate a conformational rearrangement of the 
intracellular domains of ErbB receptor dimers 
The enhancement of EGFR activation by cytohesins could be due to different effects: First, 
cytohesins are known to be involved in endocytosis and may augment EGFR activation 
indirectly by modulating the endocytosis or degradation of the EGFR. Second, the increase of 
EGFR activation by cytohesins could be caused by alterations in the clustering of EGFR. 
Third, cytohesins may promote EGFR dimerization or, fourth, may induce a conformational 
change in the cytoplasmic domains of EGFR which facilitates EGFR autophosphorylation. 
To distinguish between these possibilities I conducted the following experiments. 
 
IV.1.3.1 SecinH3 does not alter EGF-triggered internalization or cluster 
size of EGFR 
As the enhancement of EGFR activation by cytohesins could be indirectly caused by 
modulations in EGFR endocytosis or degradation, the effect of SecinH3 on the amount of 
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EGFR on the plasma membrane of H460 cells was analyzed. SecinH3-treated or untreated 
H460 cells were stimulated with EGF and the EGFR remaining at the plasma membrane was 
quantified on plasma membrane sheets by immunofluorescence microscopy (experiments 
were done together with David Walrafen, AG Lang, University of Bonn).  
 
Figure 21 SecinH3 does not affect EGF-triggered internalization of EGFR 
SecinH3 treated or untreated H460 cells were stimulated with EGF and the EGFR remaining at the plasma 
membrane was quantified on plasma membrane sheets by immunofluorescence microscopy. The diagram shows 
the mean of three independent experiments, comprising 22-26 membrane sheets each. Experiments were done in 
cooperation with T. Lang, University of Bonn). 
As expected, EGF stimulation enhanced EGFR internalization and led to a decrease in the 
amount of EGFR at the plasma membrane (Figure 21). However, quantification of the EGFR 
at the plasma membrane after EGF stimulation revealed no difference between untreated and 
SecinH3-treated cells, arguing against the assumption that cytohesins enhance EGFR 
activation by modulating endocytosis.  
One might expect that reduced EGFR activation after cytohesin inhibition would slow down 
EGFR endocytosis. But, recently it had been shown that receptor dimerization rather than 
receptor phosphorylation triggers EGFR endocytosis [106]. Thus, these results furthermore 
indicate that cytohesins do not affect EGFR dimerization.  
 
Depending on determinants that are as yet incompletely understood, ErbB receptor activation 
by growth factors may be accompanied by receptor clustering. To further rule out an effect of 
cytohesins on EGFR clustering, EGF-dependent EGFR clustering was examined by 
superresolution light microscopy using stimulated emission depletion (STED) on plasma 
membrane sheets. SecinH3-treated or untreated H460 cells were stimulated with EGF and 
EGFR cluster sizes were determined by STED microscopy on plasma membrane sheets 
(experiments were done by David Walrafen and Arne Schreiber, AG Lang, University of 
Bonn). EGF led to a slight increase in the measured EGFR cluster size at the plasma 
membrane of H460 cells, which was not affected by SecinH3, indicating that the reduction of 
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EGFR signaling observed after cytohesin inhibition is not a result of alterations in cluster size 
at the observed ~100nm scale (data not shown [104]). 
 
Taken together, these results indicate, that the cytohesins-dependent enhancement in EGFR 
autophosphorylation is not due to altered endocytosis or increased clustering of the receptor. 
 
IV.1.3.2 Cytohesins enhance the phosphorylation but not the dimerization 
of ErbB receptors  
One possible scenario for the positive effect of cytohesins on EGFR autophosphorylation 
could be that cytohesins induce receptor dimerization.  
To analyze the effect of cytohesins on EGFR homodimerization, H460 cells were 
preincubated with SecinH3 or transfected with ARNO, stimulated with EGF and dimeric 
receptors on the cell membrane were “trapped” by crosslinking with BS3.  
Bis(sulfosuccinimidyl)suberate (BS3) is a commonly used, water-soluble and membrane 
impermeable crosslinker [107]. It contains an amine-reactive N-hydroxysulfosuccinimide 
(NHS) ester at each end of an 8-carbon spacer arm (11.4 angstrom). NHS esters react with 
primary amines (found in the side chain of lysine residues and at the N-terminus of proteins) 
to form stable amide bonds, along with release of the N-hydroxysulfosuccinimide leaving 
group. BS3 can be used to crosslink adjacent proteins on the cell membrane and it has been 
often used to crosslink ErbB receptors. Due to its stability under reducing conditions 
crosslinked EGFR dimers can be analyzed by SDS-PAGE using low-percentage 
polyacrylamide gradient gels. Because of the high molecular weight of crosslinked EGFR 
dimers (>300kDa) western blotting has to be done using the wet blot system (tank-system). 
Transferred proteins were detected with the indicated antibodies.  
Figure 22 (upper blot) shows the amount of monomeric (indicated by an asterisk) and dimeric 
(indicated by an arrow) EGFR before/after stimulation with EGF and incubation with 
SecinH3. Stimulation with EGF led to a strong induction of EGFR dimer, which was not 
altered by SecinH3 treatment. The lower blot displays the phosphorylation levels of 
monomeric and dimeric receptors. As expected, EGF stimulated the phosphorylation of 
EGFR dimers which was clearly diminished by SecinH3. The diagram shows the 
phosphorylation of the crosslinked, i.e. dimeric receptors after normalization for total dimeric 
receptor.  
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Figure 22 SecinH3 inhibits the phosphorylation but not the dimerization of EGFR 
H460 cells were treated with SecinH3, stimulated with EGF for 5min and treated with crosslinker. Receptor 
phosphorylation was analyzed by a phosphospecific antibody (pEGFR_Y1086). Arrows indicate receptor dimers, 
asterisks indicate receptor monomers. The diagram summarizes the relative phosphorylation of the crosslinked, 
i.e. dimeric receptors only, after normalization for total dimeric receptor (n=9). Data are shown as mean ±SEM, 
*: p<0.05. 
 
These results show that cytohesin inhibition does not affect receptor dimerization but clearly 
reduces the phosphorylation of the dimerized receptors.  
 
I repeated the same experiment for H460 cells overexpressing ARNO instead of SecinH3 
treatment. Consistently, ARNO overexpression in H460 cells led to a more than 2fold 
increase in phosphorylation of EGFR dimers, whereas it had no effect on EGFR dimerization 
(Figure 23).  
 
Figure 23 ARNO enhances the phosphorylation but not the dimerization of EGFR 
H460 cells were transfected with ARNO or empty vector for 48h, stimulated with EGF for 5min and treated 
with crosslinker. Receptor phosphorylation was analyzed by a phosphospecific antibody (pEGFR_Y1086). 
Arrows indicate receptor dimers, asterisks indicate receptor monomers. The diagram summarizes the relative 
phosphorylation of the crosslinked, i.e. dimeric receptors only, after normalization for total dimeric receptor 
(n=5). Data are shown as mean ±SEM, ***: p<0.001. 
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Having shown that cytohesins facilitate EGFR autophosphorylation without altering the 
dimerization of the receptor, I analyzed whether the same was true for HER3. Therefore, I 
treated SkBr3 cells with SecinH3, stimulated with HRG and chemically crosslinked the 
receptor. Analysis of crosslinked receptors were performed as described for the H460 cells.  
 
Figure 24 SecinH3 inhibits the phosphorylation but not the dimerization of HER3 
SkBr3 cells were treated with SecinH3, stimulated with HRG for 5min and treated with crosslinker. Receptor 
phosphorylation was analyzed by a phosphospecific antibody (pHER3_Y1289). Arrows indicate receptor dimers, 
asterisks indicate receptor monomers. The diagram summarizes the relative phosphorylation of the crosslinked, 
i.e. dimeric receptors only, after normalization for total dimeric receptor (n=9). Data are shown as mean ±SEM, 
*: p<0.05. 
 
In agreement with the results obtained for the EGFR, chemical inhibition of cytohesins with 
SecinH3 led to strong reduction in the phosphorylation if dimeric HER3, but did not alter the 
amount of dimeric HER3 (Figure 24).  
 
Figure 25 ARNO enhances the phosphorylation but not the dimerization of HER3 
SkBr3 cells were transfected with ARNO or empty vector for 48h, stimulated with HRG for 5min and treated 
with crosslinker. Receptor phosphorylation was analyzed by a phosphospecific antibody (pHER3_Y1289). 
Arrows indicate receptor dimers, asterisks indicate receptor monomers. The diagram summarizes the relative 
phosphorylation of the crosslinked, i.e. dimeric receptors only, after normalization for total dimeric receptor 
(n=5). Data are shown as mean ±SEM, ***: p<0.001. 
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Furthermore, overexpression of ARNO in SkBr3 cells increased HER3 phosphorylation 
without altering HER3 dimerization. (Figure 25) 
 
Taken together, these data suggest that ARNO facilitates the activation of already dimerized 
ErbB receptors. 
 
IV.1.3.1 SecinH3 does not alter HER2/HER3 heterodimerization 
In order to gain more insight into the effect of cytohesins on HER3 activation, I analyzed the 
amount of HER2/HER3 heterodimers in SkBr3 cells after treatment with SecinH3.  
I performed coimmunoprecipitation studies for the HER2/HER3 heterodimer. SkBr3 cells, 
which express both HER2 and HER3, were treated with SecinH3 or solvent, starved 
overnight and stimulated with heregulin to induce HER2/HER3 heterodimer formation. The 
cell lysate was subjected to immunoprecipitation using a HER3 specific antibody coupled on 
agarose beads. After washing, I eluted precipitated HER3 and analyzed the eluate by SDS-
PAGE, western blotting and immunodetection with a HER2 specific antibody. 
 
 
Figure 26 SecinH3 does not alter the amount of HER3/HER2 dimers in SkBr3 cells 
SkBr3 cells were treated with SecinH3 and the lysates were subjected to immunoprecipitation using an HER3 
specific antibody. Precipitated HER3 and coprecipitated HER2 were analyzed by immunoblotting of the eluate.  
Left: representative western blot of precipitate. 
Right: Control of receptor levels in the lysates used for immunoprecipitation. Proteins were detected as described 
above. 
As expected, stimulation with heregulin induced the formation of HER2/HER3 heterodimers 
which was manifested in a distinct coimmunoprecipitation of HER2 and phosphorylation of 
HER3 (Figure 26). Treatment with SecinH3 did not alter the amount of coprecipitated HER2 
nor did it change total receptor expression levels, even so it clearly decreased HER3 
phosphorylation. Taken together these results implement that cytohesins do not affect 
HER2/HER3 heterodimer formation.  
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IV.1.3.2 Cytohesins facilitate the phosphorylation of constitutively 
dimerized EGFR 
To substantiate the assumption that cytohesins facilitate the activation of already dimerized 
ErbB receptors, a constitutively dimerized EGFR (lz-EGFR) was constructed by replacing the 
extracellular domain of the receptor with a dimerization module consisting of a leucine zipper 
and a single cysteine residue that forms a disulfide bridge upon dimerization (Figure 27, 
cloning done by Anton Schmitz). If the mode of action for cytohesins is to facilitate the 
activation of already dimerized receptors they should also be able to increase the activity of 
the constitutively dimerized lz-EGFR.  
 
 
Figure 27 Schematic of the constitutively dimerized lz-EGFR 
The extracellular domain of EGFR was replaced by a FLAG-tagged disulfide-bridged leucine zipper module. 
I used HEK293 cells for transfection of lz-EGFR to avoid interference with endogenous 
wild-type EGFR. HEK293 have only a very low endogenous level of EGFR and can be easily 
transfected using Metafectene (Biontex) and are therefore perfectly suited for these kinds of 
experiments.  
First, I had to test the integrity of the lz-EGFR. HEK293 cells were transfected with 
increasing amounts of lz-EGFR (+ and ++) or empty vector (-). After 48h, cells were 
harvested and proteins were separated by reducing or non-reducing SDS-PAGE and lz-EGFR 
was detected by anti-FLAG antibody.  
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Figure 28 lz-EGFR is expressed as a constitutive dimer 
Western blot of HEK293 cells transfected with increasing amounts of lz-EGFR (+ and ++) or empty vector (-). 
Proteins were separated by reducing or non-reducing SDS-PAGE and lz-EGFR was detected by anti-FLAG 
antibody, phosphorylated lz-EGFR (plz-EGFR) by anti pEGFR_Y1086) antibody. The arrow indicates receptor 
dimers, the arrowheads monomers. The double bands under non-reducing conditions correspond to 
unphosphorylated (lower) and phosphorylated (upper) lz-EGFR.  
Under non-reducing conditions, I found the lz-EGFR exclusively expressed as dimer (Figure 
28, arrow, upper panel, right half). Consistent with its constitutive dimerization lz-EGFR was 
phosphorylated (lower panel). The double bands (arrow heads) under reducing conditions 
correspond to unphosphorylated (lower) and phosphorylated (upper) forms of monomeric lz-
EGFR (plz-EGFR). Under non-reducing conditions the two forms were not separated. 
 
Secondly, I had to test whether the activation of the lz-EGFR kinase domain was still 
dependent on the formation of the asymmetric dimer. Therefore I analyzed the effect of 
MIG6 on the autophosphorylation of the lz-EGFR. MIG6 is known to inhibit receptor 
autophosphorylation by preventing the formation of the active asymmetric EGFR dimer [34]. 
I transfected HEK293 cells with either lz-EGFR alone or in combination with a myc-tagged 
form of the EGFR-binding domain of MIG6 (MIG6-EBR), which was shown to be sufficient 
for inhibiting EGFR signaling [34]. Cell lysates were analyzed as above under reducing 
conditions. Hsc70 served as a loading control.  
As Figure 29 shows, coexpression of MIG6-EBR reduced lz-EGFR autophosphorylation 
(please also note the shifting of the upper band of lz-EGFR), suggesting that the activation of 
the lz-EGFR still depends on the formation of the asymmetric dimer. Thus, regarding the 
allosteric activation of the kinase domains, the lz-EGFR appears to behave like an authentic 
EGFR. Therefore, the lz-EGFR is a suitable model to ask whether cytohesins enhance the 
activation of the EGFR kinase after its dimerization. 
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Figure 29 MIG6 inhibits the autophosphorylation of lz-EGFR 
Representative western blot of HEK-293 cells transfected with lz-EGFR alone or in combination with a myc-
tagged form of MIG6-EBR. Proteins were separated by reducing SDS-PAGE and lz-EGFR was detected by an 
anti-FLAG antibody, MIG6-EBR by an anti-myc antibody and the phosphorylation of lz-EGFR by a 
phosphospecific antibody (pEGFR_Y1086). Hsc70 served as loading control.  
 
To address this question I transfected HEK293 cells with lz-EGFR and incubated the cells 
with SecinH3. Cell lysates were analyzed as described. In the presence of SecinH3 the 
autophosphorylation of lz-EGFR was reduced, whereas there was no change in total lz-EGFR 
expression (Figure 30). The control compound XH1009 had no effect (data not shown [104]). 
The diagram shows lz-EGFR phosphorylation after normalization for total receptor, with 
solvent-treated cells set as 1.  
 
 
Figure 30 SecinH3 decreases the autophosphorylation of constitutively dimerized EGFR 
HEK293 cells were transfected with lz-EGFR and treated with SecinH3. The phosphorylation of lz-EGFR (plz-
EGFR) was analyzed by a phosphospecific antibody (pEGFR_Y1086) and total expression level of lz-EGFR by 
an anti-FLAG antibody (Flag). The diagram shows receptor phosphorylation after normalization for total 
receptor. Data are represented as mean ± SEM, n=5. 
These results show that SecinH3 is capable to inhibit autophosphorylation of already 
dimerized receptors. 
 
To test whether ARNO is capable of activating already dimerized EGFR, I co-transfected 
HEK293 cells with both lz-EGFR and ARNO and analyzed lz-EGFR phosphorylation 48h 
after transfection as described. 
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Figure 31 ARNO enhances autophosphorylation of lz-EGFR 
HEK293 cells were co-transfected with lz-EGFR and ARNO. The phosphorylation of lz-EGFR (plz-EGFR) 
was analyzed 48h after transfection by immunoblotting using a phosphospecific antibody (pEGFR_Y1086) and 
total expression level of lz-EGFR by an anti-FLAG antibody (Flag). The diagram shows receptor 
phosphorylation after normalization for total receptor. Data are represented as mean ± SEM, n=5. 
Consistently, coexpression of ARNO and lz-EGFR in HEK293 cells led to an increased 
autophosphorylation of lz-EGFR (Figure 31).  
These data provide strong evidence for the hypothesis that cytohesins facilitate the activation 
of already dimerized EGFR.  
 
IV.1.3.3 ARNO facilitates a conformational rearrangement of the 
intracellular domains in EGFR dimers 
Cytohesins enhance the activation of EGFR dimers without altering EGFR receptor 
endocytosis, clustering or dimerization. These findings suggests the assumption that 
cytohesins act by facilitating conformational rearrangements in the intracellular domain of 
EGFRs.  
I used steady-state fluorescence anisotropy measurements to visualize conformational changes 
of the EGFR cytoplasmic domains in living cells.  
 
IV.1.3.3.1 Principles of steady-state fluorescence anisotropy 
Anisotropy measurements are based on the principle of photoselective excitation of 
fluorophores by polarized light and provide information of the size and the shape 
(=conformation) of the protein to which the fluorophore is coupled.  
Fluorophores preferentially absorb photons whose electric vectors are aligned parallel to the 
transition moment of the fluorophore. Thus, upon excitation with polarized light, one 
selectively excites those fluorophore molecules whose absorption transition dipole is parallel 
to the electric vector of the excitation (photoselective excitation). Emission also occurs with 
the light polarized along a fixed axis in the fluorophore, leading to an anisotropic, directional 
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emission. The term anisotropy (r) defines the extent of polarization of the emitted light. 
Anisotropy can be determined by measuring the intensity of emitted light oriented parallel 
ሺI צ ሻ and perpendicular ሺI ٣ሻ to the direction of the polarized excitation with the help of an 
emission polarizer. These intensity values are used to calculate the anisotropy [108]: 
ݎ ൌ I צ െI ٣I צ ൅2 I ٣ 
Several phenomena can affect the anisotropy of a fluorophore. First, rotational diffusion of 
fluorophores cause a decrease in anisotropy. The extent to which a fluorophore rotates during 
the excited-state lifetime determines its anisotropy and is described by the Perrin equation (see 
fluorescence anisotropy measurements): 
ݎ0
ݎ ൌ  1 ൅
߬
Θ 
where r is the measured anisotropy, r0 is the intrinsic anisotropy of the totally immobile 
fluorophore, τ is the fluorescence lifetime and θ is the rotational correlation time. That 
implies, the faster a fluorophore rotates the smaller the anisotropy will be. Second, changes in 
the fluorescence lifetime of the fluorophore affect anisotropy; the longer the lifetime gets the 
smaller the anisotropy will be. Third, resonance energy transfer (FRET) between two 
fluorophores also leads to a decrease in anisotropy due to a “distribution” of the excitation to 
adjacent fluorophore molecules with differently oriented transition moment (Figure 32).  
 
 
 
Figure 32 Principle of fluorescence anisotropy measurements 
Upon excitation with polarized light ሺE צ ሻ, only those fluorophores are excited whose transition moments are 
aligned parallel to the electric vector of the photons (yellow molecules, left picture). Therefore, emission 
(fluorescence) occurs only along this axis of the fluorophores ሺF צ ሻ, leading to an anisotropic, directional 
emission (high anisotropy). However, homo-FRET between homologous fluorophores leads to the excitation of 
adjacent fluorophores and thereby to the “spreading” of the excitation, which results in an undirected, scattered 
emission (low anisotropy, right picture). Thus, changes in the relative orientation between two fluorophores 
(results in changes in homo-FRET) can be detected by measurement of anisotropy. 
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Since resonance energy transfer critically depends on both the distance and the orientation of 
the fluorophores, anisotropy measurements can be used to visualize conformational changes 
in the excited proteins [109-112].  
 
I made use of steady-state fluorescence anisotropy measurements to visualize conformational 
changes in the intracellular domain of EGFR in living cells. For this purpose we constructed a 
mCitrine-tagged form of the constitutively dimerized lz-EGFR by fusing the fluorescent 
protein mCitrine to the C-terminus of each lz-EGFR (lz-EGFR-mCitrine, Figure 33, cloning 
done by Anton Schmitz).  
Although fluorescence resonance energy transfer is commonly measured between two 
different molecules, it can also occur between chemically identical molecules. Such transfer, 
which is termed homotransfer or homo-FRET, typically occurs for fluorophores which 
display small Stokes shifts, like citrine (516/529nm, Stoke shift = 13nm). 
 
 
Figure 33 Schematic of the constitutively dimerized lz-EGFR fused to mCitrine (lz-EGFR-mCitrine) 
Each molecule in the dimeric lz-EGFR was tagged with the fluorescent protein mCtrine at its C terminus (lz-
EGFR-mCitrine). 
Changes in the position of the two mCitrine moieties relative to each other result in changes 
in the fluorescence resonance energy transfer between these proteins (homo-FRET, Figure 
32). The efficiency of homo-FRET can be determined by measuring the steady-state 
fluorescence anisotropy of the transfected cells (the higher the efficiency of homo-FRET the 
lower the anisotropy will be). This technique has recently been used to monitor 
conformational changes in the neurotrophin receptor [112]. 
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IV.1.3.3.2 Evaluation of the system 
I used Cos-7 cells for all steady-state fluorescence anisotropy measurements because of their 
flat morphology which simplifies microscopy. First, I transfected Cos-7 cells with lz-EGFR-
mCitrine or empty vector, under the same conditions as later used for the steady-state 
fluorescence anisotropy measurements, to check the integrity of lz-EGFR-mCitrine as 
described for the lz-EGFR. Like the untagged lz-EGFR, the fusion protein was constitutively 
dimerized and autophosphorylated (Figure 34). In contrast to HEK293 a strong signal for the 
endogenous EGFR was detected. Since trans-membrane receptors fused to a fluorescence 
protein often show defects in subcellular localization, we further confirmed the integrity of lz-
EGFR-mCitrine by investigating its expected cellular localization in the plasma membrane. 
Lz-EGFR-mCitrine reached the membrane, as visualized by fluorescence microscopy on 
plasma membrane sheets (data not shown), demonstrating that the mCitrine did not perturb 
receptor localization. 
 
Figure 34 Lz-EGFR-mCitrine is constitutively dimerized and phosphorylated 
COS-7 cells were transfected with lz-EGFR-mCitrine or empty vector under the same conditions as used for 
anisotropy measurements. Proteins were separated by reducing or non-reducing SDS-PAGE. Lz-EGFR-mCitrine 
was detected by anti-EGFR antibody and by a phosphospecific antibody (pEGFR_Y1086). The arrows indicate 
receptor dimers, the arrowheads monomers. The asterisk indicated endogenous EGFR. 
To test whether this construct is also suited to detect conformational changes in the EGFR 
cytoplasmic domains, I transfected Cos7-cells with either lz-EGFR-mCitrine alone, together 
with MIG6 or together with the control protein Rheb (ras homolog enriched in brain, G-
protein) and measured steady-state fluorescence anisotropy as described [110]. Shortly, Cos-7 
cells were seeded on glass bottom dishes, adhered for at least 6h and transfected with low 
amounts of the indicated plasmids using FuGene (Roche) for ~ 12-18h. Before microscopy I 
changed the medium to DMEM without phenol red. Microscopy was done using an inverted 
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microscope. A linear dichroic polarizer was placed in the illumination path of the microscope, 
and two identical polarizers were placed at orientations parallel and perpendicular to the 
polarization of the excitation light. I performed the experiments at the MPI in Dortmund 
under the supervision of Peter Verveer.  
Whereas MIG6 is expected to change the steady-state fluorescence anisotropy of lz-EGFR-
mCitrine, Rheb, which is not involved in EGFR signaling, should have no effect. Figure 35 
shows representative micrographs of cells transfected with lz-EGFR-mCitrine alone (left) or 
together with MIG6 (middle) or Rheb (right). The pictures were artificially colorized to 
visualize the measured values for steady-state fluorescence anisotropy. The diagram shows the 
statistical evaluation of all experiments. 
 
 
Figure 35 Steady-state fluorescence anisotropy of lz-EGFR-mCitrine 
Representative micrographs of Cos-7 cells transfected with lz-EGFR-mCitrine alone (-) or together with either 
MIG6-EBR (MIG6) or Rheb. Whereas MIG6-EBR is known to prevent the formation of the asymmetric EGFR 
dimer Rheb is not involved in EGFR signaling. The diagram shows the statistical evaluation of 5 experiments 
(n=25 fields of view with 1-4 cells each). Data are represented as mean ±SEM. **: p<0.01. 
 
As expected, co-expression of MIG6-EBR led to a change in the steady-state fluorescence 
anisotropy of lz-EGFR-mCitrine whereas co-expression of Rheb did not. Thus, anisotropy 
measurements are suited to detect differences in lz-EGFR-mCitrine conformation. 
 
IV.1.3.3.3 ARNO induces a change in steady-state fluorescence anisotropy of 
lz-EGFR-mCitrine 
To detect ARNO-dependent conformational changes in the cytoplasmic domains of EGFR 
dimers, I transfected Cos-7 cells with lz-EGFR-mCitrine either alone or in combination with a 
low (+) or high (++) amount of ARNO and measured steady-state fluorescence anisotropy as 
described. 
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Figure 36 ARNO facilitates a conformational rearrangement of the intracellular domains of 
constitutively dimerized EGFR 
Representative micrographs of Cos-7 cells transfected with lz-EGFR-mCitrine alone or together with increasing 
amounts of ARNO. Steady-state fluorescence anisotropy was measured as described. The diagram shows the 
statistical evaluation of 5 experiments (n=25 fields of view with 1-4 cells each). Data are represented as mean 
±SEM. *: p<0.05 ***: p<0.001. 
 
The co-expression of ARNO led to a decrease in anisotropy as compared to lz-EGFR-
mCitrine alone indicating that ARNO co-expression resulted in an altered conformation of 
the cytoplasmic domains of the EGFR dimer (Figure 36).  
Although the final geometries of the EGFR dimers in the EGFR-ARNO and EGFR-MIG6 
complexes are expected to be different, a decrease in fluorescence anisotropy was detected in 
both cases. At first view, these results seem mutually contradictory as it might intuitively be 
anticipated that changes in anisotropy produced by an inhibitor would oppose those of an 
activator. However, it should be noted that it is not possible to deduce from similar anisotropy 
values of two situations that the underlying geometries are similar. Fluorescence anisotropy 
depends on both, the distance and the relative orientation of the fluorophores. Thus, even if 
the anisotropy is equal in two situations the underlying geometry can be quite different. For 
instance, in one case the distance between the fluorophores may be larger but the relative 
orientation may be more favorable for FRET and in the other case the distance may be 
smaller but the orientation unfavorable. Therefore, although a specific conformation cannot 
be deduced from a certain value or prefix of changes in anisotropy, they are a reliable indicator 
for changes in geometry. 
The results show that both proteins, ARNO and MIG6, change the geometry of the EGFR 
dimers. However, it is not possible to deduce the resulting conformation from the change in 
anisotropy.  
Together with the analysis of receptor crosslinking and phosphorylation, these results support 
the hypothesis that cytohesins enhance ErbB receptor activation by facilitating a 
conformational rearrangement in the cytoplasmic domains of the dimerized EGFR. 
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IV.1.3.3.4 Control measurements 
Fluorescence anisotropy can also be affected by changes in the fluorescence lifetime. To 
address this point I repeated fluorescence anisotropy measurements with lz-EFGR-mCitrine 
and performed fluorescence lifetime measurements at the same time (experiments were done 
together with Franziska Thorwirth at the MPI in Dortmund). Although ARNO induced a 
strong decrease in fluorescence anisotropy of lz-EGFR-mCitrine there was no change in the 
average fluorescence lifetime (τAV=3.086 ns for lz-EGFR-mCitrine alone and AV=3.058 ns for 
coexpression of lz-EGFR-mCitrine and ARNO). This result strongly argues against the 
possibility that ARNO decreases fluorescence anisotropy by changing fluorescence lifetime of 
lz-EGFR-mCitrine.  
Another explanation for the obtained decrease in fluorescence anisotropy caused by ARNO 
coexpression would be that ARNO directly interacts with the citrine moiety of the lz-EGFR-
mCitrine. To rule out this possibility of direct interaction between ARNO and mCitrine I used 
a leucine zipper mCitrine construct (lz-mCitrine, cloning done by Anton Schmitz), in which 
the mCitrine moiety was directly fused to the transmembrane segment of lz-EGFR, i.e. this 
construct lacks the intracellular domain of EGFR. In contrast to lz-EGFR-mCitrine, the 
fluorescence anisotropy of lz-mCitrine was not affected by co-transfection of ARNO (data 
not shown). 
Having shown that ARNO does neither affect lz-mCitrine anisotropy nor the fluorescence 
lifetime of lz-EGFR-mCitrine the observed decrease in lz-EGFR-mCitrine anisotropy due to 
co-expression of ARNO is likely explained by a change in homo-FRET, indicating a 
conformational change in the intracellular domain of the EGFR. 
 
IV.1.4 Cytohesins interact with the EGFR 
IV.1.4.1 ARNO forms a complex with EGFR in cells 
ARNO´s function as a conformational activator of the EGFR implies ARNO and the EGFR 
to physically interact. Immunofluorescence microscopy of plasma membrane sheets showed 
that ARNO and the EGFR colocalize in H460 cells (experiments were performed by David 
Walrafen, AG Lang, University of Bonn, data not shown [104]). To substantiate this 
observation I performed coimmunoprecipitation of ARNO and EGFR. I imunoprecipitated 
EGFR from H460 cell lysates using an EGFR specific antibody coupled to agarose beads. 
Agarose-coupled normal mouse IgG was used as a control matrix. After washing I eluted the 
receptor and the elution was analyzed by SDS-PAGE and immunoblotting using an EGFR- 
or ARNO-specific antibody.  
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Figure 37 Coimmunopreciptation of ARNO with EGFR 
EGFR was coimmunoprecipitated from H460 cells with agarose-coupled anti-EGFR antibody. Coprecipitated 
ARNO was detected by an ARNO-specific antibody. Agarose-coupled normal mouse IgG was used as control 
matrix. 
Figure 37 indicates complex formation between EGFR and ARNO, whereas no ARNO could 
be detected in the elution of the control matrix.  
In conclusion, these results suggest an interaction between EGFR and ARNO, but, however, 
do not proof the direct interaction between these two proteins. 
 
IV.1.4.2 Cytohesins directly bind to the intracellular domain of the EGFR 
To gain further evidence for direct interaction of ARNO and the cytoplasmic domain of 
EGFR, I used a cell free reconstitution system. The complete cytoplasmic domain of the 
EGFR (EGFR-ICD), EGFR-ICD lacking the C-terminal 188 amino acid (EGFR-ICD-1022), 
segment 1 of MIG6-EBR (MIG6-S1), full length ARNO (ARNO-FL), wild-type and GEF-
inactive Sec7 domain of ARNO (ARNO-Sec7wt, ARNO-Sec7-E156K) were heterologously 
expressed and purified (done by Anton Schmitz and Volkmar Fieberg). Figure 38 shows 
coomassie stains of the purified proteins and lysozyme. All proteins, except for the EGFR, 
where labelled with the fluorescent dye fluorescein using Fluorescein isothiocyanate (FITC). 
Labelling efficiency was between 0.4 and 1 molecules fluorescein per protein molecule, as 
determined by spectroscopy. 
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Figure 38 Coomassie stains of proteins used in cell-free binding and autophosphorylation experiments 
Proteins were separated by SDS-PAGE and stained with Coomassie. Destained gels were scanned and analyzed. 
Interactions between the proteins were analyzed by fluorescence anisotropy measurements.  
Fluorescence anisotropy can be used to determine the dissociation constant for the interaction 
between a fluorescently labeled and an unlabeled protein.  
 
 
Figure 39 Principle of anisotropy measurements used to detect protein-protein interactions 
Fluorescein-labeled protein A interacts with protein B leading to an increase in fluorescence anisotropy. Small 
fluorescence complexes (protein A) can rotate freely in the solution, thereby emitting fluorescence at a different 
direction as the exciting light (low anisotropy). Upon interaction with another protein (protein B) the size of the 
complex is increased, which leads to a deceleration of rotation and a less “scattering” and thus to an increase in 
anisotropy.  
 
As mentioned above, fluorescence anisotropy depends on the rotation of the fluorophore. If a 
fluorescence molecule is moving, it will tend to "scatter" the polarization of the light by 
radiating/emitting at a different direction from the incident/exciting light. According to the 
Perrin equation, the "scattering" effect is greatest with small fluorescently labeled molecules 
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freely rotating in solution (low anisotropy) and decreases with reduced rotating rates (high 
anisotropy). Upon binding of an unlabeled protein to a fluorescein-labeled protein the size of 
the rotating complex increases, which leads to a deceleration of rotation and thus to an 
increase in anisotropy (Figure 39). 
 
To exclude the possibility that EGFR-ICD aggregated during binding experiments which 
could confound the measurements, I first analyzed solubility of EGFR-ICD, under the same 
conditions as in the binding experiment. I centrifuged the reaction for 5min at 20000x g in 
order to separate protein aggregates. Figure 40 depicts a western blot of the reaction before 
(total) and after centrifugation (soluble = supernatant, pellet = aggregated protein). EGFR-
ICD was found exclusively in the soluble fraction. 
 
 
Figure 40 EGFR-ICD is soluble under the conditions used for cell-free binding and 
autophosphorylation experiments 
EGFR-ICD solubility was analyzed by centrifugation under the conditions for a typical binding experiment. 
Fractions were analyzed by western blot using streptactin or anti-EGFR antibody for detection. Total: before 
centrifugation, soluble: soluble fraction, pellet: precipitate. 
 
For determination of the dissociation constant, EGFR-ICD was titrated in increasing 
concentration to the indicated FITC-labeled proteins (constant concentration of 1µM) and 
fluorescence anisotropy was measured (Figure 41). Blotting the concentration of EGFR-ICD 
against the measured anisotropy revealed a single-binding site kinetic and the obtained binding 
curves were fitted using non-linear regression and a one site binding model (GraphPadPrism) 
to calculate the apparent dissociation constant (KD).  
Full-length ARNO, the isolated Sec7 domain and the GEF-inactive Sec7-E156K domain 
bound to the EGFR-ICD with apparent dissociation constants around 1µM. Segment 1 of 
MIG6-EBR (MIG6-S1), a known binding partner of the EGFR-ICD bound with a 
dissociation constant around 2µM. No binding was observed between lysozyme and EGFR-
ICD, nor did ARNO full-length or ARNO-Sec7 show binding to MIG6-S1, indicating that 
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the observed binding is specific. These data indicate the direct interaction between EGFR and 
ARNO´s Sec7 domain. 
 
 
Figure 41 ARNO interacts with the intracellular domain of EGFR in vitro 
The indicated proteins were labeled with FITC and the unlabeled ligand was added at increasing concentrations. 
Binding was measured by fluorescence anisotropy. KD values were calculated assuming a 1:1 stoichiometry and 
are given as mean ±SEM, n=4.  
In order to restrict the binding site of ARNO in the intracellular domain of EGFR, I titrated 
EGFR-ICD lacking the C-terminal 188 amino acids (EGFR-ICD-1022) to FITC-labeled 
ARNO-Sec7-wt (Figure 41). EGFR-ICD-1022 bound to ARNO-Sec7-wt with the same 
affinity as the complete EGFR-ICD confining ARNO´s binding site to the kinase or 
juxtamembrane, but not the C-terminal domain of the EGFR. 
 
Recently it was shown, that Dok-7 regulates the activity of the RTK MuSK by binding to the 
partially phosphorylated receptor [113-114]. To test whether the binding of ARNO-Sec7 to 
the EGFR-ICD also required phosphorylation of the receptor, I titrated ARNO to EGFR-
ICD, preincubated with ATP, which resulted in strong autophosphorylation of EGFR-ICD.  
 
 
Figure 42 ARNO binds to EGFR independent of the phosphorylation status 
Interaction of ARNO-Sec7 and EGFR-ICD was measured by fluorescence anisotropy in the presence or absence 
of ATP (diagram). Addition of ATP results in autophosphorylation of EGFR-ICD as detected by 
immunoblotting (left).  
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As Figure 42 shows, the binding of ARNO-Sec7-wt to the EGFR-ICD did not require 
phosphorylation of the EGFR-ICD, as binding of ARNO-Sec7 and EGFR-ICD was 
independent of the phosphorylation status of EGFR-ICD. This result is in agreement with 
ARNO functioning upstream of EGFR autophosphorylation.  
 
IV.1.5 ARNO stimulates autophosphorylation of EGFR by direct 
interaction 
Having shown that ARNO directly interacts with EGFR-ICD, I analyzed the 
autophosphorylation of EGFR-ICD in the presence of ARNO in a cell free system. Due to 
the presence of the juxtamembrane segment, EGFR-ICD forms a dimer resembling the 
intracellular domains of the ligand-bound EGFR and thus can be used to investigate the 
autophosphorylation of the EGFR in a cell-free system. Addition of ATP in the presence of 
DTT and MgCl2, is known to induce autophosphorylation of the receptor. To test whether the 
conformational requirements for the activation of the authentic EGFR are still preserved in 
EGFR-ICD, I also included MIG6-S1, which is known to inhibit the formation of the 
asymmetric dimer of the EGFR, and GST, which was used as a negative control, in the 
experiment. I preincubated EGFR-ICD either with MIG6-S1, GST or ARNO full-length 
(ARNO-FL) and initiated the reaction by addition of ATP. At the indicated time points before 
(0min) and after addition of ATP (1min and 3min) samples were taken and the reaction was 
stopped by addition of loading buffer and boiling. All samples were analyzed by SDS-PAGE 
and western blotting, followed by immunodetecting using anti-phosphotyrosine- and His- 
antibodies. 
 
 
Figure 43 ARNO enhances autophosphorylation of EGFR-ICD 
Representative western blots of autophosphorylation experiments of EGFR-ICD in the presence of full-length 
ARNO (ARNO-FL), segment 1 of MIG6-EBR (MIG6-S1) or GST before (0’) or 1min/3min after addition of 
ATP (1’, 3’) . Proteins were separated by SDS-PAGE and were analyzed by immunoblotting. EGFR-ICD and 
ARNO were detected by anti-His antibody, phosphorylated EGFR-ICD by anti-pY antibody, MIG6 and GST by 
anti-GST antibody. 
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As expected, addition of ATP led to a time dependent phosphorylation of EGFR-ICD (Figure 
43, upper panel). Whereas preincubation with GST had no effect, preincubation with MIG6-
S1 reduced EGFR-ICD autophosphorylation, validating that the activation of the EGFR-ICD 
kinase still depends on the formation of the asymmetric dimer. When ARNO-FL was added 
to the reaction an increased autophosphorylation or EGFR-ICD was found. Total protein 
loading was controlled by detection of His or GST, respectively (middle and lower panels).  
A similar level of stimulation of EGFR-ICD autophosphorylation was seen when the isolated 
Sec7 domain or Sec7-E156K of ARNO was added to an autophosphorylation reaction of 
EGFR-ICD.  
 
Figure 44 ARNO-Sec7 and GEF-inactive ARNO enhance autophosphorylation of EGFR-ICD 
Representative western blots of autophosphorylation experiments of EGFR-ICD in the presence of full-length 
ARNO (ARNO-FL), ARNO-Sec7 or the GEF-inactive Sec7 mutant ARNO-Sec7-E156K. Proteins were 
separated by SDS-PAGE and were analyzed by immunoblotting. EGFR-ICD and ARNO were detected by anti-
His antibody, phosphorylated EGFR-ICD by anti-pY antibody. 
Taken together these results strongly argue for cytohesins acting directly on the intracellular 
domains of dimerized EGFR as conformational activators. 
 
IV.1.6 Chemical inhibition of cytohesins diminishes proliferation of 
human lung cancer cell lines in vitro and in vivo 
Lung cancer is a multifaceted disease and can broadly be divided into small-cell lung cancer 
(SCLC, comprising 20% of lung cancers), and non-small-cell lung cancer (NSCLC, comprising 
80% of lung cancers). Whereas SCLC is a tumor of neural crest origin, NSCLC is thought to 
originate in lung epithelial cells, and comprises diverse histological subtypes including 
adenocarcinoma, bronchioloalveolar, squamous, anaplastic and large-cell carcinomas [48]. 
Advanced non-small-cell lung cancer (NSCLC) is the leading cause of cancer related deaths in 
the world and can be divided in different groups based on the status of EGFR: EGFR or its 
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ligands are overexpressed in 50% of NSCLCs. Furthermore, EGFR mutations are present in 
~10% of cases in North America and Western Europe, but ~30–50% of cases in individuals 
of East Asian descent. Molecular analysis of EGFR in NSCLCs revealed a group of specific 
mutations in the gene that encodes EGFR. Exon 19 mutations characterized by in-frame 
deletions of amino-acids 747–750 account for 45% of mutations, exon 21 mutations resulting 
in L858R substitutions account for 40–45% of mutations, and the remaining 10% of 
mutations involve exon 18 and 20. Additionally, a second site mutation in Exon 18, T790M, 
which leads to resistance to Iressa (Gefitinib) is found in ~50% of NSCLCs with mutated 
EGFR. In addition, about 15–30% of NSCLCs harbor activating mutations in codons 12 and 
13 of the KRAS gene. Interestingly, KRAS and EGFR mutations seem to be mutually 
exclusive in NSCLC [46, 48, 115]. 
 
IV.1.6.1 SecinH3 decreases proliferation of human lung cancer cell lines 
expressing wild-type EGFR 
IV.1.6.1.1 SecinH3 inhibits proliferation of H460 and A549 cells 
H460 and A549 cells are known to harbor an activating mutation of KRAS and therefore to 
express normal levels of wild-type EGFR [103]. Although these cells are described as resistant 
to Iressa they still depend on the signaling of EGFR, since knockdown of EGFR with siRNA 
resulted in reduced cell proliferation and induction of apoptosis [116-117].  
Having shown that ARNO enhances EGFR activation in H460 cells I wondered whether 
cytohesins may also promote the proliferation of the tumor cells. To test this possibility I 
determined the proliferation rate of H460 cells in the presence or absence of SecinH3.  
I seeded the cells in 96well plates and after adherence cells were treated with different 
concentrations of SecinH3 or Secin16, the control compound XH1009, the known EGFR 
kinase domain inhibitor Iressa (Gefitinib) or solvent alone (DMSO, 0.4% final concentration, 
RPMI, 1%FCS). After 72h the numbers of cells were quantified by using a commercially 
available 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
(CellTiter96 Non-Radioactive Cell Proliferation Assay, Promega). The assay is based on the 
cellular conversion of a soluble tetrazolium salt into an insoluble formazan product which can 
be detected colometrically, after lysis of the cells and resolubilisation of the reduced formazan.  
Figure 45 shows the relative cell number after 72h of proliferation. The cell number in the 
solvent-treated samples was set to 1. 
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Figure 45 Secins inhibit the proliferation of H460 cells 
The diagram represents the relative cell number (MTT assay) after 72h treatment with the indicated compounds 
and concentrations. The cell number in solvent-treated samples was set to 1. Data are represented as mean 
±SEM, ***: p<0.001, n=12. 
SecinH3 significantly (p<0.001, n=12) inhibits cell proliferation in a concentration dependent 
manner (IC50: SecinH3 14.6µM), whereas the control compound XH1009 showed no effect. 
Iressa showed only moderate cell proliferation inhibition, confirming the reported resistance 
of H460 cells to this drug. 
The recently identified cytohesin inhibitor Secin16, which showed a significantly better IC50 
in vitro as compared to SecinH3, was also tested for inhibition of cell proliferation. Secin16 
inhibited proliferation of H460 cells in a concentration dependent manner with an IC50 of 
1.4µM (p<0.001, n=12). 
I also analyzed the effect of SecinH3 and Secin16 on the proliferation of A549 cells, which 
resemble H460 cells as they express wild-type EGFR and contain an activating mutation in 
KRAS. The obtained IC50 values (SecinH3: 15µM, Secin16 2.5µM) for the inhibition of 
proliferation in A549 cells were in a similar range as for H460 cells.  
Interestingly, the maximal observed reduction in cell number after treatment with SecinH3 
and Secin16 was around 60% in either cell line as compared to the untreated cells. This 
observation might indicate a cytostatic rather than a cytotoxic effect of the compounds.  
Taken together, these results show that inhibition of cytohesins leads to a diminished 
proliferation of H460 and A549 cells.  
 
IV.1.6.1.2 SecinH3 reduces growth of H460 cell tumor xenografts in nude 
mice 
To test whether SecinH3 was also capable of reducing tumor growth in vivo, tumor 
xenografts were generated by subcutaneous injection of H460 cells into nude mice (all mice 
experiments were done by Lukas Heukamp and Katharina König, Pathology, University of 
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Bonn, with my assistance). After tumor establishment, mice were randomized in two groups 
and treated with SecinH3 (2.5mM in 50% isotonic glucose/DMSO solution) or carrier alone 
(50% isotonic glucose/DMSO solution) by daily intraperitoneal injection (100µl). Tumor 
volume was measured daily and calculated by using the formula π/6 × larger diameter × 
(smaller diameter)2.  
 
Figure 46 SecinH3 decreases proliferation of H460 xenografts in nude mice 
Mice bearing H460 tumor xenografts were treated daily with SecinH3 or solvent by intraperitoneal injection. 
Tumor volume was measured daily. 
A: The diagram summarizes the mean tumor volume measured on the indicated day after begin of treatment (day 
8 p=0.035*, day 9 p=0.0024**, n=14 for each group). Data are represented as mean ±SEM. 
B: Scatter blot of measured tumor volumes on day 9. Shown are the measured tumor volumes on day 9 and the 
mean ±SEM (p=0.0024**, n=14 for each group). 
As Figure 46 depicts, treatment with SecinH3 resulted in significantly reduced tumor growth. 
Mice were sacrificed on day 9 after tumor establishment due to a tumor volume of >1000mm3 
in accordance with the German Laws for Animal Protection and with the guidelines of the 
local animal protection committee.  
Furthermore, immunohistochemical staining for apoptosis by terminal deoxynucleotidyl 
transferase dUTP nick end labelling (TUNEL) revealed an elevated rate of apoptosis in tumor 
xenografts treated with SecinH3 (Figure 47). 
 
Figure 47 SecinH3 induced apoptosis in H460 xenografts 
TUNEL assay of H460 xenografts in nude mice after treatment with SecinH3 or solvent (DMSO) for 9days. 
Data are represented as mean ±SEM (n=14, ***: p<0.001). 
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Taken together, these data demonstrate that the chemical inhibition of cytohesins reduces the 
proliferation of H460 in vitro and in vivo.  
 
IV.1.6.2 SecinH3 also reduces growth of lung cancer cell lines with EGFR 
mutations 
In frame deletion of amino-acids 747–750 of EGFR is the most abundant mutation found in 
NSCLCs. To test whether cells harboring this mutation still depend on cytohesins, I analyzed 
the proliferation of PC9 cells, that express the del(747-750) variant of EGFR, in the presence 
of SecinH3 and Secin16 as previously described.  
 
Figure 48 Secins inhibit the proliferation of PC9 cells 
The diagram represents the relative cell number (MTT assay) after 72h treatment with the indicated compounds 
and concentrations. The cell number in solvent-treated samples was set to 1. Data are represented as mean 
±SEM, ***: p<0.001, n=9. 
As Figure 48 demonstrates PC9 are highly sensitive to chemical inhibition of cytohesins. Both 
SecinH3 and Secin16 showed a concentration dependent inhibition of cell proliferation with 
an IC50 of 3.3µM and 0.6µM, respectively, whereas XH1009 had no effect. As expected even 
low concentrations of Iressa (0.1µM) nearly completely blocked cell proliferation. 
In summary, proliferation of PC9 cells, which contain the del(747-750) variant of EGFR, still 
depends on cytohesins. 
 
IV.1.6.3 SecinH3 induces cell-cycle arrest in PC9 cells 
As inhibition of EGFR signaling in EGFR-dependent cells results in cell-cycle arrest and 
induction of apoptosis, I first examined SecinH3-treated PC9 cells for changes in cell-cycle. 
The eukaryotic cell cycle is comprised of four phases: G1, S, G2 and M phase. Chromosome 
duplication occurs during S phase (S for synthesis), which requires 10-12 hours and occupies 
about half of the cell-cycle time in a rapidly dividing mammalian cell. After S phase, 
chromosome segregation and cell division occurs in M phase (M for mitosis), which requires 
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less than an hour. These main phases of cell cycle are separated by two gap phases (G1 and 
G2 phase), which allow the cell to control and eventually delay the next phase. The G1 phase 
between M phase and S phase enables the cell to check for external conditions and 
extracellular signals. In the absence of external proliferation stimuli, cells can delay progress in 
the cell cycle through G1 and can even enter a permanent resting state called G0. Once 
extracellular signals are favorable for cell growth, the cells pass a restriction point near the end 
of G1 and proceed to DNA replication, even if the extracellular signals are removed. After 
DNA synthesis the cell enters the second gap phase, G2, with the G2/M checkpoint, in which 
the cells prepare for mitosis. G2 and S phase are often referred to as interphase [118]. 
One technique to assess the stage that a cell has reached in the cell cycle is by measuring its 
DNA content. I used flow cytometry in order to analyze the cell-cycle of PC9 cells. Therefore, 
I preincubated the cells for 12h with SecinH3 or solvent (DMSO 0.4%) in basal medium 
containing 1% FCS and harvested the cells by trypsinization. Subsequently cells were fixed in 
methanol and stained with the fluorescent DNA-binding dye TOPRO-3 iodide (Invitrogen). 
After washing, I analyzed the DNA content of the cells by flow cytometry [118-119].  
 
Figure 49 Cell cycle analysis of PC9 cells 
Typical histogram obtained for DNA-staining of PC9 cells. The signal distribution was fitted by the Watson 
model showing G1 (green), S (yellow) and G2/M (blue) phases of cell cycle. PC9 cells were fixed with methanol 
and stained with TOPRO-3 iodide (DNA dye). DNA content was analyzed by flow cytometry. Count: number of 
cells, APC-A: DNA content (TOPRO signal). 
Figure 49 shows a typical result obtained for proliferating PC9 cells. Since TOPRO-3 iodide 
becomes fluorescent when it binds to DNA, the amount of detected fluorescence per cell is 
directly proportional to the amount of DNA in the cell. Two different “peaks” connected by 
an intermediate signal are visible which correspond to the cells in G1, S or G2/M phase: Cells 
that have an unreplicated complement of DNA are in G1 (first, green peak, ~50% of all cells), 
those that have a fully replicated complement of DNA with twice the DNA content compared 
to G1 are in G2 or in the beginning of M phase (~20% of all cells, last peak, blue), and those 
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that have an intermediate amount of DNA are in S phase (~30% of all cells, yellow). The 
histograms were quantitatively analyzed by FlowJo-software to obtain the percentage of cells 
in the different phases of cell-cycle (Watson model). 
Figure 50 illustrates typical histograms of SecinH3-treated and untreated cells. SecinH3 
increased the percentage of cells in the G1 phase of the cell-cycle (~68%) and accordingly 
decreased the cells in S (~23%) and G2/M phases (~10%), indicating an arrest in G1 of the 
cell cycle. The diagram summarizes the percentage of cells in the indicated cell-cycle phases. 
All changes were significant (***, p<0.0001, n=6). 
     
Figure 50 SecinH3 induces G1 arrest in PC9 cells 
PC9 cells were treated with SecinH3 (15µM) or DMSO for 24h, fixed and stained with TOPRO-3 iodide. DNA-
content was analyzed by flow cytometry. The histogram shows the DNA-content of SecinH3 or DMSO treated 
cells. The diagram summarizes the percentage of cells in the indicated cell-cycle phases. Data are represented as 
mean ±SEM. All changes were significant (***, p<0.0001, n=6). Count: number of cells, APC-A: DNA content 
(TOPRO signal). 
 
These results indicate that chemical inhibition of cytohesins induces growth arrest in PC9 cells 
probably as a reaction of diminished EGFR signaling. 
 
IV.1.6.4 SecinH3 induces apoptosis in PC9 cells 
Cells arrested in G1 might either enter a resting state (G0) or might initiate apoptosis due to 
the lack of pro-proliferating or anti-apoptotic signals.  
To investigate the fate of G1 arrested PC9 cells I performed an Annexin V apoptosis assay by 
flow cytometry. This assay is based on characteristic changes in the plasma membrane of 
apoptotic cells. The negatively charged phospholipid phosphatidylserine is normally 
exclusively located in the inner leaflet of the lipid bilayer of the plasma membrane, but flips to 
the outer leaflet in apoptotic cells, where it can serve as a marker. The phosphatidylserine on 
the surface of apoptotic cells can be visualized with a labelled form of the protein Annexin V, 
which specifically binds to this phospholipid [120].  
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I preincubated PC9 cells for 48h with 15µM SecinH3, 1µM Secin16 or solvent (0.4%DMSO) 
in basal medium containing 1% FBS, harvested by trypsinization and stained the cells with a 
FITC-labelled form of Annexin V and with TOPRO 3 iodide. Since the cells were not fixed, 
the membrane impermeable dye TOPRO 3 iodide could only stain cells which already 
acquired damage in their plasma membrane due to the process of cell death. I analyzed the 
cells by flow cytometry and blotted the measured signals for Annexin V and TOPRO in a dot 
blot.  
 
 
Figure 51 Secins increase the number of apoptotic PC9 cells  
Dot blot of TOPRO-3 and FITC-Annexin V stained PC9 cells after 48h treatment with solvent (0.4% DMSO), 
15µM SecinH3 or 1µM Secin16. FITC-A: Annexin V, APC-A: TOPRO. Quadrant I: unstained or healthy cells, 
quadrant II: early apoptotic cell, quadrant III: intermediate apoptotic cells, quadrant IV: late apoptotic cells.   
The cells fall into four categories represented by the four quadrants of the dot blot: Unstained 
or solvent-treated cells show little TOPRO staining of DNA (quadrants 1+2), due to an intact 
plasma membrane and show only weak staining for phosphatidylserine (quadrants 1+4) and 
are therefore mainly found in quadrant 1 (FITC -, TOPRO -). Treatment with SecinH3 or 
Secin16 led to a strong increase in FITC positive/TOPRO negative (quadrant 2, early 
apoptotic), double positive (quadrant 3, intermediate apoptotic) and TOPRO positive/FITC 
negativ (quadrant 4, late apoptotic) cells and to a concomitant decrease of double negative 
cells (quadrant 1, healthy cells). Figure 52 summarizes the percentage of apoptotic cells 
(quadrants 2-4) in solvent- and SecinH3/Secin16 treated cells (***, p<0.001). 
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Figure 52 SecinH3 and Secin16 induce apoptosis in PC9 cells 
Quantitative analysis of apoptotic PC9 cells (quadrants 2-4) after 48h treatment with solvent (0.4% DMSO), 
15µM SecinH3 or 1µM Secin16. (***, p<0.001, n=3). 
Taken together, these data demonstrate that chemical inhibition of cytohesins in EGFR-
dependent PC9 cells inhibits proliferation by inducing a growth arrest in the G1 phase of cell-
cycle, which leads to apoptotic cell death. 
 
IV.1.6.5 SecinH3 reduces growth of PC9 tumor xenografts in nude mice 
Having shown that SecinH3 decreases the proliferation of PC9 cells by inducing a G1 arrest 
followed by apoptosis, I was interested whether SecinH3 treatment reduces tumor growth in 
vivo. Therefore tumor xenografts were generated by subcutaneous injection of PC9 cells into 
nude mice (experiments were done by Roman Thomas, Roland Ullrich and Sampurna 
Chatterjee, MPI Köln). After tumor establishment mice were randomized in two groups and 
treated with SecinH3 (2.5mM in 75% isotonic glucose/25% DMSO solution) or carrier alone 
(75% isotonic glucose/25% DMSO solution) by daily intraperitoneal injection (100µl). Cell 
proliferation in the tumor was followed by [18F]fluoro-L-thymidine uptake positron emission 
tomography ([18F]FLT PET). Therefore [18F]FLT was administered i.v. (tail vein) on day 7 
into experimental animals. PET images were performed 60 min after injection. Data 
evaluation was based on a region of interest (ROI) analysis of PET images to determine 
maximal radioactivity concentration within the tumors. To determine the uptake ratio a 
reference ROI was placed in the mediastinum.  
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Figure 53 SecinH3 reduces [18F]FLT uptake of PC9 xenografts in nude mice 
Representative [18F]fluoro-L-thymidine uptake positron emission tomography ([18F]FLT PET) images of mice 
bearing PC9 xenografts before and 7 days after treatment with SecinH3 or DMSO. The diagram summarizes the 
change in maximal FLT uptake. **, p<0.01, n=7) 
As Figure 53 depicts, tumors in the SecinH3 treated mice showed significantly less uptake of 
[18F]FLT after 7 days of treatment in comparison to tumors in the solvent treated mice, 
indicating reduced tumor growth. The diagram represents the mean percentage of injected 
dose per gram (%ID/g) measured in the tumor of 7 animals (**, p<0.01). 
Furthermore, immunohistochemical staining of the cell proliferation marker Ki-67 [121-122], 
which is expressed in all active phases of cell-cycle (G1, S, G2 and M phase) but not in resting 
cells (G0), in resected tumors confirmed reduced cell proliferation (Figure 54A). 
TUNEL staining showed an increase in apoptotic cells in the tumors of SecinH3-treated 
animals (Figure 54B, experiments done by Lukas Heukamp). 
 
 
Figure 54 SecinH3 decreases proliferation of PC9 xenografts and induces apoptosis 
A: Ki-67 staining of PC9 xenografts in nude mice after treatment with DMSO or SecinH3 for 7 days. 
B: TUNEL assay of PC9 xenografts in nude mice after treatment with DMSO or SecinH3 for 7 days. The 
diagram shows the number of TUNEL-positive cells per high power microscopic field. Per treatment group 10 
representative fields were counted, ***p<0.001). Data are represented as mean ±SEM. 
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Taken together, these data demonstrate that chemical inhibition of cytohesins reduces the 
proliferation of EGFR-dependent tumor cells in vitro and in vivo. 
 
IV.1.6.6 Chemical inhibition of cytohesins decreases proliferation in 
various EGFR-dependent cell lines independent of the EGFR 
mutation status 
To further substantiate the finding that chemical inhibition of cytohesins reduces proliferation 
of EGFR-dependent lung cancer cells, I performed cell proliferation assays in a set of 
different EGFR dependent lung adenocarcinoma derived cell lines, harboring the most 
common mutations in EGFR. Table 1 summarized the obtained IC50 values for SecinH3 and 
Secin16, and the known IC50 values for Iressa. XH1009 showed no effect (data not shown).  
 
Cell 
line 
EGFR KRAS further 
anomaly 
IC50 
SecinH3 
IC50 
Secin16  
IC50 
Iressa  
H460 wt mut, G61H  15µM 1.5µM >5µM [103]
A549 wt mut, G12S  15µM 2.5µM >5µM [123]
H3255 L858R wt  13µM 1.0µM 89nM [124]
H1975 L858R, T790M wt  n.d. 5.0µM >5µM [124]
PC9 del(E747_A750) wt  3.3µM 0.6µM 31nM [124]
H1781 HER2 
G776insV_G/C 
wt  15µM 0.5µM >5µM [125]
H1838 wt, amplf. wt MET amplf. n.d. n.d. 2µM [123]
 
Table 1 Characteristics of the used human lung cancer cell lines 
Used human lung cancer cell lines. EGFR status, KRAS status, anomalies and IC50 values for Iressa are given as 
reported in the literature. IC50 values for SecinH3 and Secin16 were determined by MTT proliferation assays. 
n.d.: not detectable 
Chemical inhibition of cytohesins significantly decreases cell proliferation in all tested EGFR-
dependent cell lines except of the cell line H1838, which is described as partially or weakly 
EGFR-dependent due to strong expression of the receptor tyrosine kinase MET, suggesting 
an EGFR specific inhibition of proliferation. SecinH3 and Secin16 were even capable of 
inhibiting proliferation of the HER2 dependent cell line H1781. Since Secin16 showed only a 
weak inhibitory effect on the cell line H1975 (in comparison to H3255 cells), carrying the gate 
keeper mutation T790M which renders the receptor resistant to Iressa treatment, I further 
investigated whether this mutation also mediate resistance to chemical inhibition of 
cytohesins.  
Therefore I made use of the murine bone marrow–derived cell line Ba/F3. Ba/F3 cells 
depend on the growth factor interleukin-3 (IL-3). Expression of oncogenes, including EGFR, 
renders the cells IL-3 independent and critically addicts the cells to the oncogene. Therefore, 
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Ba/F3 cells transfected with EGFR provide valuable system to investigate the selectivity of 
EGFR targeting compounds. 
I treated Ba/F3 cells expressing different variants of EGFR, with SecinH3, Secin16 or Iressa 
in the absence of IL-3 for 72h and measured cell proliferation by MTT as described.  
Iressa efficiently blocked the proliferation of EGFR L858R and EGFR del(E747_A750) 
dependent Ba/F3 cells, whereas there was no effect on the proliferation of wild-type cells or 
Ba/F3 cells carrying the gate keeper mutation T790M, validating the EGFR signaling 
dependency of the cells and the functionality of the EGFR mutations.  
 
Figure 55 Secins inhibit proliferation of EGFR dependent BA/F3 cells 
The diagram shows the relative cell number (MTT assay) after 72h treatment with the indicated compounds and 
concentrations. Wild-type BA/F3 cells (wt) were grown in the presence of IL-3, whereas BA/F3 cells stably 
transfected with EGFR del (E747_A750), EGFR L858R alone or in combination with T790M were grown the in 
the presence of G418. Data are represented as mean ±SEM. ***, p<0.001 for all tested concentrations and in 
comparison to wt BA/F3, n=8. 
 
Ba/F3 SecinH3 IC50 Secin16 IC50 
wt, IL-3 dependent n.d. n.d. 
EGFR L858R 10µM 520nM 
EGFR L858R + T790M 10µM 580nM 
EGFR E747_A750 4.5µM 560nM 
EGFR E747_A750 + T790M 3.5µM 500nM 
 
Table 2 IC50 values of SecinH3 and Secin16 for inhibition of cell proliferation in Ba/F3 cells 
IC50 values for SecinH3 and Secin16 were determined in MTT proliferation assays. n.d.: not detectable. 
 
Whereas SecinH3 and Secin16 had only a very weak effect of on the proliferation of 
untransfected, wild-type and IL-3 dependent Ba/F3 cells, SecinH3 and Secin16 showed a 
significantly pronounced effect on the proliferation of EGFR-dependent Ba/F3 cells (***, 
p<0.001 for all tested concentrations, n=8). Cells expressing the del(E747_A750) form of 
EGFR of EGFR showed a higher sensitivity to inhibition of cytohesins by SecinH3 and 
Secin16 as compared to cells expressing EGFR L858R. There was no significant difference 
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between cells carrying a second site mutation in EGFR (T790M) in comparison to cells 
harboring only one mutation in EGFR.  
Table 2 summarizes the obtained IC50 values. 
In conclusion these data indicate that chemical inhibition of cytohesins diminishes 
proliferation of EGFR-dependent lung cancer cell lines, independent of their EGFR status.  
 
IV.1.7 Overexpression of cytohesins in human lung adenocarcinoma 
correlates with enhanced EGFR signaling 
IV.1.7.1 Cytohesins are overexpressed in human lung adenocarcinoma 
Enhanced EGFR signaling is known to be a hallmark in many cancers. Having shown that 
ARNO enhances EGFR activation and that proliferation of EGFR-dependent human lung 
adenocarcinoma derived cell lines is strongly reduced by chemical inhibition of cytohesins; I 
wondered whether ARNO or other cytohesins are overexpressed in lung cancer.  
 
 
Figure 56 ARNO is overexpressed in human lung adenocarcinoma 
Sections of resected human lung adenocarcinomas were stained for ARNO/cytohesin-1 and DAPI. 
ARNO/cytohesin-1 expression level was analyzed using a four-tier scoring system. Shown are representative 
images of (A) lung tissue without tumor, (B) tumor with background/negative, (C) weak, (D) strong, (E) very 
strong ARNO/cytohesin-1 expression. The diagram (F) summarizes the frequencies of tumors with the 
respective ARNO staining. 
To address this question, a collection of primary human lung adenocarcinomas were 
immunostained with an antibody detecting ARNO and cytohesin-1 (there was no ARNO 
specific antibody available). Staining intensities were individually evaluated by three 
independent observers, applying a four-tier scoring system: no or background staining (0), 
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weak (1), strong intensity (2), very strong (3) (experiments were done by Lukas Heukamp, 
Sebastian Zimmer and Lisa Meffert, Pathology, University of Bonn).  
 
Whereas normal lung tissue showed only background or weak staining, 82% of the carcinomas 
showed moderate to strong ARNO/cytohesin-1 staining, demonstrating cytohesin 
upregulation in a large fraction of lung adenocarcinomas (Figure 56).  
 
IV.1.7.2 Cytohesin overexpression correlates with enhanced EGFR 
signaling in human lung adenocarcinomas 
According to the data obtained in cell culture, increased cytohesin expression should result in 
enhanced EGFR autophosphorylation in these tumors. To investigate this hypothesis, the 
same set of adenocarcinomas was stained for phosphorylated EGFR, total EGFR, 
phosphorylated Akt and phosphorylated p42/p44 and scored as described (Figure 57, 
experiments were done by Lukas Heukamp, Sebastian Zimmer and Lisa Meffert, Pathology, 
University of Bonn). To test for a correlation between the expression level of 
ARNO/cytohesin-1 and the level of phosphorylated EGFR or downstream proteins, I 
performed a Spearman correlation analysis assuming Gaussian distribution (GraphPadPrism 
software). Indeed, I found a highly significant correlation between the expression level of 
ARNO/cytohesin-1 and the levels of EGFR autophosphorylation (p=0.002). Increased 
EGFR phosphorylation was not due to overexpression of the receptor because total EGFR 
expression was independent of ARNO/cytohesin-1 expression (p=0.581). The 
phosphorylation of Akt and p42/44 (Erk1/2) was also significantly correlated with higher 
ARNO/cytohesin-1 expression (p=0.002 and p=0.025, respectively), suggesting that the 
enhanced activation is not restricted to the EGFR itself but continues along these two major 
branches of the EGFR signaling pathway. 
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Figure 57 High expression levels of ARNO/cytohesin-1 correlate with increased EGFR signaling in 
human lung adenocarcinomas 
Consecutive sections of human lung adenocarcinoma were stained for ARNO/cytohesin-1 (A), pEGFR_Y1086 
(B), pAkt_T308 (C) or pp44/42_T202/Y204 (D). Shown are representative images of tumors with background 
(left) or high (middle) expression of ARNO/cytohesin-1. The diagrams depict the phosphorylation levels of the 
respective protein in correlation to the cytohesin score (p=0.002 for pEGFR, p=0.002 for pAkt, p=0.025 for 
pp44/42, n=45). 
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IV.2 Identification of  improved cytohesin antagonists in 
vitro 
IV.2.1 Virtual screening  
High-throughput screening (HTS) currently plays a major role as a source of novel active 
molecules that serve as leads for drug development and as tools for biomedical research. As an 
alternative, virtual screening of chemical libraries formatted in silico can be applied to identify 
new active chemotypes. Virtual screening is based on structural information about the target 
and/or known ligand. That is why most ligand based methods require as many active and 
inactive reference compounds as possible, since the probability of success substantially 
increases with the amount of available compound and structure-activity-relationship (SAR) 
data. However, in the case of cytohesins, only one inhibitory chemotype, the pan-active 
cytohesin inhibitor SecinH3 is known. Structure-activity-relationship studies revealed a limited 
number of SecinH3 related compounds, without significant improvements in the inhibitory 
potency. Based on these limited information a virtual screening approach combining 
fingerprint similarity searching and support vector machine was tailored to identify new small 
molecule chemotypes for the study of cytohesins. In this way, a library containing 145 
structures was established (calculations were done by Dagmar Stumpfe and Jürgen Bajorath, 
University of Bonn) and subsequently named as second generation SecinH3 chemotypes 
[126]. 
 
IV.2.2 Establishment of a GDP/GTP-exchange assay for ARF1 
In order to test the predicted structures for an inhibitory effect on cytohesins, I set out to 
establish a simple and robust assay for monitoring the exchange activity of cytohesins, based 
on the protocol for an already published exchange assay on ADP ribosylation factor 1 (ARF1) 
[127].  
Guanine nucleotide exchange factors (GEFs) catalyze the dissociation of the nucleotide from 
the G protein by modifying the nucleotide-binding site in such a way, that the nucleotide 
affinity is decreased, which results in the release of the nucleotide [77]. Since G proteins show 
a nanomolar to picomolar affinity for GDP and GTP, the GEF is subsequently replaced by a 
new nucleotide. Cytohesins bind to the binary complex of ARF and GDP, in which the GDP 
is sandwiched between two loops called switch 1 and switch 2 (residues 38–52 and 69–84 in 
Arf1), which are connected by an interswitch region comprising two ß-strands [76, 78, 128-
129]. Switch regions 1 and 2 interact with the phosphates of GDP and a coordinating 
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magnesium ion, thereby stabilizing the GDP bound conformation of ARF. In the cytosolic 
full-length form of ARF-GDP the myristoylated amphipathic amino-terminal helix locks the 
interswitch in a retracted conformation that blocks nucleotide exchange. Its reversible binding 
to membrane releases the hasp and opens up the locked conformation of the interswitch to 
enable nucleotide exchange [74].  
Binding of cytohesin displaces switch 1 to open up the nucleotide binding site and GDP is 
kicked out of the transiently formed ternary complex between cytohesin, ARF and GDP. A 
glutamate acid finger of the cytohesin Sec7 domain approaches the negatively charged 
phosphate of GDP and displaces the coordinated magnesium ion thereby perturbing the 
interaction surface in the phosphate-binding region, which leads to nucleotide release [129]. In 
the course of the exchange reaction a new nucleotide displaces the GEF, since the nucleotide 
weakens the affinity of the G protein for the GEF.  
Conformational changes accompanying ARF activation can be monitored by measuring the 
intrinsic fluorescence of ARF. In proteins, the three aromatic amino acids phenylalanine, 
tyrosine and tryptophan are fluorescent [108]. A valuable feature of intrinsic protein 
fluorescence is the high sensitivity to its local environment. Changes in the emission spectra of 
tryptophan often occur in response to conformational transition. In the case of ARF1, an 
increase in intrinsic tryptophan fluorescence can be used to monitor GDP to GTP exchange 
[127].  
To enable measurements of nucleotide exchange on ARF1 in the absence of membranes I 
made use of N∆17ARF1, a truncated form of ARF1, lacking the first 17 amino acids, holding 
the protein in an exchange-active state [74-75].  
First, I preloaded purified N∆17ARF1 (1µM) with GDP (80µM) in the presence of EDTA 
(2mM) by chelating the magnesium ion responsible for nucleotide binding and stabilized the 
resulting N∆17ARF1-GDP complexes by addition of MgCl2. Second, 250nM of GDP 
preloaded N∆17ARF1 was mixed with 15nM of purified ARNO-Sec7 in the absence or 
presence of inhibitor. I started the reaction by injection of GTP (50µM) and measured the 
tryptophan fluorescence at 280nm (excitation) and 340nm (emission). All measurements were 
performed in PBS, pH 7.4, 3mM MgCl2 at 37°C in 96well plates. 
Figure 58 displays the results of a typical exchange reaction. After injection of GTP a linear, 
ARNO-Sec7 dependent increase in tryptophan fluorescence can be detected, which is 
inhibited in the presence of SecinH3. For analysis of the exchange rate, I calculated the initial 
slope of fluorescence increase by linear regression (GraphPadPrism software), as shown in 
Figure 58. It is important to note, that only initial, linear regions of fluorescence increase were 
used to calculate the exchange rate of ARNO-Sec7. 
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Figure 58 ARNO-Sec7 catalyzed GDP/GTP exchange on N∆17ARF1 
GDP preloaded N∆17ARF1 was incubated with or without the Sec7 domain of ARNO in the presence of 15µM 
SecinH3 or DMSO (0.4%DMSO). The exchange reaction was started by addition of GTP. Conformational 
changes caused by GDP/GTP exchange on N∆17ARF1 were detected by tryptophan fluorescence 
(ex280/em340nm). 
A: Measured tryptophan fluorescence. The slope of the reaction was calculated by fitting the linear phase in 
tryptophan fluorescence by linear regression (fit shown as a line). 
B: Calculated slope of the reactions 
Data are represented as mean ±SEM, n=2. 
To “measure” the suitability of the described GDP/GTP exchange assay on ARF1 for use as 
a screening assay, I calculated the Z’-factor. This coefficient reflects both the dynamic range 
of the signals (or the signal-to-noise-ratio) and the variation of the obtained signals. The Z’-
factor is a useful tool to describe the quality of an assay system and is often utilized for assay 
validation [130]. It is calculated as: 
ܼԢ ൌ 1 െ 3ݔܵܦ௣௖ ൅ 3ݔܵܦ௡௖หμ௣௖ െ μ௡௖ห  
where SD is the standard deviation and µ the mean of the positive control (pc) or negative 
control (nc) values.  
For the described GDP/GTP exchange assay on ARF1 I calculated a Z’-factor of 0.59 out of 
fourteen independent measurements with the reaction in the presence or absence of ARNO-
Sec7 used as a positive or negative control, respectively, rating it as an suitable assay for 
screening.  
 
IV.2.3 Screening of second generation SecinH3 chemotypes 
In order to test the 145 second generation SecinH3 chemotypes predicted by virtual screening, 
I performed the GDP/GTP exchange assays on N∆17ARF1 as described in the presence of 
5µM compound (0.4% DMSO). All compounds were tested in independent duplicates and the 
relative exchange rate was calculated with the reaction in the presence of 5µM SecinH3 set to 
1.  
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Figure 59 summarizes the relative exchange rates for all tested compounds which showed at 
least 10% stronger inhibition than SecinH3. Of these 15 compounds, 3 compounds (Secin69, 
Secin16, Secin87) showed a relative exchange rate of at most 70% (meaning at least 30% 
stronger inhibition than SecinH3) and were defined as hits (Figure 60). Retesting of Secin16 
and Secin69 validated dose-dependency and yielded IC50 values of 3.7±0.4µM and 
2.1±0.3µM, respectively, compared to 11.4±0.7µM for SecinH3. In addition, both compounds 
were applied in cellular assays. As Secin69 showed severe solubility problems, Secin16 was 
defined as a new lead compound. 
 
Figure 59 Ranking of second generation SecinH3 chemotypes 
Relative exchange rate for second generation SecinH3 chemotypes (5µM) with SecinH3 (5µM) set to 1, shown as 
mean ±SEM, n=2.  
 
Figure 60 Structures of selected second generation SecinH3 chemotypes and SecinH3 
 
IV.2.4 Structure-activity-relationship studies for Secin16 
Although Secin16 displayed a roughly three fold higher potency than SecinH3 in the inhibition 
of GDP/GTP exchange on N∆17ARF1, it showed reduced solubility in aqueous solutions 
(~7µM Secin16, ~15 µM SecinH3), making it difficult to determine further biochemical 
characteristics. Therefore, I performed a structure-activity-relationship study for a small set of 
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Secin16 analogs (synthesized by Jeffrey Hannam), to further improve the solubility and 
inhibitory potency of Secin16. 
 
Figure 61 Secin16 modifications 
Shown are the structures and the IC50 (GDP/GTP exchange on ARF1) of all tested Secin16 modifications.  
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Figure 61 gives an overview of the molecules tested, with the nuance indicating the 
modification. 16 Secin16 analogs were tested in GDP/GTP exchange on N∆17ARF1 and 
IC50 values were calculated as described. Table 3 displays the obtained IC50 values.  
The solubility of a compound is determined by many factors. The logP (logarithm of the 
partition coefficient) describes the ratio of concentrations of a compound in the two phases of 
a mixture of a hydrophobic and hydrophilic solution at equilibrium. Hence it is often used to 
predict the solubility of the compound, as lipophilic compounds have a high logP value (pure 
solubility in water) and hydrophilic compounds a low logP value (good solubility in water) 
[131]. I calculated the predicted clogP value for each molecule (ChemDraw software, using a 
fragment based prediction, “c” stands for calculated/simulated). 
 
Compound IC50 [µM] clogP Compound IC50 [µM] clogP
Secin16 3.1±0.5 4.31 Secin16mod8 9.6±2.0 2.92
SecinH3 11.4±0.7 4.35 Secin16mod9 not active 2.53
Secin16mod1 2.2±0.4 2.60 Secin16mod10 not active 2.75
Secin16mod2 4.5±0.6 4.19 Secin16mod11 5.3±0.5 3.28
Secin16mod3 8.4±1.0 2.48 Secin16mod12 8.7±0.4 3.08
Secin16mod4 not active 3.45 Secin16mod13 4.3±0.4 3.08
Secin16mod5 not active 0.70 Secin16mod14 2.8±0.3 7.05
Secin16mod6 2.9±0.6 2.76 Secin16mod15 3.9±0.5 3.24
Secin16mod7 6.0±0.9 2.38 Secin132 8.0±0.8 3.59
 
Table 3 Secin16 modifications 
Shown are the IC50 and the predicted clogP value (ChemDraw). IC50 values are given as mean ±SEM of at least 
4 independent experiments. 
Only two Secin16 analogs, Secin16mod1 and Secin16mod6, missing the tertiary-butyl-moiety 
or 4’-fluoride substituted at the benzoate, respectively, showed an improved IC50 value 
combined with a predicted >10fold increase in solubility, compare to Secin16. Both 
compounds were further evaluated in cell proliferation assays, where they did not proof their 
superior to Secin16 (data not shown). Further substitutions at the benzoate (Secin16mod7, 
Secin16mod8) did not improve inhibitory potency. Instead substitution of the tertiary butyl 
benzoate (Secin16mod5) or furoyl-acrylic moiety for acetyl (Secin16mod4) rendered the 
molecule inactive. Introduction of an acetylthiophene (Secin16mod9) or phenylthioacetyl 
(Secin16mod10) moiety had the same inactivating effect. Interestingly, substitution of the 
furoyl-acrylic moiety with a second tertiary-butyl-benzoate slightly improved the IC50 value, 
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but dramatically worsened the clogP value (Secin16mod14). In respect of subsequent binding 
studies with immobilized Secin16, two positions for a propylamino-linker were tested 
(Secin16mod12+13), favoring the terminal position.  
 
IV.2.5 Screening of third generation SecinH3 chemotypes 
Based on the results obtained from the structure-activity-relationship study for Secin16 a 
second virtual screening approach was performed as described, yielding 88 new third 
generation SecinH3 chemotypes. Again, I tested all 88 compounds for their potential to inhibit 
the GDP/GTP exchange on ARF1 at a concentration of 2.5µM. I normalized the calculated 
exchange rates in relation to the exchange rate obtained in the presence of DMSO only.  
 
Figure 62 Screening of third generation SecinH3 chemotypes 
Relative exchange rates for third generation SecinH3 chemotypes (2.5µM) with the reaction in the presence of 
DMSO set to 1, shown as mean ±SEM, n=2. Blue bars: 20% stronger activity, orange bars: similar activity as 
Secin16, grey bars: not active. 
In my primary screen 6 compounds which showed at least 20% stronger inhibition compared 
to Secin16 (Figure 62, blue bars, Secin16 red bar) at a concentration of 2.5µM were classified 
as a hit (B7, B5, D3, A5, A6, D6, for structure see Figure 63). 19 compounds showed similar 
activity as Secin16 (+/- 20%, orange bars) and 52 compounds were classified as non active 
(light grey bars). 11 compounds showed strong autofluorescence and could hence not be 
evaluated. All 6 hits were re-screened at different concentrations to verify dose-dependency. 
Table 4 combines the IC50 values for all 6 hits in comparison with Secin16. 
 
Compound B7 B5 D3 A5 A6 D6 Secin16 
IC50 [µM] 
0.44 
± 0.06 
1.19 
± 0.15 
1.34 
±- 0.16
1.18 
± 0.17 
0.79 
± 0.15 
1.86 
± 0.30 
3.74 
± 0.37 
 
Table 4 IC50 values of third generation SecinH3 chemotypes 
Numbers represent IC50 values ±SEM for all 6 hits in the GDP/GTP-exchange assay on ARF1. Each individual 
experiment was performed at least 8 times. 
Taken together these data introduce a new class of potent inhibitors for cytohesin-catalyzed 
GDP/GTP exchange on ARF1.  
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Figure 63 Structure of selected 3rd generation SeicnH3 chemotypes and Secin16 
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IV.3 Evaluations of  3rd generation SecinH3 chemotypes in 
human glioblastoma cell lines 
IV.3.1 Third generation Secins are potent inhibitors of glioblastoma 
cell proliferation 
Gliomas are the most common subtype of primary brain tumors and are responsible for about 
2% of all deaths from cancer. The epidermal growth factor receptor (EGFR) is a primary 
contributor to glioblastoma initiation and progression. EGFR amplification and 
overexpression is the most common genetic alteration in primary glioblastoma with a 
frequency of 40-70%, commonly accompanied with additional mutations in EGFR. The most 
abundant mutation, which is found in approximately 50-60% of glioblastoma that overexpress 
the EGFR, is the EGFR variant III (EGFRvIII). This mutant lacks domains I and II of the 
extracellular part of the EGFR. Although EGFRvIII is incapable of ligand binding it is 
constitutively tyrosine phosphorylated and therefore constitutively activates EGFR 
downstream signaling [66, 132]. 
When grown in vitro, glioblastoma cells lose their native EGFRvIII expression over time, 
making it necessary to replace this oncogene for further studies. I used two pairs of 
established glioblastoma cell lines: Gli36 wild-type and U87 wild-type cells and their respective 
isogenic line, which differs only in the expression of the stably transfected EGFRvIII. By 
comparing the effect of the compounds on the parental and the EGFRvIII expressing cell line 
I was able to screen for compounds which selectively inhibit the EGFRvIII dependent cell 
proliferation. 
To identify new inhibitors of glioblastoma cell proliferation I validated all 88 third generation 
SecinH3 chemotypes for their effect on cell proliferation. Cells were treated with 250nM of 
the compounds. At this concentration Secin16 shows only weakly affects cell proliferation. 
After 72h the relative number of cells was quantified by a MTT assay as described before.  
The primary screen identified 11 compounds that inhibited the proliferation of both parental 
cell lines by more than 30% as compared to the solvent only (DMSO) control (Figure 64). 
These primary hits were classified into two groups: group one, consisting of compounds A4, 
B5, B7, B8, B10 (Figure 1B, dark blue bars, red box in), showed an inhibitory effect of more 
than 50% as compared to the solvent only control in both cell lines, whereas group two 
(compounds A1, A5, A6, B6, D4, D5, B, orange bars or green box in) decreased cell 
proliferation in both cell lines between 30% and 50%. Comparison of the two parental cell 
lines U87 and Gli36 revealed a significant correlation (p<0.0001, r=0.9, Pearson-model, 
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GraphPadPrism software) between the inhibitory effects of all 88 compounds on the 
proliferation of both cell lines (Figure 65). 
 
Figure 64 Effect of 3rd generation SecinH3 chemotypes on glioblastoma cell proliferation 
Results of the primary screen on glioblastoma cell proliferation. Cells were incubated with the respective 
compound (250nM) and the relative cell number was determined after 72h using a MTT-assay. Data are 
normalized with the absorbance in the solvent (DMSO) only control set as 1 and represent the mean values of 
duplicates ±SEM, error bars correspond to SEM. Blue bars correspond to the most active compounds, which 
decreased proliferation in both parental cell lines more than 50%, orange bars to compounds with 30-50% 
inhibition and grey bars to compounds with little effect on cell proliferation. 
A: U87 wild-type cells, B: Gli36 wild-type cells 
 
Figure 65 Comparison of the inhibitory effects on proliferation of U87 and Gli36 wild-type cells 
Scatter blot showing the relative cell numbers after 72h incubation with the compounds (250nM) with the 
DMSO treated sample set to 1. Boxes: compounds which inhibit cell proliferation more than 50% (red box) or 
more than 30% (green box) in both cell lines. Data points represent the mean value of duplicates.  
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To identify compounds that selectively inhibit proliferation of the EGFRvIII-containing cell 
lines, the inhibitory effects of all 88 compounds on the proliferation of the parental cell line 
and on the respective EGFRvIII-expressing cell line was correlated. Whereas there was only 
little difference in the Gli36 cells, three compounds (A11, C1, C10) preferentially diminished 
the proliferation of the U87-EGFRvIII cell line (Figure 66). 
 
Figure 66 Correlation between relative cell numbers of parental wild-type and EGFRvIII expressing cell 
lines after treatment with 3rd generation Secin chemotypes 
Scatter blot showing the relative cell numbers (left: U87, right: Gli36) after 72h incubation with the compounds 
(250nM). The DMSO treated sample set to 1. Most selective compounds are labeled. Data points represent the 
mean value of duplicates (p<0.0001, U87 r=0.71, Gli36 r=0.76). 
A secondary screen of 14 compounds (11 pan- and 3 selective inhibitors) confirmed the 
results of the primary screen and showed dose-dependent effects for all test compounds.  
After this second screen five compounds were selected for further testing: compounds B7 and 
B8 as the most potent pan-inhibitors and compounds A11, C1, C10 as EGFRvIII-selective 
inhibitors. These compounds were again re-screened at concentrations ranging from 2.5nM to 
2µM to determine IC50 values and to test whether there was significant difference in IC50 
values between the parental and EGFRvIII-containing cell line (Figure 67). Whereas B7 and 
B8 showed a very potent inhibition of cell proliferation in all four cell lines, C1 selectively 
inhibited the proliferation of the EGFRvIII-containing cells. This effect was most prominent 
in the U87 cell lines. C1 diminished the proliferation of U87 EGFRvIII-cells more than 10-
fold better compared to the parental cell line. IC50 values for all 5 compounds in comparison 
to Secin16 are shown in Table 5. 
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Figure 67 Inhibition of glioma cell proliferation by third generation Secins 
Cells were treated 72h with the respective compound or solvent only (DMSO). Relative cell numbers (solvent 
only control set as 1) are shown. ± SEM, n=3, for each cell line. 
IC50/Compound B7 B8 A11 C1 C10 Secin16 
U87 wt 28nM ± 1.3 106nM ± 1.2 1366nM ± 1.4 2086nM ±1.2 922nM ± 1.5 958nM ± 1.4
U87 EGFRvIII 83nM ± 1.2 126nM ± 1.2 198nM ± 1.3 186nM ± 1.2 224nM ± 1.3 453nM ± 1.3
Gli36 40nM ± 1.6 102nM ± 1.2 589nM ± 1.3 732nM ± 1.2 609nM ± 1.3 750nM ± 1.5
Gli36 EGFRvIII 35nM ± 1.5 92nM ± 1.3 360nM ± 1.3 314nM ± 1.1 279nM ± 1.5 724nM ± 1.8
 
Table 5 IC50 values for inhibition of glioblastoma cell proliferation 
Numbers represent IC50 values ±SEM (error of the fit!) for the two most potent (B7 and B8) and three selective 
(A11, C1, C10) compounds in the glioblastoma cell proliferation assay. Secin16 is shown for comparison. Each 
individual experiment was performed at least three times. 
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Furthermore I also analyzed compounds A5, A6, B5 and B6, which showed an inhibition of 
<30% in the primary screen, and compounds D3 and D6, which were among the 6 most 
potent inhibitors for GDP/GTP exchange on ARF1, for their potential to inhibit proliferation 
of U87 wild-type and U87 EGFRvIII cells. Table 6 gives an overview of the obtained IC50 
values. 
 
IC50/Compound A5 A6 B5 B6 D3 D6 
U87 wt 168nM ± 1.8 243nM ± 1.3 118nM ± 1.7 89nM ±1.9 297nM ± 1.6 367nM ± 1.9
U87 EGFRvIII 46nM ± 1.2 67nM ± 1.2 148nM ± 1.3 372nM ± 1.2 105nM ± 1.3 84nM ± 1.3
 
Table 6 IC50 values of 3rd generation Secin chemotypes for the inhibition of glioblastoma cell 
proliferation 
Numbers represent IC50 ±SEM values (error of the fit!) for the indicated compounds in the glioblastoma cell 
proliferation assay. Each individual experiment was performed at least three times. 
In conclusion these results define a new class of potent inhibitors for glioblastoma cell 
proliferation including potential EGFRvIII selective inhibitors. 
 
IV.3.2 GDP/GTP- exchange assay versus glioma cell proliferation 
The Sec7 domain of cytohesins was found to mediate activation of ErbB receptors in lung 
human adenocarcinoma derived cell lines, while not requiring the GEF function of this 
domain.  
To investigate whether inhibition of glioblastoma cell proliferation by 3rd generation Secin 
chemotypes is caused by an interference of the compounds with the GEF-independent 
function of cytohesins or is a mere consequence of decreased GEF-activity, I correlated the 
relative inhibitory activity of the compounds in the exchange assay with their relative effect on 
proliferation of the parental cell lines. The scatter blots revealed a significant positive 
correlation between the inhibitory effect of the compounds (2.5µM) on the exchange activity 
of the cytohesins (Figure 68) and the inhibition of cell proliferation (250nM) in both parental 
cell lines (p<0.0001, r=0.6 U87, r=0.67 Gli36, data normalized, Secin16 set to 1).  
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Figure 68 Correlation between the inhibitory effect of 3rd generation Secin chemotypes on GDP/GTP-
exchange and cell proliferation 
Scatter blots (left: U87, right: Gli36 cells) showing the relative exchange activity in presence of the respective 
compound (2,5µM) and the relative cell numbers after 72h incubation with the compounds (250nM).The Secin16 
treated sample set to 1. Boxes: compounds which inhibited cell proliferation more than 50% (red box) or more 
than 30% (green box) in both cell lines. Data points represent the mean value of duplicates (p<0.0001, r=0.6 
U87, r=0.67 Gli36). Correlation was analyzed using the Pearson model. 
Furthermore I compared the obtained IC50 values for inhibition of the GDP/GTP exchange 
on ARF1 with the IC50 values for inhibition of cell proliferation in U87 and U87 EGFRvIII 
cells (Figure 69). Statistical analysis revealed a highly significant correlation (***, p<0.0001, 
r=0.94) between the IC50 values obtained in both assays. Beyond, a significant correlation 
between the IC50 value obtained in the exchange assay and for the inhibition of U87 
EGFRvIII proliferation was found when the selective compounds A11, C1 and C10 were 
omitted (*, p=0.01, r=0.76).  
 
Figure 69 Correlation between the IC50 values in cell proliferation and GDP/GTP exchange 
Scatter blots showing the obtained IC50 values for inhibition of cell proliferation and cytohesin catalyzed 
GDP/GTP-exchange on ARF1. Correlation was analyzed using the Pearson model.  
Left: U87 wild-type cells, ***, p<0.0001, r=0.94 
Right: U87 EGFRvIII cells, *, p=0.01, r=0.76. The red box indicates selective compounds. 
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In summary these data implicate a correlation between the inhibitory activity on the 
GDP/GTP-exchange on ARF1 and the potential to inhibit proliferation of glioblastoma cell 
lines.  
 
IV.3.3 Third generation SecinH3 chemotypes induce distinct 
phenotypes in glioblastoma cells 
To further elucidate the effect of third generation SecinH3 chemotypes on the proliferation of 
glioblastoma cells, I examined the phenotypes of U87, U87 EGFRvIII, Gli36 and Gli36 
EGFRvIII after 18h/36h treatment with 2µM of B7, A11, C1, 5µM Secin16, 15µM SecinH3 
or solvent (0.4% DMSO) alone. Figure 70 displays representative micro photographs of 
treated cells after 18h and 36h incubation with the indicated compounds.  
Only B7 affected the growth of the typically outstretched, foci forming U87 wild-type cells, 
detected as a decrease in total cell number. Whereas C10 and A11 had only little effect on the 
proliferation of the parental U87 cell line, both compounds clearly reduced the number of 
vital cells in the EGFRvIII expressing U87 cell line, underlining the observed selectivity for 
EGFRvIII expressing cells. Similar to its effect on the parental cell line, B7 simply diminished 
the total number of U87 EGFRvIII cells without affecting the appearance of the cells. On the 
other hand, C10 and A11 dramatically altered the phenotypes of the cells. U87 EGFRvIII cells 
normally appear as fusiforme cells. Treatment of these cells with C10 or A11resulted in more 
rounded phenotype and an increase in detached, floating cells. Again SecinH3 and Secin16 
showed no effect. 
The same result was obtained for Gli36 wild-type and Gli36 EGFRvIII expressing cells. Again 
B7 reduced the cell number of both cell lines, without altering the phenotype of the cells. In 
contrast, C10 and A11, only slightly influenced proliferation of the wild-type Gli36 cells but 
clearly reduced the number of attached, vital Gli36 EGFRvIII cells. Whereas Secin16 
inhibited the proliferation of EGFRvIII expressing Gli36 cells, SecinH3 had no effect on 
either cell line. 
Taken together, these data confirm the high potency of B7 to inhibit glioblastoma cell 
proliferation and indicate a distinct effect of C10 and A11 on EGFRvIII expressing 
glioblastoma cells.  
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Figure 70 Phenotypes of glioblastoma cells after treatment with third generation Secins 
Representative microphotographs of glioblastoma cells after treatment with the indicated compounds (15µM 
SecinH3, 2µM C1, B7, A11, 5µM Secin16) or DMSO (0.4%, untreated). 
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IV.3.4 Compounds A11, C1 and C10 induce apoptosis selectively in 
EGFRvIII expressing glioblastoma cells  
The obtained reduction in cell number after treatment of glioblastoma cells with the 
compounds Secin16, B7, A11 or C10 might be due to the induction of a resting state or an 
increase in apoptosis due to the lack of pro-proliferation signals. Therefore, the distinct 
phenotypes observed after treatment with the compounds suggest different fates of the cells.  
To test this possibility I performed an Annexin V apoptosis assay by flow cytometry as 
described above. I preincubated U87/Gli36 wt or EGFRvIII expressing cells for 48h with 
5µM Secin16, 2µM B7, A11, C1 or C10 or solvent (0.4%DMSO) in basal medium containing 
1% FBS, harvested by trypsinization and stained the cells with a FITC-labelled form of 
Annexin V and with TOPRO 3 iodide. I analyzed the cells by flow cytometry as previously 
described. 
 
Figure 71 Selective third generation Secins induce apoptosis in EGFRvIII expressing glioblastoma cell 
lines 
Quantitative analysis of apoptotic glioblastoma cells (quadrants 2-4) after 48h treatment with solvent (0.4% 
DMSO) or 2µM A11, C1, C10 (*** p<0.001, ** p<0.01, ** p<0.05, n=3). 
Whereas Secin16 and B7 had no effect in any cell line (data not shown), treatment with 
compounds A11, C1 and C10 led to a significant increase in apoptotic cells (defines as 
quadrants 2-4) most pronounced in EGFRvIII expressing cells as compared to the wild-type 
cells (Figure 71). Again, the selective effect was more distinct in the U87 cell line. These data 
support the selectivity of compounds A11, C1 and C10 for EGFRvIII expressing glioblastoma 
cell lines and are in line with the observed distinct phenotype of rounded, detached cells 
induced by treatment with A11 or C10, which is likely explained by apoptosis. B7 and Secin16 
do neither induce apoptosis nor change the phenotype of the cells, but inhibit glioblastoma 
cell proliferation. This finding might indicate a different mode of cell proliferation inhibition, 
like the induction of a resting state. 
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IV.3.5 Effect of compounds A11, C1 and C10 on EGFR 
phosphorylation 
Having shown that chemical inhibition of cytohesins leads to a decreased EGFR activation in 
human lung and breast adenocarcinoma derived cell lines, I investigated whether the selective 
effect of A11, C1 and C10 on the proliferation of EGFRvIII expressing U87 glioblastoma 
cells can be explained by reduced EGFR signaling.  
Therefore, I treated the cells overnight with 5µM A11, C1, C10 or 2µM B7 (highest possible 
concentration due to the weak solubility) in basal media containing 1% FBS (0.4% DMSO end 
concentration). Wildtype U87 cells were stimulated with 50ng/ml EGF for 5min at 37°C 
before harvesting. EGFRvIII expressing U87 were harvested without stimulation, since 
addition of EGF showed no increase in EGFR phosphorylation. Phosphorylation levels of 
EGFR were detected as described using immunoblotting and an antibody against pY1068 of 
EGFR.  
 
Figure 72 Third generation Secins do not inhibit EGFR phosphorylation in U87 cells 
Quantitative analysis of EGFR phosphorylation (EGFR_Y1086) after overnight treatment of U87 wild-type and 
U87 EGFRvIII cells with the indicated compounds (2µM B7, 5µM A11, C1, C10). Data are represented as mean 
±SEM, n≥2.  
Treatment of wild-type U87 cells with B7, A11 and C10 resulted in a weak inhibition of 
EGFR phosphorylation (Figure 72). Although the cells showed severe changes in the 
phenotype (rounding, detaching, and beginning fragmentation) no clear effect on the 
phosphorylation level of EGFR could be observed in the EGFRvIII expressing U87 cells, 
indicating that the induction of apoptosis is not a results of EGFR inhibition.  
 
IV.3.6 Compounds A11, C1 and C10 influence repair of DNA double 
strand breaks in glioblastoma cells  
Apoptosis can be induced by several intracellular and extracellular stimuli.One of the most 
potent inducer of apoptosis is DNA damage [133]. Every cell is under constant attack not 
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only from exogenous also from endogenous mutagenic influences (chemicals, radiation, free 
radicals) causing DNA damage. The accumulation of DNA damage can lead to oncogenesis, 
cell death, and severe dysfunction of cells. Therefore, the DNA repair system is crucially 
important for survival of cells. In most cells an elevated level of DNA damage causes delay in 
the cell cycle via checkpoint mechanisms, which ensure that DNA damage is repaired before a 
cell divides. Accumulation of DNA damage, however, leads to apoptotic cell death. 
DNA damage targeting the bases or nucleotides itself typically involves only one strand 
(single-strand break), preserving the information of the other strand. An accidental lesion on 
one strand can therefore be cut out and resynthesized by referring to the information in the 
undamaged strand (base and nucleotide excision repair). Repair of double-strand brakes in the 
DNA helix, however, often leads to rearrangements in the DNA sequence. The repair of 
double-strand breaks in somatic cells is mediated through non-homologous or homologous 
recombinatorial repair. In non-homologous repair (non-homologous end-joining, NHEJ) the 
broken ends of both strands are simply brought together and rejoined by DNA ligation, 
leading to the loss of one or more nucleotides at the site of joining. On the other hand, 
homologous recombination results in the transfer of genetic information between two DNA 
duplex segments of similar nucleotide sequence and is essential for both, the error-free repair 
of chromosome damage in all cells and for crossing-over of chromosomes that occur during 
meiosis. The recombination event is guided by a specialized set of proteins, involving the 
mammalian homolog of RecA, called RAD51. Binding of RAD51 to double-strand breaks in 
the DNA helix is initiated by the phosphorylation of a member of the histone family H2A, 
which is one of the five types of histones that package and organize eukaryotic DNA into 
chromatin. In response to double-strand breaks, the conserved C-terminal tail of H2AX 
becomes rapidly phosphorylated at serine-139 by PI3-K like kinases, including ATM, ATR 
and DNA-PKcs (DNA-dependent protein kinase catalytic subunits). The phosphorylated 
H2AX, named γH2AX, is one of the first proteins involved in DNA damage response 
pathways and is required for DNA damage signal amplification and subsequent accumulation 
of numerous repair proteins (like RAD51) at double-strand breaks sites [134-136]. 
To test whether the induction of apoptosis in EGFRvIII expressing glioblastoma cells 
induced by treatment with the selective compounds A11, C1 and C10 is caused by an 
accumulation of double-strand breaks, I incubated wild-type or EGFRvIII expressing Gli36 
cells for 24h with 2µM of A11, B7, C1, C10 or Secin16. Cell lysates were subjected to SDS-
PAGE followed by immunoblotting. Levels of RAD51 or γH2AX were detected by using 
specific antibodies.  
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Figure 73 Third generation Secins lead to an increase in DNA double-strand breaks in glioblastoma 
Quantitative western blot analysis of RAD51 and γH2AX levels in Gli36 glioblastoma cells after 24h treatment 
with 2µM of the indicated compounds (Secin16 5µM). Data are represented as the mean ±SEM of relative 
expression levels, with the solvent (DMSO) treated sample set to 1, n=2-3.  
Whereas treatment of wild-type Gli36 cells with the selective compounds A11, C1 and C10 
only weakly induces phosphorylation of H2AX, it resulted in a strong increase in γH2AX in 
EGFRvIII expressing Gli36 cells, indicating an accumulation of double-strand breaks in these 
cells (Figure 73, right panel). B7 and Secin16 had no effect on the level of γH2AX in either 
cell line, demonstrating once more the differential mode of inhibition. An increase in 
phosphorylation of H2AX and thereby an increase in double-strand breaks can be either 
caused by facilitating double-strand breaks or by inhibition of double-strand break repair and 
the subsequent accumulation of double-strand breaks. To distinguish between these 
possibilities I detected the protein level of RAD51. The increase in γH2AX was accompanied 
by a reduction in RAD51 protein level, rather than an increase in RAD51 expression due to 
enhanced double-strand repair activity, indicating an effect of the compounds on double-
strand repair (Figure 73, left panel). Again, the effect on RAD51 expression level was more 
pronounced in EGFRvIII expressing Gli36 cells as compared to the wild-type cell line. B7 and 
Secin16 showed no effect on RAD51 protein level in EGFRvIII Gli36 cells.  
To gain further insight into the underlying mechanism of the EGFRvIII selective proliferation 
inhibition and the subsequent induction of apoptotic cell death in Gli36 cells, I performed a 
kinetic for the appearance of double-strand breaks after treatment with C1. Therefore, I 
incubated the cells 4h, 8h or 24h with 2µM C1 as described above. To exclude any effects due 
to different proliferation times all cells were harvested at the same time, after transfer in basal 
media containing 1% FBS and addition of C1 at the indicated time points. In addition, 
untreated cells were analyzed for every time point.  
Figure 74 depicts a representative blot for detection of RAD51 and γH2AX. In correlation 
with the previous experiments, γH2AX level was elevated in cells treated with C1 after 24h, 
accompanied by a decrease in RAD51 protein level. Shorter incubation times had no effect. 
RAD51
Gli36 wt Gli36 EGFRvIII
0.0
0.5
1.0
1.5
DMSO
A11
B7
C1
C10
Secin16
re
la
tiv
e 
le
ve
l o
f R
AD
51
yH2AX
Gli36 wt Gli36 EGFRvIII
0
2
4
6
8
DMSO
A11
B7
C1
C10
Secin16
re
la
tiv
e 
le
ve
l o
f y
H
2A
X
Results  
 
 
 - 94 - 
Again, the effect in EGFRvIII expressing Gli36 cells was more pronounced compared to the 
wild-type cell line.  
 
Figure 74 Kinetic for C1 induced accumulation of DNA double-strand breaks 
Gli36 wild-type or EGFRvIII expressing cells were treated for the indicated time periods with 2µM C1. RAD51 
and γH2AX levels were detected by western blotting using specific antibodies. Hsc70 served as loading control. 
Taken together, these data suggest an accumulation of double-strand breaks due to reduced 
RAD51 levels in cells treated with compounds A11, C1 and C10, which subsequently leads to 
increased apoptotic cell death. Hence, the selective effect of the compounds might be 
explained by the slightly higher proliferation rate of EGFRvIII expressing cells. A higher 
replication rate could facilitate replication prone double-strand breaks. Reduced RAD51 
expression levels, would lead to a faster accumulation of double-strand breaks and to 
induction of apoptosis in EGFRvIII expressing cells. 
Unfortunately, no signals for RAD51 or γH2AX could be obtained in U87 cells.  
 
IV.3.7 EGFRvIII expressing glioblastoma cell lines show an increase 
in ARF6 expression 
Recently it has been shown, that ARF6 is required for EGF dependent proliferation of 
glioblastoma cells [137]. However, the precise mechanism is still unknown. Since the third 
generation SecinH3 chemotypes bore a high inhibitory effect on the cytohesin catalyzed 
GDP/GTP-exchange on ARF1 in vitro and also decreased ARF6 activation in cells (data not 
shown), the selectivity for EGFRvIII expressing cells might be explained by a higher 
dependency on ARF6 activity. To investigate this hypothesis, I analyzed the expression level 
of ARF1 and ARF6 in wild-type and EGFRvIII expressing U87 and Gli36 glioblastoma cells 
by quantitative real-time PCR.  
Figure 75 depicts the relative expression of ARF1 and ARF6 in EGFRvIII expressing cells 
normalized to the respective expression in wild-type cells. ARF6 showed a ~6fold higher 
expression in EGFRvIII expressing U87 cells as compared to the wild-type cell line. 
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Expression of ARF1 was almost doubled. In EGFRvIII expressing Gli36 cells, both ARF1 
and ARF6 expression level were elevated ~2fold as compared to the wild-type cell line.  
 
Figure 75 ARF expression is increased in EGFRvIII expressing glioblastoma cell lines 
Quantitative PCR analysis of ARF1 and ARF6 expression levels in EGFRvIII expressing glioblastoma cells in 
comparison to wild-type glioblastoma cells. Bars represent the relative increase in ARF expression (mean ±SEM, 
n=3) as compared to the respective wild-type cell line.  
These results might indicate an increased dependency of EGFRvIII expressing glioblastoma 
cells on ARF proteins and might provide an explanation for the observed high sensitivity of 
EGFRvIII expressing cells for the tested cytohesin inhibitors.  
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IV.4 A new real-time FRET-based assay to monitor 
GDP/GTP exchange on N∆17ARF1 
IV.4.1 Recent approaches 
Multiple techniques are available to study the activation of small GTPases by their GEFs 
[138]. Based on the step of the activation reaction used for analysis they can be divided in 
different classes: The first group directly monitors the activation of the GTPase by utilizing 
conformational changes induced upon binding of the GEF and the subsequent exchange of 
the nucleotide. As an alternative, one can directly measure binding of GTP to the GTPase 
which is relative to the exchange rate of the protein. The third group of assays is based on the 
selective interaction of the activated GTP-bound GTPase with its effector protein. Whereas 
the first two methods are based on fluorescence spectroscopy which allows for real-time 
monitoring, analysis of protein interactions are commonly end point measurements lacking 
kinetic information.  
ARF1 lacking the first 17 amino acids (N∆17ARF1) is the most often used ARF protein to 
measure GDP/GTP exchange in vitro. The lack of the N-terminal part of the proteins 
renders its activation independent from the presence of liposomes. Various assays to monitor 
GDP/GTP exchange on N∆17ARF1, referring to all three classes described, can be found in 
literature. The most abundant assay is based on the change in the tryptophan fluorescence of 
N∆17ARF1 upon activation by its GEF, which can be monitored in real-time by measuring 
tryptophan excitation and emission at 280/340nm, respectively [127]. However, some small 
molecules show a strong absorption of light, especially of shorter wavelength and may 
interfere with the intrinsic fluorescence assay. An alternative approach to measure the GEF-
catalyzed activation of N∆17ARF1 is to use GDP or GTP analogs labeled with an 
environment sensitive fluorescent group, like N-methylanthranyloyl (or mant) group [139-
140]. The fluorescence of the mant GDP/GTP analogs is sensitive to the environment of the 
fluorophore, exhibiting both an increased fluorescence quantum yield upon protein binding 
and a blue-shift of 10–20 nm in fluorescence emission maximum. Mant guanine nucleotides 
can be excited at a wavelength of ~360nm and show protein-binding dependent emission at 
440nm, remote from the wavelength region where proteins or small molecules absorb. By 
using mant-nucleotides, activation of N∆17ARF1 can be followed kinetically in two ways: 
First one can simply monitor binding of mant-GTP to N∆17ARF1, by measuring the 
fluorescence of mant-GTP at ex360/em440nm. As a variant, the displacement of mant-GDP 
by GTP on mant-GDP preloaded N∆17ARF1 can also be measured. Furthermore, it is 
possible to use fluorescence resonance energy transfer (FRET) between tryptophan and mant 
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nucleotide to follow the exchange reaction (ex280nm/em440nm). Here the tryptophan 
residue is excited and acts as a donor to induce the fluorescence of the acceptor mant group. 
Although the mant fluorescent group is small and in general does not disturb the binding of 
small molecules, this point has to be considered when using mant-labeled nucleotides. 
A different, fluorescence independent approach to measure GDP/GTP exchange on 
N∆17ARF1 makes use of radioactive labeled nucleotides [127]. For this purpose, the exchange 
reaction is conducted in the presence of radioactive labeled GTP. GTP loading on 
N∆17ARF1 is detected after washing and separation of N∆17ARF1 by quantification of the 
bound radioactivity. To prevent hydrolysis of the bound GTP, an uncleavable form of GTP, 
in which the γ-phosphate group is substituted by sulfur (GTPγS), is commonly used in these 
kinds of experiments. However, because of limited sample number, determination of kinetic 
parameters is difficult.  
The last group of assays is based on the specific interactions of ARF1-GTP with its effector 
proteins, which mediate ARF1 function [141]. ARF1-GTP is an important regulator of 
membrane traffic and binds to coat proteins such as coatomers, clathrin adaptor protein (AP) 
complexes 1 and 3, and γ-adaptin homology‐Golgi associated ARF‐binding (GGA) proteins 
[142-143]. By binding to ARF-GTP these proteins are recruited to the cell membrane where 
they initiate the formation of transport vesicles. Whereas coatomers and AP proteins exist as 
multimeric protein complexes, the GGA proteins are monomeric polypeptides, which are 
comprised of four domains: VHS (binds to DXXLL sorting motifs), GAT (binds ARF-GTP), 
hinge (binds clathrin), and GAE (binds various proteins involved in vesicle formation). The 
GAT domain of GGAs 1-3, which can be expressed separately in bacteria, specifically interact 
with the switch regions 1 and 2 of ARF1-GTP and can be used as a tool to quantify the 
amount of ARF1-GTP in vitro and in vivo. For this purpose, a GTS tagged GGA-GAT 
domain can be added to an exchange reaction or cell lysate and after precipitation of GGA-
GAT the amount of bound N∆17ARF1-GTP can be detected by SDS-PAGE and western 
blotting [138]. Although this technique provides important information about the ability of 
N∆17ARF1 to interact with its endogenous effector protein in the presence of a small 
molecule, it is very elaborate and therefore incompatible with high throughput screening 
approaches. 
In order to combine the advantages of the rapid and high-sensitive real-time fluorescence 
measurements with the possibility to identify small molecule inhibitors of the interaction 
between N∆17ARF1-GTP and GGA3, I developed a new FRET-based assay for the 
cytohesin catalyzed GDP/GTP exchange on N∆17ARF1.  
 
Results  
 
 
 - 98 - 
IV.4.2 A new FRET-based assay for the cytohesin catalyzed 
GDP/GTP exchange on N∆17ARF1 
Figure 76 displays the principles of the assay. N∆17ARF1, C-terminally tagged with the 
fluorescent protein CyPET, is preloaded with GDP in the presence of EDTA and 
subsequently incubated with the Sec7 domain of ARNO. To monitor binding of N∆17ARF1-
CyPET-GTP to its effector protein GGA3, GGA3-GAT domain with its N-terminus fused to 
the fluorescent protein YPET is added. After starting the exchange reaction by addition of 
GTP, one can follow N∆17ARF1-CyPet activation by detection of tryptophan fluorescence at 
ex280/em340 nm. Furthermore, binding of N∆17ARF1-CyPET-GTP to YPET-GGA3 can 
be analyzed in real-time by FRET between the CyPET moiety of N∆17ARF-CyPET and the 
YPET moiety of YPET-GGA3 at ex436/em535 nm at the same time.  
CyPET is excited at 436nm and acts as a donor to induce fluorescence of YPET. CyPET and 
YPET are FRET-optimized variants of the fluorescence proteins CFP and YFP, respectively, 
and have been recently used to monitor ARF6 activation in living cells [144]. Since 
fluorescence energy transfer critically depends on the proximity of the two fluorophores 
involved, binding of GTP-loaded N∆17ARF-CyPET to YPET-GGA3 leads to an increase in 
FRET between CyPET and YPET, and therefore to enhanced emission of YPET at 535nm.   
 
 
Figure 76 A FRET-based assay for the cytohesin catalyzed GDP/GTP exchange on N∆17ARF1 
GDP preloaded N∆17ARF1-CyPET is incubated with the Sec7 of ARNO and YPET-GGA3. The exchange 
reaction is started upon addition of GTP. Conformational changes caused by GDP/GTP exchange on 
N∆17ARF1-CyPET are detected by tryptophan fluorescence (ex280/em340nm). Simultaneously, the amount of 
GTP loaded N∆17ARF1-CyPET in the reaction can be monitored by FRET (ex436/em535), resulting from the 
interaction between N∆17ARF1-CyPET-GTP with YPET-GGA3.  
 
IV.4.2.1 Proof of principle I: The FRET signal depends on the 
concentration of YPET-GGA3 
To test whether GDP/GTP exchange on N∆17ARF-CyPET can still be induced by ARNO-
Sec7 in the presence of YPET-GGA3, I measured the exchange on N∆17ARF-CyPET 
(0.7µM) in the presence and absence of ARNO-Sec7 (15nM) and added increasing amounts of 
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YPET-GGA3 (0.2-1µM) to the reaction. All measurements were performed in PBS, pH 7.4, 
3mM MgCl2 at 37°C in black 96well plates, in a total volume of 200µl. 
 
 
Figure 77 The FRET signal depends on the concentration of YPET-GGA3 
A/C: Detected tryptophan fluorescence (A) or FRET (C) of N∆17ARF1-CyPET in the presence (black, red, 
green, blue) or absence (orange) of ARNO-Sec7 or different concentrations of YPET-GGA3 (red, green, blue). 
The slope of the reaction was calculated by fitting the linear increase in tryptophan fluorescence or FRET by 
linear regression (shown as a line). 
B/D: Calculated slope for the initial increase in tryptophan fluorescence (B) or FRET signal (D).The color 
scheme is the same as in A/C. 
All measurements were performed in PBS, pH 7.4, 3mM MgCl2 at 37°C in black 96well plates, in a total volume 
of 200µl and 0.7µM N∆17ARF1-CyPET. Fluorescence was measured every ~20sec. Data represent the means of 
duplicates of one representative measurement (out of three independent measurements). 
Figure 77 depicts the obtained signals at 280/340nm (exchange = tryptophan fluorescence, A) 
and 436/535nm (FRET = interaction between N∆17ARF-CyPET-GTP and YPET-GGA3, 
C) and the calculated slope for the initial, linear phase of the reaction (B, D). GDP/GTP 
exchange on N∆17ARF-CyPET critically depends on the presence of ARNO-Sec7 (Figure 76, 
black and orange bars). Although increasing amounts of YPET-GGA3 raised the fluorescence 
signal at the starting point due to higher absolute protein concentrations they did not 
influence the slope of the reaction (red, green, blue). Thus, YPET-GGA3 does not interfere 
with the Sec7-catalyzed exchange reaction. No FRET signal could be detected in the absence 
of YPET-GGA3 (black, Figure 77C/D). As expected, increasing amount of YPET-GGA3 
enhanced the FRET signal (red, green, blue), which was detected simultaneously to the 
tryptophan fluorescence, due to increased complex formation between ∆17ARF-CyPET-GTP 
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and YPET-GGA3. In agreement to tryptophan fluorescence, only a weak FRET signal was 
detected in the absence of ARNO-Sec7 with the highest concentration of YPET-GGA3 
(orange). Based on these results a concentration of 0.5µM of YPET-GGA3 was selected for 
further experiments.  
Taken together, these data show that fusion of ∆17ARF with CyPET does not interfere with 
its exchange activity and that the FRET-signal obtained for the interaction of ∆17ARF-
CyPET-GTP and YPET-GGA3 critically depends on the presence of ∆17ARF-CyPET-GTP 
and the concentration of YPET-GGA3. 
 
IV.4.2.2 Proof of principle II: The FRET signal depends on the amount of 
∆17ARF-CyPET-GTP 
To demonstrate, that different amounts of ∆17ARF-CyPET-GTP can be detected with this 
FRET assay, I conducted an exchange assay in the presence of increasing concentrations of 
ARNO-Sec7 (3.5-30nM) or ∆17ARF-CyPET (0.1-1.3µM). 
As expected, the measured slopes for tryptophan fluorescence were directly dependent on the 
concentration of ARNO-Sec7 and ∆17ARF-CyPET, reflecting increasing concentrations of 
∆17ARF-CyPET-GTP (Figure 78). The slopes of the signals obtained for FRET between 
∆17ARF-CyPET-GTP and YPET-GGA3 directly mirrored the slopes of the tryptophan 
fluorescence, demonstrating the suitability of this assay to quantitatively monitor the 
GDP/GTP exchange on ∆17ARF1.  
 
 
Figure 78 The FRET signal depends on the amount of N∆17ARF1-CyPET-GTP 
Calculated slope for the initial increase in tryptophan fluorescence (A) or FRET signal (B). Increasing 
concentrations of ARNO-Sec7 (0-30nM) were titrated to 0.7µM N∆17ARF1-CyPET (red bars) or the 
concentration of N∆17ARF1-CyPET was varied in the presence of 15nM ARNO-Sec7 (blue bars).  
All measurements were preformed in the presence of 0.5µM YPET-GGA3. 
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IV.4.2.3 Proof of principle III: The FRET-based assay is suitable for 
screening 
Next I examined whether the FRET based exchange assay is suited to detect chemical 
inhibition of cytohesins by SecinH3 and Secin16. For this purpose I performed an exchange 
assay on ∆17ARF1-CyPET in the presence of SecinH3 (15µM), Secin16 (2.5µM) or solvent 
(1%DMSO). As Figure 79 shows, inhibition of ARNO-Sec7 with SecinH3 or Secin16 is 
detected by a reduced slope in both, the tryptophan fluorescence (Figure 79A) and the FRET 
signal (Figure 79B). Again, both detection methods revealed consistent results. 
 
 
Figure 79 Inhibition of cytohesin with SecinH3 or Secin16 decreases the FRET signal for GDP/GTP 
exchange on ∆17ARF-CyPET 
Calculated slopes for the initial increase in tryptophan fluorescence (A) or FRET signal (B) of N∆17ARF1-
CyPET (0.7µM) in the presence of 15µM SecinH3 (red), 2.5µM Secin16 (orange) or solvent (0.4% DMSO, blue). 
All measurements were preformed in the presence of 0.5µM YPET-GGA3. Data represent the mean of 3 
independent measurements.  
To test the suitability of the FRET based GDP/GTP exchange assay on ∆17ARF1-CyPET 
for use as a screening assay, I determined the Z’-factor [130]. This factor reflects both the 
dynamic range of the signals (or the signal-to-noise-ratio) and the variation of the obtained 
signals and is therefore a useful tool to describe the quality of an assay system. For the 
tryptophan fluorescence as well as for FRET based detection of GDP/GTP exchange on 
∆17ARF1-CyPET a Z’-factor of 0.6 was calculated out of six independent measurements with 
the reaction in the presence or absence of ARNO-Sec7 used as a positive or negative control, 
respectively. This Z´-value rates the assay as being suitable for screening.  
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V Discussion 
V.1 Cytohesins are cytoplasmic ErbB receptor activators 
The known function of cytohesins is to act as a GEF on ARF proteins. In the last years, 
several publications furthermore implemented cytohesins in the regulation of cell signaling. 
Kliche et al. have shown that cytohesin-1 binds to and enhances the transforming potential of 
transmembrane protein kaposin A in tumor cells by selective activation of the mitogen-
associated protein (MAPK)-signaling pathway [88]. Recently, Hafner et al. reported the 
involvement of cytohesins in insulin-signaling. Inhibition of cytohesins with SecinH3 blocks 
the transcription of insulin-dependent genes in human HepG2 cells and in murine liver cells in 
vivo: SecinH3 most likely inhibits the binding of adapter molecules like IRS-1 (insulin receptor 
substrate 1) to the activated insulin receptor. In parallel, Fuss et al. described a Drosophila 
mutant in which expression of the only cytohesin homolog Steppke is strongly reduced [102]. 
These flies show the typical phenotype caused by diminished insulin signaling. These findings 
where substantiated by an additional study of Lim et al. showing that cytohesins interact with 
the Connector Enhancer of KSR1 (CNK1), thereby promoting insulin receptor signaling [96].  
 
The results described in this work are the first evidence that cytohesins act as cytoplasmic 
ErbB receptor activators. 
 
V.1.1 Inhibition of cytohesins reduces ErbB receptor signaling 
Treatment of H460 cells with the cytohesins antagonist SecinH3 reduces EGFR 
phosphorylation and signaling in H460 cells (Figure 13). This effect can be directly ascribed to 
cytohesin inhibition for the following reasons: First, transfection of the cytohesin specific 
aptamer M69 [95] mirrored the effect of SecinH3 (data not shown, experiments were done by 
Jin-Na Song [104]). Second, treatment with the control compound XH1009 [145] that is 
structurally related to SecinH3 but does neither bind nor inhibit cytohesins had no effect on 
EGFR phosphorylation (Figure 14). Third, knockdown of cytohesins with specific siRNAs 
also decreased EGFR phosphorylation (data not shown, experiments were done by Jin-Na 
Song). In addition, the re-expression of ARNO in siRNA-treated cells rescued the effect of 
ARNO knockdown in EGFR autophosphorylation (Figure 20), showing a direct connection 
between cytohesins protein level and EGFR phosphorylation. 
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Cytohesins are not only involved in EGFR signaling but in the signaling of the whole ErbB 
receptor subfamily of receptor tyrosine kinases (RTKs). In agreement, treatment of 
HER2/HER3 expressing SkBr3 cells with SecinH3 decreases HER3 phosphorylation and 
signaling (Figure 15). Again, the involvement of cytohesins in the activation of HER3 was 
confirmed by the aptamer M69, the control compound XH1009 and cytohesin specific 
siRNAs.  
Interestingly, M. Theis observed an inhibition of serum mediated MAPK activation upon 
treatment of HeLa cells with the cytohesin specific aptamers M69 and K61 [89], which might 
now be explained by ErbB receptor signaling inhibition.  
 
V.1.2 Cytohesins enhance ErbB receptor activation independently 
of their GEF activity 
Overexpression of cytohesin-2 (ARNO) enhances ligand-induced EGFR phosphorylation 
(H460 cells, Figure 16) and HER3 phosphorylation (SkBr3 cells, Figure 17). In this thesis, 
ARNO was selected for all overexpression studies, since it shows higher expression than 
cytohesin-1 and -3 in both cell lines. 
The Sec7 domain of ARNO is sufficient to enhance ligand-induced EGFR phosphorylation 
(Figure 18). However, overexpression studies with the GEF-inactive ARNO mutant ARNO-
E156K [79] showed that the GEF activity of the Sec7 domain is not required for the ARNO-
mediated activation of ErbB receptors (Figure 19). The ability of ARNO-E156K to enhance 
ErbB receptor activation is not due to its overexpression. This is because ARNO-E156K 
expressed as endogenous ARNO protein level is able to rescue the inhibition of EGFR 
phosphorylation induced by ARNO knockdown (Figure 20).  
Besides, knockdown of neither ARF1 nor ARF6 by RNA interference had an influence on the 
activation of the EGFR (data not shown, experiments were done by Jin-Na Song [104]), 
substantiating the finding that the cytohesin-mediated activation of ErbB receptors is 
independent of GEF activity.  
Summing up, cytohesins facilitate the activation of ErbB receptors in a GEF-activity 
independent mechanism.  
These results establish a new function of cytohesins, since the so far described functions of 
cytohesins in cell signaling all depend on the GEF activity of those proteins. Only two reports 
of GEF-independent activity of cytohesins can be found in the literature. Firstly, Theis et al. 
developed an aptamer that specifically binds to cytohesin-2 without disturbing the GEF 
activity toward ARF1. Transfected into HeLa cells this aptamer abrogated MAP-signaling and 
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reporter gene transcription directed by serum response elements [89]. Based on the function 
of cytohesins as ErbB receptor activators described in this work, the inhibition of MAPK 
signaling might be explained by reduced ErbB signaling due to cytohesin inhibition. Secondly, 
Kolanus et al. identified cytohesin-1 as a regulator of integrin β binding to ICAM-1 in immune 
cells [83]. The GEF-inactive cytohesin E157K enhanced integrin β binding to ICAM-1 as 
efficiently as the wild-type protein [87]. Interestingly, the Sec7 domain of cytohesin-1 was 
found to be sufficient for interaction with integrin β. However, the presence of the PH 
domain is crucial for cytohesin-mediated integrin activation [80, 83]. 
The finding that the Sec7 domain of cytohesins is sufficient to mediate activation of ErbB 
receptors while not requiring the GEF function of this domain, thus implicate a hitherto 
unknown GEF-independent function of cytohesins.  
SecinH3 targets the Sec7 domain of cytohesins and inhibits its GEF function [90, 145]. The 
finding that cytohesin-mediated activation of ErbB receptors is independent of GEF activity 
raises the question, why SecinH3 inhibits cytohesin-mediated ErbB receptor activation.  
To address this point it is important to consider that SecinH3 was identified as a cytohesin 
Sec7-domain inhibitor completely independently of whether or not the binding had an effect 
on the GEF activity of the Sec7 domain [90]. Thus, SecinH3 (which stands for Sec7-domain 
inhibitor) should be seen as a Sec7 inhibitor rather than (exclusively) as a GEF inhibitor. 
Apparently, binding of SecinH3 to the Sec7 domain inhibits both, the GEF-dependent and 
the GEF-independent functions of this domain. To understand the molecular basis of this 
dual function of the Sec7 domain as well as the inhibitory function of SecinH3 on GEF 
activity and ErbB receptor activation, the EGFR should be co-crystallized with the Sec7 
domain in both the presence and absence of SecinH3. Such an analysis will give more insights 
into the mechanism of cytohesin-mediated ErbB receptor activation that can be useful to 
explain the inhibitory function of SecinH3.  
 
V.1.3 Cytohesins facilitate a conformational rearrangement in the 
intracellular domains of EGFR dimers 
Activation of ErbB receptors was originally considered to result solely from the ligand 
induced dimerization of the intracellular domains which leads to subsequent kinase activation 
[22]. From crystallographic, biochemical and biophysical data it is becoming increasingly 
evident that EGFR dimerization and activation of the kinase domains are distinctly regulated 
and thoroughly balanced processes. The mechanisms by which this balance is achieved are still 
largely elusive.  
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In 2002, two papers were published back to back shedding new light on the ligand induced 
dimerization of EGFR. The studies of Garret et al. and Ogiso et al. [15-16] redeem the prior 
model, in which the bivalent ligand, by binding to both receptor monomers, functions as a 
clamp driving receptor dimerization [13], as it can often be found in receptor tyrosine kinases. 
Opposed of this, EGFR dimerization is solely mediated by receptor-receptor contacts 
facilitated by rearrangements of the extracellular domains due to ligand binding (see 
introduction). Although these data enormously advanced the understanding of EGFR 
activation, there are still some open questions that cannot be explained by this model. Since 
the early studies of EGFR, it has been known that there are two affinity classes for EGF 
binding to its cell surface receptor [146]. Several studies try to correlate the two affinity states 
of EGFR with the current models, but come to conflicting results [17, 147-148]. Another 
issue is the existence of preformed EGFR dimers on the cell surface, showing that the mere 
dimerization of the EGFR is not sufficient for activation [149-151]. Recent crystallographic 
studies extend the model of dimerization-driven EGFR activation by the finding, that only a 
subset of the dimers are catalytically active. These are those that adopt a distinct conformation 
called the asymmetric dimers, where one kinase acts as an allosteric activator for the other [23, 
25-26] (see introduction, II.1.4.2). Activity studies with the purified kinase domains indicate 
the existence of an autoinhibited state of the kinase domains and further substantiate an 
allosteric model of EGFR activation, in which the activation of EGFR results from the 
intrinsic ability of the receptor kinase domains to form active (asymmetric) dimers as soon as 
they are released from their default autoinhibited state [23, 152-155]. The only activator 
required in this model is the ligand itself, which binds to the ectodomain of the receptor and 
induces or stabilizes the structural rearrangements that release the kinase domains from their 
autoinhibited state [17, 47]. The finding that EGFR activation is enhanced by cytohesins 
indicates that EGFR activation is likely not to be comprehensively explained by ligand-
induced release from autoinhibition and the subsequent spontaneous formation of the 
asymmetric dimer. The question arises, how the cytohesins can be implemented into this 
system. 
ErbB receptor clustering on the cell membrane has been intensively discussed in the literature 
as an additional effect that may affect ErbB receptor activation. However, several studies have 
reported contradictory findings about the connection between ErbB activation and receptor 
clustering [156-158]. These contradictions may be due to the application of different imaging 
methods with different resolution scales or to varying expression levels of the studied 
receptors. In our system, using superresolution light microscopy (STED microscopy = 
stimulated emission depletion microscopy) on H460 plasma membrane sheets, EGF 
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stimulation induces a slight increase in the measured EGFR cluster size, which was not 
affected by SecinH3 (data not shown, experiments were done by David Walrafen and Arne 
Schreiber), indicating that the reduction of EGFR signaling observed after cytohesin 
inhibition is not a result of alterations in cluster size at the observed ~100nm scale. 
Cytohesins are known as GEFs for ARF proteins and are thus involved in endocytosis [82]. 
Although this function involves the GEF activity of cytohesins, which is not important for 
their activity on ErbB receptors, cytohesins may affect EGFR activation indirectly by 
modulation of endocytosis or degradation of the ErbB receptors. However, SecinH3 does not 
reduce EGF-triggered receptor internalization (Figure 21), arguing against such an indirect 
effect. Furthermore, this result also suggests that cytohesins do not affect dimerization of the 
EGFR, since dimerization rather than phosphorylation of the EGFR was reported as the 
inducer for EGFR endocytosis [106]. Indeed, cytohesins do not alter ErbB receptor 
dimerization in HER2/HER3 coimmunoprecipitations (Figure 26) and ErbB receptor 
crosslinking studies (Figure 22, Figure 23, Figure 24, Figure 25), indicating that cytohesins act 
independently of the dimerization of ErbB receptors and facilitate the activation of already 
dimerized receptors.  
This hypothesis is further supported by the result that cytohesins enhance the activation of 
constitutively dimerized EGFR (lz-EGFR experiments, Figure 30, Figure 31). Having shown 
that cytohesins do neither affect receptor clustering, nor trafficking, nor dimerization, but 
instead act on the already dimerized EGFR receptor, suggests the assumption that cytohesins 
enhance EGFR activation by facilitating conformational changes in the intracellular part of the 
receptor. Steady state fluorescence anisotropy measurements of cells transfected with the 
mCitrine labeled constitutively dimerized EGFR are in full agreement with this assumption 
(Figure 36).  
To further understand the mechanism by which cytohesins facilitate the activation of ErbB 
receptors, it is necessary to distinguish between a direct and an indirect effect of cytohesins on 
the conformation of the intracellular part of the receptor. This is the question whether 
cytohesins directly interact with and activate the receptor or an additional factor is needed. To 
gain evidence for a direct interaction of cytohesins and the cytoplasmic domain of EGFR, I 
used a cell-free reconstitution system. Purified full-length ARNO or the Sec7 domain of 
ARNO directly interacts with purified cytoplasmic domain of EGFR with an apparent 
dissociation constant around 1µM (Figure 41). In addition, ARNO directly stimulates 
autophosphorylation of EGFR in the cell-free reconstitution system (Figure 43, Figure 44). 
Together with the data obtained in the cellular assays, these results strongly argue for 
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cytohesins acting on the intracellular domains of dimerized EGFR as conformational 
activators.  
In a cellular context, the transition from the inactive symmetric to the active asymmetric dimer 
represents a stage where additional layers of modulation of receptor activation, inhibitory as 
well as stimulatory, might come into play. This additional layer of regulation would allow the 
cell to modulate or fine tune, for a given amount of ligand-bound receptor, the number of 
activated receptors according to cellular needs. Recently, MIG6 was identified as an inhibitor 
of EGFR signaling [32-33, 35, 159] that acts by blocking the formation of the asymmetric 
dimer [34], indicating that a layer of negative regulation appears actually implemented. Except 
for Dok-7, cytoplasmic activators have not been described for any receptor tyrosine kinase. 
Dok-7, a SH2-domain-containing adaptor protein for the MuSK receptor tyrosine kinase, 
enhances the activity of the muscle-specific receptor kinase MuSK by dimerizing partially 
autophosphorylated and thus partially activated receptor monomers [113-114, 160]. In 
contrast, cytohesins do neither influence receptor dimerization nor require receptor 
autophosphorylation (Figure 42) for binding but function as conformational activators of 
receptor dimer. Thus, these results establish cytohesins as the first cytoplasmic conformational 
activators of ErbB receptors. It is important to point out that the existence of cytoplasmic 
EGFR activators like cytohesins does not abolish ligand dependency of receptor activation, 
since the autoinhibition imposed on the kinase domain by the extracellular domains still has to 
be released by ligand binding [155]. Furthermore, it does not preclude receptor activation to 
occur in the absence of activators as can be seen for the intracellular domain of EGFR in the 
cell free autophosphorylation experiments (Figure 43). It remains to explain, how cytohesins 
activate the EGFR. 
A first insight into the mechanism of cytohesin-mediated EGFR activation can be obtained by 
summarizing the obtained results (Figure 80). ARNO (i) binds to intracellular region of the 
EGFR (Figure 41), (ii) does not require EGFR autophosphorylation for binding (Figure 42), 
(iii) enhances EGFR autophosphorylation by direct interaction (Figure 43), (iv) does not 
modify receptor dimerization but acts on EGFR dimers (Figure 23, Figure 31), (v) modulates 
the conformation of the EGFR dimers (Figure 36).  
Further experiments showed that the Sec7 domain of cytohesins most likely interacts with 
either the kinase domain or the juxtamembrane domain of the EGFR, since it also bound to 
an EGFR construct lacking the C-terminal 188 amino acids (EGFR-ICD1022, Figure 41). The 
C-terminal part of the EGFR has been demonstrated to exhibit regulatory activity on the 
EGFR kinase [161-162]. However, the “more N-terminal” located binding site of ARNO on 
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the EGFR might argue against a direct involvement of the C-terminus in the cytohesin-
mediated activation of ErbB receptors.  
Furthermore, ARNO does not interact with MIG6 (Figure 41), excluding a direct influence of 
ARNO on the MIG6 function.  
Even if the exact conformational rearrangement has not been established, these results show 
that ARNO functions as a conformational activator of EGFR dimers and, thus, acts by an 
unprecedented mechanism. Structural analyses of the complex between cytohesins and ErbB 
receptors are necessary to further understand the detailed mechanism of cytohesin-mediated 
ErbB receptor activation. 
 
 
Figure 80 Model of cytohesin mediated ErbB activation 
ARNO binds to the intracellular domain of EGFR dimers and induces a conformational change that facilitates 
EGFR activation. The cytohesin antagonist SecinH3 inhibits ARNO and reduces EGFR activation and signaling. 
 
Although the precise mechanism of cytohesin-mediated EGFR activation is not known, the 
cytohesin mediated activation of EGFR signaling show many features that are distinct to the 
function of cytohesins on the insulin receptor [90, 96]. In both pathways cytohesins facilitate 
the downstream signaling of the receptors. Yet, cytohesins do not increase the 
phosphorylation of insulin receptor, but instead facilitate the formation of the complex 
between the insulin receptor and the insulin receptor substrate 1 (IRS-1). This effect has been 
shown to be ARF dependent and to require the coiled-coil domain of cytohesins, which 
stands in clear contrast to the GEF activity independent function of the cytohesin Sec7 
domain on ErbB receptors. How can these differences in the mechanism of RTK signaling 
activation by cytohesins be explained?  
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For one thing, both receptors are activated in a dimeric state, but the insulin receptor exists as 
a constitutive dimer on the cell membrane, whereas the ErbB receptors exist as a dynamic 
assembly of monomers, dimers and oligomers. The associated difference in the mechanism of 
receptor activation may account for different regulation mechanisms. Whereas in insulin 
signaling the phosphorylation of adaptor proteins seems to be the important step, ErbB 
receptor activation is regulated already at the level of receptor autophosphorylation. For 
another thing, the mechanism of kinase activation is quite distinct and might therefore 
demand a different mode of action for cytoplasmic activators. The insulin receptor kinase 
requires the trans-phosphorylation of specific tyrosine residues in the so called activation loop 
of the kinase to render the kinase fully active [163]. On the contrary, EGFR kinase activation 
does not depend on phosphorylation in the activation loop of the kinase but instead requires 
the formation of an asymmetric kinase dimer [23]. However, the detailed mechanisms 
underlying the activation of different RTKs by cytohesins can just be speculated about. 
Structural analysis and crystallographic data of the complexes between cytohesins and RTK 
are needed to fully understand the mechanism of cytohesin-mediated modulation of RTK 
signaling. 
 
V.2 Pathophysiological relevance of  cytohesins in lung 
cancer 
V.2.1 Cytohesins are overexpressed in human lung 
adenocarcinomas 
Enhanced EGFR signaling is known to be a hallmark in many human cancers including non-
small cell lung cancer (NSCLC) [48]. Having shown that cytohesins enhance EGFR activation 
in H460 cells, a human NSCLC cell line, one may assume that deregulation of cytoplasmic 
EGFR activators like cytohesins might play a role in tumorgenesis.  
Immunostaining of primary human lung adenocarcinomas with an antibody detecting ARNO 
and cytohesin-1 revealed that these two cytohesins are strongly expressed in >80% of the 
carcinomas (Figure 56), demonstrating cytohesin upregulation in a large fraction of human 
lung adenocarcinomas. In agreement with the cellular data, high expression levels of 
ARNO/cytohesin-1 also correlate with increased EGFR phosphorylation and signaling 
(MAPK- and Akt-pathway) in human lung adenocarcinoma (Figure 57).  
Cancer cell commonly critically depend on a specific signaling molecular for growth and 
survival (oncogene addiction [164]). Lung cancer cells are often addicted to EGFR. The 
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majority of these tumors has either upregulated or mutant EGFR and initially responds well to 
EGFR tyrosine kinase inhibitors [48-49]. Hence, the response rate to EGFR tyrosine kinase 
inhibitor therapy can be used as a measure for EGFR addiction. Nevertheless, a significant 
fraction of lung cancers with apparently normal EGFR status also responds to EGFR 
inhibitors, reflecting their EGFR addiction [48]. How these tumor cells maintain a sufficient 
level of EGFR signaling to satisfy their EGFR addiction in the absence of activating EGFR 
mutations or increased expression levels of EGFR, is currently unclear. The observation that 
ARNO/cytohesin-1 overexpression is associated with an activated EGFR signaling pathway 
in human lung adenocarcinoma provides a possible explanation for the EGFR addiction of 
these cancer cells. 
 
V.2.2 Chemical inhibition of cytohesins diminishes proliferation of 
EGFR dependent lung cancer cell lines 
The observation that ARNO/cytohesin-1 expression correlates with increased EGFR 
signaling in human lung adenocarcinomas raises the questions whether cytohesins also 
promote the proliferation of the tumor cells. In this case attenuation of ErbB activity by 
antagonizing cytohesins with Secins (SecinH3 or Secin16) should lead to a decrease in cell 
proliferation. Indeed, treatment of a set of EGFR-dependent human lung adenocarcinomas 
with the cytohesin antagonists SecinH3 or Secin16 significantly diminishes cell proliferation 
(Figure 48, Table 1). Interestingly, the “gate keeper mutation” (T790M) which renders the 
cells resistant to Iressa treatment, does not affect the sensitivity of proliferating cells for 
cytohesin inhibition. In agreement with an EGFR-dependent inhibition of proliferation, the 
partially or weakly EGFR-dependent cell line H1838 [123, 165-166] is not affected by 
cytohesin inhibition. This EGFR-specific effect of cytohesin inhibition on the proliferation of 
EGFR-addicted tumor cells is further supported by the results obtained by using the BA/F3 
cell system. BA/F3 cells do not express ErbB receptors and critically depend on IL-3 in their 
proliferation. By transfection of oncogenes it is possible to addict the cells to the function of 
these genes rendering them independent of IL-3. Chemical inhibition of cytohesins does not 
affect the IL-3 dependent proliferation of the parental wild-type BA/F3 cell line, but does 
significantly reduce proliferation in EGFR-addicted BA/F3 cells (Table 2, Figure 55), 
underlining the EGFR-specific inhibitory effect of Secins on the proliferation of EGFR-
dependent cancer cell lines. Again, the T790M mutation did not affect the sensitivity of the 
cells for cytohesin inhibition.  
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One of the major effects of receptor tyrosine kinase inhibition in sensitive EGFR-dependent 
cells lines is the induction of apoptosis [167-168]. In accordance, chemical inhibition of 
cytohesins in EGFR-dependent PC9 cells induces a G1 arrest in cell cycle which results in the 
induction of apoptosis (Figure 49, Figure 50). The inhibitory effect of SecinH3 on the 
proliferation of PC9 can also be observed in nude mice bearing PC9 xenografts. Treatment of 
these mice with SecinH3 results in decreased tumor cell proliferation measured as the uptake 
of radiolabeled thymidine in the tumor and visualized with positron emission tomography 
(Figure 53). Histological investigations of the SecinH3 treated xenografts substantiated the 
observed decrease in proliferation (Ki-67 staining was strongly reduced) and revealed a strong 
increase in TUNEL positive cells as compared to untreated xenografts, indicating apoptosis 
(Figure 54).  
Taken together, all these results argue for an EGFR-specific effect of cytohesin inhibition on 
the proliferation of EGFR-dependent cell lines.  
However, treatment of the two cell lines H460 and A549 with SecinH3 or Secin16 also results 
in a distinct inhibition of proliferation (Figure 45, Table 1). Both cell lines harbor an activating 
mutation in KRAS and do neither have amplified nor mutated EGFR. Based on their weak 
sensitivity to EGFR tyrosine kinase inhibitors (TKI), they are classified as TKI-resistant and 
EGFR-independent [103, 123]. At first sight, these results seem mutually contradictory as it 
might be expected that (i) these cells are addicted to KRAS and that (ii) inhibition of EGFR 
activation by Secins, similar to TKI treatment, should not affect proliferation of these cells. 
However, several studies show that these cells still depend on EGFR [116-117, 169], as 
knockdown of EGFR results in decreased proliferation of both cell lines. Nevertheless, the 
lack of sensitivity to TKI still remains unclear and might support the hypothesis that the mode 
of action for EGFR TKIs is more complex than simply blocking EGFR-kinase activity and 
might involve the inhibition of further RTKs [169-171].  
Again, the impact of cytohesin inhibition on cell proliferation was also found in mice bearing 
H460 xenografts. In agreement with the results obtained for the PC9 cells, treatment of these 
tumors with SecinH3 led to a reduction in cell proliferation and tumor size as well as to the 
induction of apoptosis (Figure 46, Figure 47).  
In summary, these results implement cytohesins as cytoplasmic conformational activators of 
ErbB receptors that are of pathophysiological relevance for the proliferation of EGFR-
dependent lung cancer cell lines.  
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V.3 Identification of  improved cytohesin antagonists in 
vitro  
The pathophysiological significance of cytohesins in human cancer is underlined by the 
finding that the proliferation of EGFR-dependent tumor cells is drastically reduced by 
inhibition of cytohesins, making them an interesting target for cancer therapy.  
Yet, GEFs are not classically considered as druggable targets. Protein-protein interactions 
commonly show a high affinity and involve large contact surfaces with little cavities or 
possible binding sites for small molecules [93]. The discovery of more and more small 
molecules that target protein-protein interaction in the last years, however, sheds new light on 
the drug-ability of these targets [172]. The small molecule SecinH3, discovered by Hafner et al. 
[90], is another important example that highlights the potential of cytohesins as new targets 
for small molecule inhibitors. 
Small molecules that specifically target GEFs would also represent valuable tools to indirectly 
target another class of undruggable proteins: small GTPases of the Ras superfamily. 
Upregulated activity of small GTPases is involved in various human diseases. Unlike in the 
case of the three Ras proteins (HRas, KRas and NRas), the upregulated activity of the other 
small GTPases is commonly not caused by direct mutations but instead involves the altered 
expression or activity of their regulating proteins, like GEFs [93]. Also ARFs, regulated by 
GEFs of the cytohesin family, play an important role in the regulation of the proliferation and 
invasive capacity of cancer cells, making them attractive targets for cancer therapy [93, 137, 
173-174]. Unfortunately, no specific, direct ARF inhibitor has been described. However, 
indirect inhibition of ARFs by targeting their specific GEFs has been proven very useful to 
elucidate the cellular functions of ARFs. The fungal metabolite brefeldin A (BFA) binds to the 
complex of GDP-bound, inactive ARF1 and the Sec7 domain of large GEFs, thereby 
inhibiting GDP/GTP exchange catalyzed by this subgroup of GEFs [175]. By a similar 
mechanism, the small molecule LM11 targets the complexes of ARF1-GDP with both the 
large GEF BIG1 and BFA-insensitive ARNO. Both molecules have been shown to inhibit 
ARF-regulated traffic at the Golgi apparatus in cells [92].  
The usefulness of the cytohesin-specific inhibitor SecinH3 as an indirect inhibitor of ARF1 
and ARF6 has been proven in various studies [90, 96-101, 126]. However, the biochemical 
properties of SecinH3 make it difficult to further continue along the long way towards its 
development as a clinically applicable drug. The limited solubility of approximately 15µM in 
aqueous solution containing 0.5% DMSO and a dissociation constant in about the same 
concentration range, makes it hard to perform any biochemical characterization of the 
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compound. Although in the experiments carried out during this thesis impressive activity data 
of SecinH3 in mice was obtained, post mortal autopsies showed precipitates of the compound 
in the abdomen of the mice. Improvements in the solubility of SecinH3 may therefore lead to 
great advances in the in vivo performance of the compound.  
In order to further elucidate the potential of cytohesin inhibitors in anti-cancer therapy 
improved small molecule inhibitors are needed. 
As a first step towards this goal, I established a simple and robust assay suitable for high 
throughput screening that monitors the exchange activity of cytohesins on ARF1. It should be 
noted that this assay allows the screening of compounds that inhibit the GEF activity of 
cytohesins, but gives no information about the inhibition of GEF-independent function of 
cytohesins. However, the inhibition of GEF activity can be used as an indicator for the 
binding of the compound to the Sec7 of cytohesins. The interference of the identified 
molecules with the GEF independent function of cytohesin can then be tested in separate 
assays.  
 
V.3.1 2nd generation Secin chemotypes 
In order to identify more potent cytohesin inhibitors, 145 compounds (referred to as second-
generation Secin chemotypes) were tested for their potential to inhibit cytohesin catalyzed 
GDP/GTP exchange on ARF1. These 2nd generation Secin chemotypes were predicted by 
virtual screening based on structure activity relationship data for SecinH3 previously obtained 
in the lab. The two most potent compounds showed a 3- respectively 6-fold better inhibition 
of GDP/GTP exchange on ARF1 as compared to SecinH3 and were subjected to further 
analysis in cell culture. Because of severe solubility problems, the testing of the most potent 
compound Secin69 had to be discontinued, leaving Secin16 as the new lead compound.  
In addition to the characterization in the GDP/GTP exchange assay, all compounds were 
tested in two further assays in order to monitor their interference with cytohesin-mediated 
insulin signaling (dFOXO assay, group of Prof. Hoch, University of Bonn) [102] or cytohesin 
dependent adhesion of human leukocytes (cell adhesion assay, group of Prof. Kolanus, 
University of Bonn) [83, 126].  
Only two compounds (Secin16 and Secin132, which share a similar structure) were identified 
as hits in all three assays [126]. Secin16 was the most active compound in inhibiting the insulin 
signaling which led to the transcription of the dFOXO target gene 4EB-P and clearly 
decreased human leukocyte adhesion. Secin132 also showed inhibitory activity in all three 
assays, but was less potent than Secin16 (IC50 exchange assay; Secin16: 3.7µM, Secin132: 
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8µM). Secin69 exhibited a cytotoxic effect in the cell adhesion assay, probably due to its 
limited solubility, but was also active in the dFOXO-assay.  
 
       
Table 7 Activity of selected 2nd generation Secin chemotypes in different cytohesin-dependent assays  
Exchange: ARNO-Sec7 catalyzed GDP/GTP exchange on Δ17-ARF1, cell adhesion: assay to measure the 
adhesion of human leukocytes, FOXO: insulin signaling dependent transcription of FOXO target genes in 
Schneider 2 insect cells, Consensus: compounds were active in all three assays. 
 
All other compounds were either not active in all assays, active in only one assay or showed 
activity in only two assays (Table 7). Interestingly, there was no compound that showed 
activity in the cell adhesion- and dFOXO-assay without being active in the exchange assay, 
which might indicate the dependence on GEF activity inhibition. Although the facilitation of 
ß integrin binding to ICAM-1 is demonstrated to be GEF-activity independent [83], the LFA-
1 induced cell adhesion and cell spreading involve the GEF activity of cytohesins [80, 87]. 
Seven compounds were found to be active only in the cell adhesion assay and 4 compounds in 
the dFOXO-assay (Table 7). Whether these compounds target GEF-activity independent 
functions of cytohesins can only be speculated on, until it is demonstrated that they indeed 
target cytohesins. In a similar way, it has to be shown that the 10 compounds identified as hits 
only in the exchange assay actually target cytohesins (instead of ARF1). The lack of activity in 
cell-based assays might also be caused by solubility problems, since the concentrations used in 
these assays are much higher than in the exchange assay.  
 
V.3.2 Secin16 
As the new lead compound, Secin16 not only exhibits an improved IC50 value for the 
inhibition of ARNO-Sec7 catalyzed GDP/GTP exchange on Δ17-ARF1 (IC50 3.7µM), but 
also shows higher potency in reducing proliferation of EGFR-dependent lung cancer cell lines 
(Table 1, Figure 45, Figure 48). However, Secin16 showed a decreased solubility in aqueous 
solution as compared to SecinH3 (8µM versus 15µM, data not shown). The approximately 3 
fold improvement in potency is partially abolished by the two-fold decrease in solubility. In 
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order to optimize the relationship between potency and solubility a set of Secin16 based 
structures was tested that display a lower clogP value as compared to Secin16 (Table 3, Figure 
61). Two Secin16 analogs showed a slightly improved IC50 value combined with a predicted 
>10-fold increase in solubility, as compared to Secin16, but did not prove their superiority to 
Secin16 in cell based assays (data not shown). The latter is being probably caused by 
aggravated membrane permeability. 
In conclusion the structure activity relationship studies for Secin16 were not efficient to 
further improve the biochemical or biological properties of the lead compound Secin16. 
 
V.3.3 3rd generation Secin chemotypes 
As the modifications on Secin16 with the goal of improving its solubility and optimizing the 
ratio between potency and solubility were unsuccessful, a second virtual screening based on 
the information obtained from the 2nd generation Secin chemotypes was performed. This 
screening resulted in 88 3rd generation Secin chemotypes which were subsequently tested in 
the exchange assay. Six compounds were classified as hits (Figure 62). Although these hits 
showed IC50 values between 0.4 and 1.9µM for the inhibition of ARNO-Sec7 catalyzed 
GDP/GTP exchange on Δ17-ARF1 (Table 4), they showed severe solubility problems (data 
not shown) probably due to the shared backbone structure of three amido linked benzoic 
rings and the associated phenomena of aromatic ring stacking that is known to reduce 
solubility. However, all of these hits demonstrated dose-dependency in the exchange assay as 
well as in cell culture experiments. Furthermore, despite the highly similar backbone structure 
that is shared by all 3rd generation Secin chemotypes and the expected low solubility associated 
with it, only the mentioned six compounds exhibited potency in the tested assays. Hence it is 
unlikely that his effect is solely based on unspecific interference caused by compound 
aggregation. These contradictory results raise the question of how to deal with insoluble but 
apparently active compounds. 
Solubility is defined as the amount of a substance that dissolves in a given solvent under given 
conditions. Solubility is an important issue in drug development since it directly affects the 
ADMET parameters of the potential drug [131]. Likewise, low solubility of compounds in 
screening assays can cause false-positive hits  [176] or as stated by Di and Kerns “low 
solubility affects bioassays by causing […] discrepancies between enzyme and cell assays” and 
it is important to ensure that “low-solubility compounds are fully solubilized in 
bioassays”[177]. In order to answer this claim it is necessary to determine the solubility of a 
given compound. Various methods are available to measure the solubility of small molecules. 
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The most common methods involve the addition of different serial dilutions of the compound 
in DMSO to the buffer used in the screening assay. Compound solubility is either measured 
directly by UV-absorption after separation of aggregated compound by centrifugation or 
filtration, or indirectly by light scattering of the aggregates [131, 178]. However, all these 
assays only predict the solubility in the given test system which may vary from the conditions 
used for cell-based assays. Furthermore, the set up of the solubility measurement itself may 
influence the solubility of the compounds. Therefore, the measured solubility should be 
understood as an important benchmark and can serve as an early warning of possible 
difficulties [179]. In such a case special attention should be given to the compounds behavior 
in vitro or in cell based assays to avoid false-positive results. It is important to point out that 
such an interpretation of the solubility problem may cause work and costs for no purpose and 
that there is no guarantee of success. However, the interpretation of the specific activity 
pattern of a given compound in different assays may be more meaningful as its (bio)chemical 
in-vitro characterization. 
 
V.3.4 Further directions 
In silico prediction of potential small molecule chemotypes for the inhibition of cytohesins has 
proven to be useful. However, in order to combine the improvement in solubility and potency 
at the same time, it is inevitable to include the solubility as an additional parameter in the 
algorithm. This combined approach may yield more valuable inhibitors of cytohesins for in 
vivo applications. In addition, the value of a compound should not only be scored by its 
potency or IC50 value but should also include biochemical properties like solubility. 
 
Virtual screening uses structure-activity data of already known inhibitors and is, therefore, 
intrinsically biased. As an alternative approach for an unbiased screen, I developed a new 
FRET-based assay to monitor GDP/GTP exchange on ARF1 (Figure 76) that combines the 
advantages of rapid and high-sensitive real-time fluorescence measurements with the 
possibility of identifying small molecule inhibitors of the interaction between N∆17ARF1-
GTP and GGA3. In addition to the commonly used tryptophan fluorescence to monitor the 
GDP/GTP-exchange on ARF1, this assays utilizes a second longer wavelength for the 
detection of activated ARF1, reducing the probability of detecting false-positive hits due to 
interference of the compounds with the intrinsic fluorescence. The interaction between 
N∆17ARF1-GTP and its effector protein GGA3 has already been widely used to monitor the 
level of activated ARF in the sample. For this purpose, a GTS tagged GGA-GAT domain can 
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be added to an exchange reaction or cell lysate, and after precipitation of GGA-GAT the 
amount of bound N∆17ARF1-GTP can be detected by SDS-PAGE and western blotting 
[138]. However, these analyses of protein interactions are commonly end-point measurements 
lacking kinetic information. Although this technique provides important information about 
the ability of N∆17ARF1 to interact with its endogenous effector protein in the presence of a 
small molecule, it is very elaborate and therefore incompatible with high throughput screening 
approaches. The new established assay represents the first system to directly measure the 
interaction between N∆17ARF1-GTP and its effector protein GGA3 in real-time and in a 
homogenous format using FRET. It allows the simultaneous identification and distinction of 
small molecule inhibitors that interfere with the cytohesin-catalyzed N∆17ARF1-activation 
and/or with the interaction between N∆17ARF1-GTP and its effector protein GGA3. By 
applying this assay it is possible to identify new inhibitors for the cytohesin-catalyzed 
GDP/GTP exchange on N∆17ARF1 and to screen for inhibitors of the interaction between 
N∆17ARF1-GTP and GGA3. Those inhibitors could make major contributions to the 
development of new drugs for anti cancer therapy. 
 
V.4 Third generation Secins are potent inhibitors of  
glioblastoma cell proliferation 
V.4.1 Inhibition of glioblastoma cell proliferation 
Third generation Secin chmotypes have been proven to be very effective inhibitors of 
cytohesin catalyzed GDP/GTP-exchange in ARF1. It is therefore likely that they bind either 
to the Sec7 domain of ARNO, to ARF1 or to the complex between the two proteins. 
However, this observation gives no hints about their potential to inhibit GEF-activity 
independent cytohesin functions and raises the question whether 3rd generation Secins are also 
capable to interfere with cytohesin mediated GEF-activity independent functions. 
In order to answer this question and to concurrently explore a new potential application field 
for cytohesin inhibitors, I decided to move to a new test system: the proliferation of 
glioblastoma cells. Gliomas are the most common subtype of primary brain tumors. EGFR is 
a primary contributor to glioblastoma initiation and progression. The most abundant mutation 
found in glioblastomas is the EGFR variant III (EGFRvIII), which lacks domains I and II of 
the extracellular part of the EGFR and is demonstrated to constitutively activate EGFR 
downstream signaling [66, 132]. Since these cells are clearly addicted to EGFR signaling, 
glioblastomas are a useful and promising system to test the potency of cytohesin inhibitors.  
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The third generation Secin chemotypes appeared to be extremely effective in reducing the 
proliferation of the two human glioblastoma cell lines U87 and Gli36 (Figure 64). Comparison 
of the impact of every single compound in each cell line revealed a clear correlation, indicating 
that the active compounds are effective in inhibiting both independent cell lines (Figure 65). 
In order to gain more evidence for an EGFR-dependent mechanism of inhibition, I tested the 
compounds for their effect on the proliferation of two further cell lines (directly arising from 
the two cell lines U87 and Gli36, tested previously) which stably overexpress EGFRvIII. The 
comparison yielded a significant correlation between the effects on proliferation in the 
parental and EGFRvIII expressing cell lines (Figure 66). Most of the compounds showed a 
slightly better inhibition in the EGFRvIII expressing cell lines, supporting an EGFR 
dependent effect. Three compounds (A11, C1 and C10) selectively reduced the proliferation 
of EGFRvIII expressing cell lines and were subsequently classified as EGFRvIII selective 
compounds. This effect was more pronounced in the U87 cell line system.  
 
V.4.2 Inhibition of proliferation versus inhibition of GDP/GTP-
exchange 
Interestingly, compounds which were found to be most active in inhibiting the proliferation of 
glioblastomas were also most potent in inhibiting GDP/GTP-exchange on ARF1 (Figure 68, 
Figure 69). Table 8 summarizes the features of the most active compounds in both assays. 
Compounds which are extremely active in diminishing GDP/GTP-exchange on ARF1 are 
shown in orange (dark: IC50<1µM, light: IC50>1µM) and compounds inhibiting glioblastoma 
cell proliferation are shown in green (dark: IC50<200nM, light: IC50<400nM). EGFRvIII 
selective compounds are marked in violet.  
These findings raise the question how the clear correlation between inhibition of GEF-activity 
and inhibition of proliferation can be explained. The clear correlation between the inhibition 
of exchange and proliferation suggests that the inhibition of proliferation is GEF-activity- or 
even ARF-dependent rather than EGFR-dependent. There are some results, however, which 
argue against this assumption. 
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  exchange proliferation 
  U87wt U87vIII Gli36wt Gli36vIII 
A5 1,18µM 168nM 46nM   
A6 0,79µM 243nM 67nM   
A11 4,57µM 1366nM 198nM 589nM 360nM 
B5 1,19µM 118nM 148nM   
B6 2,1µM 89nM 372nM   
B7 0,44µM 28nM 83nM 40nM 35nM 
B8 2,58µM 106nM 126nM 102nM 92nM 
C1 7,27µM 2086nM 186nM 732nM 314nM 
C10 2,69µM 922nM 224nM 609nM 279nM 
D3 1,34µM 297nM 105nM   
D6 1,86µM 367nM 84nM   
Secin16 3,71µM 958nM 435nM 750nM 724nM 
SecinH3 11,4µM - - - - 
 
Table 8 Characteristics of most active 3rd generation Secin chemotypes 
Shown are the IC50 values for the indicated compounds in the GDP/GTP-exchange assay on ARF1 (exchange) 
and in glioblastoma proliferation assays (proliferation, cell line indicated). Colors highlight most active 
compounds. Exchange: dark orange: IC50<1µM, light orange: IC50>1µM. Proliferation: dark green: 
IC50<200nM, light green: IC50<400nM, violet: EGFRvIII selective compounds. 
Firstly, most of the compounds show a slightly better inhibition in the EGFRvIII expressing 
cell lines supporting EGFR-dependency. Secondly, the compounds that were found to be 
active in reducing glioblastoma proliferation were also active in reducing the proliferation of 
EGFR-dependent lung cancer cell lines, but were not active in EGFR-independent H1838 
cells. For a discussion of the EGFRvIII-selective compounds see below (V.4.3). Thirdly, 
concentrations needed to inhibit the GDP/GTP-exchange on ARF1 are approximately 10fold 
higher than the concentration needed to inhibit glioblastoma cell proliferation. Although a 
direct and quantitative comparison between these two assays is difficult it might indicate an 
inefficient inhibition of the cellular GEF activity of cytohesins at the used concentrations. 
On the other hand, in support of a GEF activity dependent inhibition of glioblastoma cell 
proliferation, Li et al. demonstrated that the EGF-dependent proliferation of U87 cells 
depends on ARF6 [137]. EGF stimulation of U87 wild-type cells led to ARF6 expression and 
an increase in proliferation. Knockdown of ARF6 with siRNA reduced U87 cell proliferation. 
In agreement with these results, I found an increased expression level of ARF1 and ARF6 in 
EGFRvIII expressing glioblastoma cells in comparison to the parental cell lines (Figure 75). 
The increased expression of ARFs might provide an alternative explanation for the slightly 
higher sensitivity of EGFRvIII expressing glioblastoma cells towards 3rd generation Secin 
chemotypes. Furthermore, B7, the most active compounds in both assays, showed no effect 
on the phosphorylation of EGFRvIII or on the downstream signaling (Figure 72) in U87 cells, 
making it unlikely that this compound directly interferes with EGFR signaling.  
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Figure 81 Effect of 3rd generation Secin chemotypes on the proliferation of EGFR dependent lung 
cancer cell lines 
The diagram represents the relative cell number (MTT assay) after 72h treatment with the indicated compounds 
(250nM). The cell number in solvent-treated samples was set to 1. Data are represented as mean ±SEM, n=2. 
In summary, the current results suggest, that 3rd generation Secin chemotypes reduce 
glioblastoma cell proliferation in an indirectly EGFR-dependent mechanism, i.e. they do not 
directly interfere with EGFR signaling but do clearly show a preference for EGFR dependent 
cell lines. If this activity directly depends on the inhibition of the GEF-activity of cytohesins 
has to be further elucidated, since the high potency in the exchange assay may simply 
represents the high affinity of these compounds for cytohesins and might therefore explain 
the good correlation between the inhibitory activities in both assays. 
 
V.4.3 EGFRvIII selective compounds 
The existence of EGFRvIII selective compounds adds new information to the mechanism of 
glioblastoma cell proliferation inhibition by 3rd generation Secins. These compounds do not 
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exhibit a significantly improved activity in the exchange assay, instead C1 shows an nearly two 
fold less inhibitory potential as compared to Secin16 (Table 8). In accordance to the observed 
correlation between inhibition of exchange and proliferation, these compounds only weakly 
inhibit proliferation of the wild-type glioblastoma cell lines. However, they efficiently inhibit 
the proliferation of EGFRvIII expressing glioblastoma cell lines (Table 8, Figure 66, Figure 
69).  
So how is this selective effect of compounds A11, C1 and C10 characterized? Firstly, it has to 
be pointed out, that these compounds show an EGFRvIII-dependent rather than a commonly 
EGFR-dependent activity, since they do not inhibit the proliferation of EGFR-dependent 
lung cancer cell lines (Figure 81). This finding differs from the results obtained for the 
“unselective” 3rd generation Secin chemotypes. Secondly, a closer look on the phenotypes of 
glioblastoma cells after treatment with 3rd generation Secin chemotypes reveals an additional 
difference between the two classes of compounds: Whereas the “unselective” compounds B7 
and Secin16 seem “simply” to reduce the cell number without altering the appearance of the 
cells, the selective compounds A11 and C10 induce drastic changes in the phenotype of the 
EGFRvIII expressing cells (Figure 70). Apoptosis assays further support this difference, as in 
contrast to A11, C1 and C10, the compounds Secin16 or B7 did not induce apoptosis in 
glioblastoma cells (Figure 71). In agreement with the selective quality, the proapoptotic effect 
of compounds A11, C1 and C10 was more pronounced in EGFRvIII expressing glioblastoma 
cells. In conclusion, compounds A11, C1 and C10 clearly show selectivity for EGFRvIII 
expressing cells and induce a distinct, apoptotic phenotype in glioblastoma cells. These 
characteristics obviously separates compounds A11, C1 and C10 as an own class of 3rd 
generation Secin chemotypes (Table 9, Table 10).  
 
  exchange proliferation phenotype apoptosis
    wt vIII wt vIII wt vIII
B7 0,44µM 28nM  83nM   - - 
A11 4,57µM 1366nM 198nM -  - +++
C1 7,27µM 2086nM 186nM       - +++
C10 2,69µM 922nM 224nM -  - +++
Secin16 3,71µM 958nM 435nM - - - - 
SecinH3 11,4µM - - - -     
 
Table 9 Characteristics of selected 3rd generation Secin chemotypes in U87 glioblastoma cells 
Summary of characteristics for selected 3rd generation Secin chemotypes in comparison to Secin16 and SecinH3. 
Orange: most active compound in the exchange assay, violet: EGFRvIII selective compounds, red: Secin16, blue: 
SecinH3. : reduction in cell number, : cell death, -: no effect, blank: not tested, + to +++: positive effect. 
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  exchange proliferation phenotype apoptosis RAD51 yH2AX 
    wt vIII wt vIII wt vIII wt vIII wt vIII 
B7 0,44µM 40nM 35nM   - - + - - - 
A11 4,57µM 589nM 360nM -  ++ +++ + + + +++ 
C1 7,27µM 732nM 314nM       ++ +++ + +++ + +++ 
C10 2,69µM 609nM 279nM -  ++ +++ + ++ + +++ 
Secin16 3,71µM 750nM 724nM -  - - + - - + 
SecinH3 11,4µM - - - -             
 
Table 10 Characteristics of selected 3rd generation Secin chemotypes in Gli36 glioblastoma cells 
Summary of characteristics for selected 3rd generation Secin chemotypes in comparison to Secin16 and SecinH3. 
Orange: most active compound in the exchange assay, violet: EGFRvIII selective compounds, red: Secin16, blue: 
SecinH3. : reduction in cell number, : cell death, -: no effect, blank: not tested, + to +++: positive effect. 
 
So how can the EGFRvIII selectivity of compounds A11, C1 and C10 be explained? The 
simplest explanation of an EGFRvIII selective effect would be a direct impact on EGFRvIII. 
However, the compounds showed no clear effect on the phosphorylation of wild-type EGFR 
or EGFRvIII (Figure 72), making this scenario rather unlikely. To gain further insight into the 
molecular mechanisms induced by the EGFRvIII selective compounds I focused on a 
potential connection between inhibition of EGFRvIII signaling and induction of apoptosis in 
glioblastoma cells. Inhibition of EGFRvIII signaling in glioblastoma cell lines is known to 
induce apoptosis in a yet not totally identified mechanism involving the appearance of DNA 
double-strand breaks. As nicely reviewed by Norbury and Zhivotovsky [133] DNA damage is 
a potent inducer of apoptosis. Glioblastomas are reported to critically depend on DNA repair 
mechanisms, accounting for their resistance to radiotherapy or treatment with cis-platin. This 
dependency on the DNA repair machinery seems to be controlled by EGFRvIII, as 
EGFRvIII inhibition results in an increased sensitivity for radiotherapy and the appearance of 
DNA double strand breaks [72, 136, 180-182]. And indeed, in agreement with this 
mechanism, treatment of Gli36 glioblastoma with compounds A11, C1 and C10 led to an 
increased occurrence of DNA double-strand breaks, as detected by an increase in the 
phosphorylation of the histone H2AX. The increase in DNA double-strand breaks was 
accompanied by reduced protein levels of RAD51, an important mediator of double strand 
repair (Figure 73, Figure 74) [134-135]. These effects were again more pronounced in the 
EGFRvIII expressing Gli36 cell line. Unfortunately, no signals for yH2AX could be obtained 
in U87 cells. In summary these results are consistent with an effect of the compounds on the 
EGFRvIII controlled regulation of DNA damage, probably by affecting the expression level 
of RAD51. The precise role of cytohesins in this mechanism, however, has still to be 
investigated.  
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Interestingly, recently another small molecule has been published that selectively inhibits the 
proliferation of EGFRvIII expression glioblastoma cells [73]. NSC-154829 selectively induces 
apoptosis in EGFRvIII expression glioblastoma cells without affecting matched wild-type cell 
lines. Although this compound comprises a typically purine-like structural component, it does 
not seem to interfere directly with EGFR signaling. Rather it has been shown that is 
moderately affects the expression levels of p21, without affecting p53 levels or Akt 
phosphorylation [73]. p21, a cyclin dependent kinase inhibitor, has itself been shown to be 
interrelated with RAD51 expression. Further it had been demonstrated that downregulation of 
p21 inhibits RAD51 foci formation [183]. These reports might indicate an important and 
general connection between the selectivity of some compounds for EGFRvIII expressing 
glioblastoma cells and interference with DNA double-strand break repair.  
 
Although the precise molecular inhibitory mechanism of the compounds cannot yet be 
explained, they demonstrate the high potential of cytohesins as a new target in glioblastoma 
therapy.  
 
V.5 Cytohesins as new targets in cancer therapy 
Cytohesins are the first class of cytoplasmic ErbB receptor activators, comprising a new, 
promising target for the therapy of ErbB receptor-dependent cancers. Human lung 
adenocarcinomas highly express cytohesins and the expression can directly be correlated to 
the activation level of EGFR signaling, clearly demonstrating the pathophysiological relevance 
of cytohesins in lung cancer. Inhibition of ErbB receptor activation with the cytohesin 
inhibitors SecinH3 or Secin16 results in a pronounced reduction in cell proliferation not only 
in wild-type EGFR-dependent but also in EGFR mutation harboring human lung cancer cell 
lines. The same holds true for HER2/HER3-dependent breast cancer cell lines (previously 
shown in my diploma thesis and supported by unpublished results). Although the precise 
mechanism is not yet fully understood, cytohesins have also been shown to be involved in the 
proliferation of human glioblastoma cell lines. Thus, cytohesins provide a new layer of 
regulation in tumorgenesis and open up new avenues for fighting ErbB receptor-dependent 
cancers (Figure 82). 
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Figure 82 Cytohesin facilitate ErbB receptor activation and signaling 
Cytohesins are cytoplasmic conformational ErbB receptor activators that are of pathophysiological relevance. 
 
What is the advantage to target cytohesins instead of the respective ErbB receptor? The great 
difference in both approaches lies in the nature of the target. Whereas tyrosine kinase 
inhibitors (TKI) or humanized antibodies directly affect one particular ErbB receptor, 
inhibition of cytohesins does not target the receptor itself but instead the cofactor of ErbB 
receptors. This indirect impact on receptor inhibition is of paramount importance. The 
problem of acquired resistance, due to the induced activation of other receptor tyrosine 
kinases [184-186] or the occurrence of single amino acid mutations in the receptor [46, 187], 
accounts for the only temporarily successful effect of receptor-targeting therapy in most ErbB 
dependent cancers and often renders the therapy totally inactive. Targeting cytohesins as a 
general ErbB receptor- or even RTK-activating cofactor would hamper the occurrence of 
acquired resistance due to the compensating activation of other ErbB receptor members or 
RTKs. In addition, commonly found single point mutations of EGFR that mediate resistance 
to TKIs, for example the T790M mutation which renders the EGFR resistant to Iressa 
(Gefitinib) [188], are shown to not interfere with the cytohesin-mediated inhibition of human 
lung cancer cell lines. In fact, it has been demonstrated that inhibition of cytohesins can 
synergistically improve the impact of TKIs on the proliferation of a TKI-resistant human lung 
cancer cell line (previously shown in my diploma thesis). Furthermore, the remarkable effect 
of cytohesin inhibitors on the proliferation of EGFR-dependent human lung cancer 
xenografts in nude mice might partially be explained by the concurrent inhibition of additional 
cytohesin-dependent processes, like ARF dependent proliferating properties of the cells [93].  
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In summary, the obtained results establish cytohesins as promising targets in cancer therapy 
and open up new avenues for fighting ErbB receptor-dependent cancers by targeting not the 
receptors themselves but their activators. 
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VI Methods 
VI.1 Cell culture 
VI.1.1 Cell lines 
Cells were grown at 37°C and 5% CO2 in the indicated media (Table 11) until they reached a 
maximal confluency of ~80% and were subsequently splitted every 2-3 days. Suspension cells 
were maintained at a cell density of 0,05-1,0*106 cells per milliliter.  
 
VI.1.2 Plasmids 
For expression of ARNO in mammalian cells the complete coding sequence of human 
ARNO (GenBank NM_017457) or sequences covering the indicated domains (amino acids 52 
– 400 for ARNO-CC, 1 – 246 for ARNO-PH, 52 – 246 for ARNO-Sec7) were cloned into 
pCMV-Tag2 (Stratagene) introducing a FLAG tag at the N-terminus of the protein.  
For expression of MIG6-EBR in mammalian cells the EGFR binding region of MIG6 
including surrounding stabilizing sequences (NM_018948; amino acids 282 – 396) was 
inserted into pCMV3Tag2 (Stratagene). 
For the construction of lz-EGFR the region coding for the extracellular domain of  L-gp130 
was amplified by PCR out of pMOWS-L-gp130 [189] and ligated in-frame with the sequence 
coding for the transmembrane and intracellular domains of the EGFR (NM_005228). This 
construct was cloned into pRLuc-N3 (PerkinElmer) such that it replaced the luciferase gene in 
the vector. The resulting fusion protein contains the signal peptide of gp130, a FLAG tag, a 
linker with a single cysteine residue which forms a disulfide bridge upon dimerization of the 
protein, the leucine zipper of c-jun, the membrane-proximal 15 amino acids of the 
extracellular region of gp-130, and the transmembrane and intracellular regions of the EGFR.  
The coding sequences of all constructs were verified by sequencing (GATC Biotech).  
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Cell line culture media species source/type 
CAL 120 adherent RPMI+10%FBS human breast cancer (AC)
HCC1143 adherent DMEM+10%FBS human breast cancer (AC)
MDA-MB-231 adherent RPMI+10%FBS human breast cancer (AC)
HCC1395 adherent RPMI+10%FBS human breast cancer (AC)
HCC1599 suspension RPMI+10%FBS human breast cancer (AC)
BT20 adherent RPMI+10%FBS human breast cancer (ID)
T74D adherent RPMI+10%FBS human breast cancer (ID)
MCF7 adherent DMEM+10%FBS human breast cancer (ID)
SkBr3 adherent RPMI+10%FBS human breast cancer (ID)
PC9 adherent RPMI+10%FBS human NSCLC (AC) 
H1975 adherent RPMI+10%FBS human NSCLC (AC) 
H3255 adherent RPMI+10%FBS human NSCLC (AC) 
HCC827R adherent RPMI+10%FBS human NSCLC (AC) 
H1838 adherent RPMI+10%FBS human NSCLC (AC) 
A549 adherent RPMI+10%FBS human NSCLC (AC) 
H460 adherent RPMI+10%FBS human NSCLC (AC) 
H1993 adherent RPMI+10%FBS human NSCLC (AC) 
H1781 adherent RPMI+10%FBS human NSCLC (AC) 
BA/F3 suspension RPMI+10%FBS+10ng/ml IL-3 mouse pro B cell 
BA/F3 L858R suspension RPMI+10%FBS mouse pro B cell 
BA/F3 L858R T790M suspension RPMI+10%FBS mouse pro B cell 
BA/F3 del1 suspension RPMI+10%FBS mouse pro B cell 
BA/F3 del1 T790M suspension RPMI+10%FBS mouse pro B cell 
U87 adherent DMEM+10%FBS+sodium 
pyruvate 
human glioblastoma 
U87dEGFR adherent DMEM+10%FBS+sodium 
pyruvate+1µg/ml puromycin 
human glioblastoma 
U87dEGFR-LITG adherent DMEM+10%FBS+sodium 
pyruvate+1µg/ml 
puromycin+500µg/ml G418 
human glioblastoma 
Gli36 adherent DMEM+10%FBS+sodium 
pyruvate 
human glioblastoma 
Gli36dEGFR adherent DMEM+10%FBS+sodium 
pyruvate+500µg/ml G418 
human glioblastoma 
Gli36dEGFR-LITG adherent DMEM+10%FBS+sodium 
pyruvate+1µg/ml 
puromycin+500µg/ml G418 
human glioblastoma 
HeLa adherent DMEM+10%FBS human cervix carcinoma (AC)
Hek adherent DMEM+10%FBS human embryonal kidney cells 
(transformed with Ad5) 
COS-7 adherent DMEM+10%FBS african green 
monkey 
kidney cells (transformed 
with SV40) 
Table 11 Used cell lines 
List of all used cell lines, culture type, media and origin. AC: adenocarcinoma, ID: invasive ductal, NSCLC: non-
small cell lung cancer  
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VI.1.3 Transfection 
1.3x106 SkBr3 or H460 cells were seeded in a 6cm plate, cultured for at leat 12 h and 
transfected with a total amount of 1.2 µg DNA using 4 µl Lipofectamine LTX and 1 µl Plus-
Reagent (Invitrogen). For siRNA-transfections 2,4x106 SkBr3 or H460 cells were seeded in 
6well plates, cultured for 24 h and transfected with 10-15 nM siRNA (Ambion) using 4 µl 
Lipofectamine RNAimax (Invitrogen). Aptamer transfection was carried out using 1-20 nM 
M69 aptamer or pool RNA and 4 µl Metafectene (Biontex) per 6well.  
For cotransfection of siRNA and plasmid, 2x106 H460 cells were seeded on a 6cm plate, 
incubated for at least 2h and subsequently transfected with 20nM siRNA and 1,2µg total DNA 
using 7,2µl MetafectenePro.  
3.6x106 HEK-293T cells per 6well plate were reverse transfected with a total amount of 1.6 µg 
DNA per well (0.8 µg lz-EGFR, 0.8 µg ARNO or empty vector) using 4.8 µl Metafectene. 
Transfected cells were analyzed 36-48 h after transfection, with the exception of aptamer-
transfected cells, which were analyzed 5 h after transfection.  
1x 105 COS-7 cells were seeded in a 3.5 cm glass bottom dishes (Matek), cultured for 6h and 
transfected with 1.2 µg DNA (0.6 µg lz-EGFR-mCitrine and 0.6 µg ARNO, MIG6, Rheb or 
empty vector, respectively) using 3.6 µl FuGene6 (Roche). Anisotropy was measured 12h after 
transfection.  
Lipofectamin reagents or Metafectene were premixed with serum free media, incubated for 
5min and the diluted DNA was subsequently added. FuGene6 and MetafectenePro were 
directly added to the diluted DNA/RNA. 
Transfection was performed after an additional 20min incubation by adding the transfection 
mixture to 2ml (6well plate well) or 4ml (6cm plate) of complete growth media. 
 
VI.2 Cellular assays 
VI.2.1 Protein biochemistry 
VI.2.1.1 Preperation of cell lysates 
Cells were serum-starved overnight in the presence of the indicated concentrations of 
SecinH3 or DMSO (final DMSO concentration 0.4%). The medium and inhibitors were 
refreshed 1 h prior to stimulation. H460/U87/Gli36 and SkBr3 cells were stimulated for 5 
min with 50 ng/ml EGF (Peprotech) or 25 ng/ml Heregulin-β1 (Peprotech), respectively, and 
the stimulation media was discarded (Table 12). 
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Cell line starvation media stimulation 
H460 RPMI 50ng/ml EGF
SkBr3 RPMI 25ng/ml HRG
HEK 293 DMEM, 0,1% FBS  
COS-7 DMEM  
U87/Gli36 wt DMEM, 1% FBS 50ng/ml EGF
 
Table 12 Conditions used for stimulation 
 
Cells were harvested in cold 1xPBS, 5mM EDTA on ice using a cell scraper and were 
subsequently centrifugated (500rpm, 5min, 4°C). Pellets were resuspended and lysed in 
(~30µl/6cm dish) lysis buffer supplemented with the protease-inhibitor-mix HP (Serva) for 
15min on ice. After seperation of cell debris (12000rpm, 15min, 4°C) lysates were subjected to 
protein determination by a bradford-assay. For SDS-PAGE samples were boiled in 1x SDS 
sample buffer (lämmli buffer). 
 
1x Lysis buffer 
20 mM Tris-Cl, pH7.5 
150 mM NaCl  
1 mM EDTA  
1 mM EGTA  
2.5 mM sodium pyrophosphate  
1 mM β-glycerophosphate  
1 mM sodium vanadate 
1% (v/v) Triton X-100 
1x SDS sample buffer  
8,25mM Tris-HCl pH6,8  
100mM DTT  
2,5 % (w/v) SDS  
5 % (v/v) Glycerin  
bromphenolblue 
 
 
 
VI.2.1.2 Immunoprecipitation  
Cell lysates were diluted with 1x lysis buffer to a total protein concentration of 4mg/ml. 
Normalized amounts of cells lysates (~8mg) were immunoprecipitated using 25µg agarose-
conjugated EGFR-antibody (sc-120, SantaCruz Biotechnology) or 40µg agarose-conjugated 
HER3-antibody (sc-285) over night at 4°C. Beads were seperated by centrifguation (300rpm, 
3min, 4°C) and subsequently washed three times with 200µl 1x lysis buffer. Precipitated 
proteins were eluted in 55µl sample buffer for 10 min at 55°C. 
 
VI.2.1.3 SDS-PAGE 
Protein lysates (~40-60µg/lane) or precipitates were separated by discontinuous SDS-PAGE 
(sodium dodecyl sulfate polyacrylamid gel electrophoreses). Polyacrylamide gels are formed 
from the polymerization of two compounds, acrylamide and N,N-methylene-bis-acrylamide. 
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The polymerization is initiated by the addition of ammonium persulfate (APS) along with 
N,N,N,N,- tetramethylethylenediamine (TEMED).  
The separation of molecules within a gel is determined by the relative size of the pores formed 
within the gel and the charge of the protein. For SDS-PAGE samples were boiled in 1x SDS 
sample buffer (lämmli buffer). SDS binds to polypeptides in a constant weight ratio of 1.4 g/g 
of polypeptide. In this process, the intrinsic charge of proteins becomes negligible when 
compared to the negative charges contributed by SDS, providing the same net negative charge 
per peptide.  
In discontinuous SDS-PAGE two different gels are put on top of each other. First, the 
proteins pass through the large pore stacking gel. This gel is prepared with buffer about 2 pH 
units lower than that of the running buffer or the separating gel, providing the conditions for 
a yet not fully understood process based on molar conductivity that leads to the concentration 
of the protein in a thin starting zone. This gel is cast on top of the separating gel in which the 
proteins are separated based on their size [190] 
The indicated reactions were mixed and gels were cast between two thin glass slides (Table 
13). Protein samples were loaded (~40-60µg) and separated for ~1h at 200V. Page Ruler 
Prestained Protein Marker (Fermentas) served as a size standard. 
 
Separating gel buffer (4x) 
1,5M Tris-HCl  pH 8,8 
0,4 % (w/v) SDS 
 
Stacking gel buffer (4x) 
500mM Tris-HCl pH6,8 
0,4 % (w/v) SDS
Running buffer (5x) 
125mM Tris-HCl pH8,2 
960mM Glycin 
0,5 % (w/v) SDS 
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  Separating gel stacking gel 
6% 7,50% 10% 4% 
(Bis)-acrylamide 1000 µl 1250 µl 1667 µl 213 µl 
water 2712 µl 2462 µl 2045 µl 975 µl 
separating gel buffer (4x) 1250 µl 1250 µl 1250 µl - 
stacking gel buffer (4x) - - - 400 µl 
TEMED 8 µl 2 µl 
APS 30 µl 10,4 µl 
 
Table 13 Pipet scheme for the preparation of SDS-PAG 
 
VI.2.1.4 Blotting 
After separation by SDS-PAGE proteins were transferred on nitrocellulose membranes using 
the technique of discontinuous blotting describes by Kyhse-Andersen [191]. For this purpose 
the gel was piled between different layers of filter papers, equilibrated in the indicated buffer 
(semi-dry transfer system, Table 14). Proteins were transferred on a nitrocellulose membrane 
by applying a constant power of 2mA/cm2 gel for 45min.  
 
Cathode 
2 filter papers in Cathode buffer 
Gel in Cathode buffer 
nitrocellulose membrane in Anode II buffer
1 filter paper in Anode II buffer 
1 filter paper in Anode I buffer  
Anode 
Table 14 Stacking in the semi dry transfer system 
 
 
Cathode buffer 
25mM Tris-HCl, pH 9,4 
40mM Glycin  
 
 
Anode I buffer 
300mM Tris-HCl pH 10,4 
 
Anode II buffer 
25m Tris-HCl  pH 10,4 
 
For transfer of high size proteins (for example crosslinked ErbB receptors) a tank (or wet) 
transfer systems was used (Criterion Blotter, BioRad). In this system the gel and membrane 
sandwich is held within a gel holder cassette and submerged entirely in transfer buffer. 
Transfer was performed at 4°C for 60-90min at 100V. 
 
Transfer buffer: 
25mM Tris 
192mM glycine 
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VI.2.1.5 Immunodetection 
After transfer of proteins on a nitrocellulose membrane, membranes were rinsed with 1xTBS-
T and blocked by incubation in 5% (w/v) milk powder or 5% (w/v) BSA in 1xTBS-T for at 
least 45min at RT. Subsequently, the membranes were rinsed once in 1xTBS-T and incubated 
with the primary antibody diluted 1:500-1:1000 in 5% (w/v) BSA, 1xTBS-T, 0,02% (v/v) 
thimerosal (Table 15). 
 
  antigen epitope species   company number clone 
ARF-1 N-terminus goat polyclonal SantaCruz sc-7622 
  ARF-6 aa 1-174 mouse monoclonal SantaCruz sc-7971 3A-1 
ARNO full length mouse monoclonal SantaCruz sc-59451 CYT2-21 
  cytohesin-1 full length mouse monoclonal Sigma Cyt1-82 C8979 
cytohesin-2 aa 314-399 mouse monoclonal Abnova H00009266 6H5 
  cytohesin-3  full length rat   Hafner et al.     
EGFR cytopl. domain aa1140-1160 mouse monoclonal nanoTools 0168-100 10F4 
  EGFR c-terminus mouse monoclonal SantaCruz sc-120 528 
EGFR cocktail R19/48 mouse monoclonal Thermo Scientific Ab-12 MS-400-P 
agarose-coupled EGFR extracell. domain mouse monoclonal SantaCruz sc-120 AC 528 
FLAG-M2 mouse monoclonal Sigma F1804 M2 
  GST   mouse monoclonal SantaCruz sc-138 B-14 
HER2 c-terminus rabbit polyclonal SantaCruz sc-284 
  HER3 c-terminus rabbit polyclonal SantaCruz sc-285   
agarose-coupled HER3 c-terminus goat polyclonal SantaCruz sc-285 AC 
  His   mouse monoclonal SantaCruz sc-8036 B-14 
Hsc70 mouse monoclonal Stressgen SPA-820 N27F3-4 
  normal goat IgG       SantaCruz sc-2346   
normal mouse IgG SantaCruz sc-2343 
  pAkt pT308 mouse monoclonal Cell Signaling 4056 244F9 
pEGFR pY1173 rabbit monoclonal Cell Signaling 4407 53A5 
  pEGFR pY1068 mouse monoclonal Cell Signaling 2236 1H12 
pEGFR pY1068 rabbit monoclonal Epitomics 1138-1 Y38 
  pEGFR pY1086 rabbit monoclonal Epitomics 1139-1 Y39 
pHER2 pY1221/1222 rabbit monoclonal Cell Signaling 2243 6B12 
  pHER3 pY1289 rabbit monoclonal Cell Signaling 4791 21D3 
pIRS-1 pY612 rabbit polyclonal Biosource 44-816 
  pp44/42 pT202/pY204 rabbit monoclonal Cell Signaling 4377 197G2 
pShc pY239/240 rabbit polyclonal Cell Signaling 2434 
  pY pY mouse monoclonal SantaCruz sc-7020 pY-99 
RAD51 rabbit polyclonal SantaCruz sc-8349 
  Survivin AS 1-142 mouse monoclonal SantaCruz sc-17779 D-8 
yH2AX S139 rabbit monoclonal Cell Signaling 9718 20E3 
HRP-coupled goat-IgG   rabbit   SantaCruz sc-2768   
NIRD(680)-coupled goat-IgG donkey Licor 926-32224 
HRP-coupled mouse-IgG   goat   SantaCruz sc-2005   
NIRD(800)-coupled mouse-IgG goat Thermo Scientific 35521 
HRP-coupled rabbit-IgG   goat   SantaCruz sc-2004   
NIRD(800)-coupled rabbit-IgG goat Thermo Scientific 35571 
 
Table 15 Antibodies used for immunoprecipitation and immunodetection 
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Membranes were washes three times in 1xTBS-T to discard unbound primary antibody and 
incubated in HRP- (horseradish peroxidase) or NIR dye-coupled secondary antibody (diluted 
1:10000-1:20000 in 5% (w/v) BSA, 1xTBS-T) for 1h at RT (in the dark). Visualization was 
done by enhanced chemiluminescence (Millipore) and a VersaDoc 5000 CCD camera 
(BioRad) or by near infrared (NIR) immunofluorescence and an Odyssey scanner (Licor), 
respectively. Bands were quantified with the QuantityOne software (BioRad).  
 
TBS-T buffer 
20 mM Tris-HCl pH 7,4 
136 mM NaCl  
0,1 % (v/v) Tween-20   
 
VI.2.1.6 Crosslinking 
H460 or SkBr3 cells (1.5x106 per 6 cm plate) were cultured for 24h and starved overnight in 
the presence of SecinH3 (15 µM) or DMSO (final DMSO concentration 0.4%). For 
crosslinking cells were washed twice in prewarmed (37°C) 1xPBS and stimulated as previously 
described in 2ml 1xPBS. After stimulation, freshly prepared BS3 (Pierce, solubilized in 
DMSO) was added to a final concentration of 2 mM and cells were incubated on a rocker for 
5 min at 37 °C. The reaction was quenched with 100 mM Tris-Cl, pH7.5 for 5 min at 37 °C. 
Cells were harvested as previously described and lysed in RIPA buffer (1x lysis buffer 
supplemented with 1 % (v/v) NP40 / 0.1 % (w/v) SDS / 0.5 % (w/v) NaDoc). Normalized 
amounts of proteins were separated by SDS-PAGE using precast 3 % - 8 % gradient Tris-
acetate gels (Invitrogen). Western transfer was done with the Criterion Blotter system 
(BioRad). Hi Mark Protein Standard (Invitrogen) was used as a size standard.   
 
VI.2.2 Analysis of expression levels 
VI.2.2.1 RNA purification 
Cells were lysed in 175µl RNA lysis buffer (Promega) per 24well and RNA lysates were stored 
at -80°C. RNA was purified using the SV total RNA Isolation Kit (Promega) according to the 
manufacturer`s instructions and eluted in 100µl RNAse-free water.  
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VI.2.2.2 Reverse Transcription (RT) 
After purification the RNA was reverse transcribed  using the High Capacity cDNA Archive 
Kit (AppliedBiosystems) according to the manufacturer`s instructions. 35,5µl RNA (without 
further concentration determinations) were used in every reaction.  
 
reagent 
amount stock endconcentration
RT buffer 5 µl 10x 1x
dNTPs 2 µl 25x 1x
Primer 5 µl 10x 1x
RT (Multiscripe) 
 
RNA 
2,5 µl 
 
35,5 µl 
 
 
Table 16 RT reaction (50µl) 
 
RT program 
10min at 25°C 
120min at 37°C 
 
VI.2.2.3 Quantitative real time PCR 
cDNA was analyzed by quantitative real time PCR using gene-specific TaqMan-probes 
(Applied Biosystems, Table 19). 2,5µl of cDNA (diluted 1:3 in water) was used in every 
reaction (total volume 10µl, 2xPlatinum-qPCR-Supermix, Invitrogen). The amplification 
reaction (40cycles) was performed according to the manufacturer`s instructions using a pPCR-
thermocycler (BioRad) and fluorescence was measured after every cycle. The obtained 
threshold cycle (CT) for every probe was normalized to the CT-value of ß2-microglobulin 
(ΔCT=CTgene-CTB2M). Relative expression levels were calculated using the formula: relative 
expression level =2- Δ CTgene1/2-ΔCTgene2.  
reagent amount stock endconcentration
Platinum-qPCR-Mix 5 µl 2x 1x
probe 0,5 µl 20x 1x
cDNA (1:3 diluted) 2,5 µl 
water 2 µl 
 
Table 17 qPCR reaction 
 
step temperature duration
1. initiale denaturing 95°C 2min
2. denaturing 95°C 15sec
3. extension 60°C 60sec
 
Table 18 qPCR cycling 
Steps 2 and 3 were repeated 40times.  
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target mRNA species number 
PSCD1 human Hs00245092_m1 
PSCD2 human Hs00244669_m1 
PSCD3 human Hs00188456_m1 
PSCD4 human Hs00203581_m1 
ARF1 human Hs00734523_m1 
ARF4 human Hs00743745_s1 
ARF6 human Hs01922781_g1 
B2M human Hs99999907_m1 
 
Table 19 TaqMan Gene Expression probes 
Hs: homo sapiens, _m1: probe spans an exon junction, _s1: primer and probe in same exon, _g1: position of 
probe not known (www.appliedbiosystems.com) 
 
VI.2.3 Microscopy 
VI.2.3.1 Immunofluorescence 
H460 cells were plated onto Ø 25 mm poly-L-lysine– coated coverslips as previously 
described [192], starved over night, treated with compounds and stimulated as described. The 
following antibodies were used for immunostaining: ARNO/cytohesin 1 (Santa Cruz, sc-
9729), EGFR (Santa Cruz, sc-03). As secondary antibodies, donkey-anti-goat coupled to 
Alexa488 (Invitrogen, A11055), donkey anti-rabbit coupled to Alexa594 (Invitrogen, A21207) 
were used. Before application, all antibodies were diluted (primary and Atto coupled 
secondary antibodies 1:100, all other secondary antibodies 1:200) into PBS containing 1% 
(w/v) BSA.  
Membrane sheets were generated and immunostained using standard protocols as previously 
described [193] and imaged in PBS containing 10 % of a TMA-DPH–saturated PBS solution. 
Membrane sheets were imaged using a Zeiss Axio Observer D1 fluorescence microscope with 
a 100x 1.4 NA plan apochromate objective. For image acquisition, we used a cooled digital 
12bit CCD camera (Sensicam QE, 6.45 x 6.45µm pixel size, PCO AG). The following filter 
sets were used (all filter sets were purchased from AHF Analysentechnik AG, Tübingen, 
Germany): Alexa488 fluorescence was detected using filter set F36-525 EGFP (BrightLine HC 
472/30, BS 495 and BrightLine HC 520/35), Alexa594 fluorescence was detected using filter 
set F36-503 TRITC (BrightLine HC 543/22, BS 562 and Bright Line HC 593/40) and TMA-
DPH fluorescence was detected using filter set F11000 (excitation filter D 350/50, 400 DCLP 
and emission filter E 420 LP). Comparative quantitation of immunostaining intensities was 
performed as previously described [194] using ImageJ 1.38x Software. Experiments were 
performed by the laboratory of Thorsten Lang, University of Bonn. 
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VI.2.3.2 STED 
For STED experiments membrane sheets were prepared as describe and stained for EGFR 
and goat anti-rabbit coupled to Atto 647N (Atto-Tec, Siegen, Germany). After 
immunostaining membrane sheets were mounted on glass slides in Mowiol. Images were 
acquired by Stimulated Emission Depletion (STED) Microscopy using a Leica TCS STED 
microscope (Leica Microsystems GmbH, Mannheim, Germany) with a resolution in the range 
of 100 nm applying a 1.4 numerical aperture HCX PL APO CS 100x oil objective and a 
standard STED filter set. For excitation a 635 nm pulsed diode laser (PicoQuant GmbH, 
Berlin, Germany) and for depletion a MaiTai tunable Ti:sapphire femtosecond laser at 750 nm 
(Spectra-Physics Lasers, Mountain View, USA) were applied. An Avalanche Photodiode 
(APD) was used for signal detection. At a pixel size of 20.22 nm and a 10 Hz scan frequency a 
2-line average was performed. At least 10-12 sheets for each condition and experiment were 
imaged, and 3 independent experiments were performed. Cluster size analysis was performed 
semi automized by using a self-written routine in Matlab (The MathWorks, Natick, USA). A 3-
pixel broad and 30-pixel long line scan was laid through the centres of single clusters within a 
randomly chosen 150x150 pixel region of interest (ROI) in an analyzed membrane sheet 
(original images were 512x512 pixels). Linescan traces for every measured spot were fitted 
with a Gaussian function using Origin and the size corresponding to the full width at half 
maximum (FWHM) was determined in pixel units. FWHM values were multiplied with the 
size of a single pixel (20.22 nm) and averaged. Experiments were performed by the laboratory 
of Thorsten Lang, University of Bonn. 
 
VI.2.3.3 Anisotropy Microscopy 
Anisotropy microscopy was done as described [110] in COS-7 cells. 1x 105 COS-7 cells were 
seeded in a 3.5 cm glass bottom dishes (Matek), cultured for 6h (until cells were attached and 
streched) and transfected with 1.2 µg DNA (0.6 µg lz-EGFR-mCitrine and 0.6 µg ARNO, 
MIG6, Rheb or empty vector, respectively) using 3.6 µl FuGene6 (Roche). Media was changed 
to phenol red-free media one hour before measurement.  
Images were acquired 15–24 h posttransfection, using a Olympus IX81 inverted microscope 
equipped with a MT20 illumination system. A linear dichroic polarizer (Meadowlark Optics) 
was placed in the illumination path of the microscope, and two identical polarizers were 
placed in an external filter wheel at orientations parallel and perpendicular to the polarization 
of the excitation light. The fluorescence was collected via a 20× 0.7 NA air objective, and 
parallel and polarized emission images were acquired sequentially on an Orca CCD camera 
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(Hamamatsu Photonics). Data acquisition was controlled by the CellR software (Olympus). In 
each experiment at least 25 fields of view, with 1-4 cells each, were analyzed per condition.  
 
VI.2.3.4 FLIM measurements 
For fluorescence lifetime imaging microscopy (FLIM), cells were seeded and transfected as 
transcribed for anisotropy microscopy. FLIM measurements of mCitrine were performed in 
the presence and absence of ARNO overexpression. FLIM images were obtained using a 
Fluoview 1000 microscope (Olympus, Hamburg, Germany), equipped with a Picoharp 300 
photon counting setup (Picoquant, Berlin, Germany). Images of 512 x 512 pixels were 
acquired until approximately 30.000 photons were collected per image. Images of mCitrine 
fluorescence were processed using the SymPhoTime software package (v4.2, Picoquant). The 
images were analyzed on a pixel-by-pixel basis using a mono-exponential fitting model 
including background. 
 
VI.2.4 Proliferation assays 
3x103 cells per 96well were seeded into a clear, flat bottom 96well plate (TPP). After 24hours 
the media was discarded by inversion of the plate and cells were treated with the respective 
concentration of SecinH3 or solvent (final DMSO concentration 0.4%) in fresh media 
containing 1% FCS. Media was changed daily for additional 3 days and cell proliferation was 
analyzed after 72h treatment using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay as described in the manufacturer’s protocol. The assay is based on the 
cellular conversion of a tetrazolium salt into a formazan product that can be detected 
colometrically. Briefly, 15µl of Dye solution media was added directly into the media of the 
cells (100µl). After 4h incubation at 37°C, 5% CO2, 100µl solubilization solution was added to 
solubilize the formazan product and the absorbance at 570nm was measured in a Varioscan 
microplate reader (Thermo Scientific).  
12000 Ba/F3 cells (50µl, FBS free media) per well were seeded into a clear, flat bottom 96well 
plate (TPP) and the same volume of media (2% FBS) containing the 2-fold concentration of 
compound and solvent was added. Proliferation was analyzed 72h after addition of the 
compounds.  
All assays were performed at least in triplicates. For calculation of the relative proliferation 
rate/cell number the mean absorbance in the solvent (DMSO) only treated cells were set as 1.  
Commercially available solutions were later on substituted by self-made solutions. 
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MTT staining solution 
5mg/ml MTT in PBS 
 
MTT lysis buffer 
250ml DMF 
250ml water 
100g SDS 
10ml acetic acid 
pH~4,7 
 
VI.2.5 Apoptosis assays 
1,3x106 cells were seeded on 10 cm dishes in full growth media containing 10% FBS. After 24 
h incubation media was changed to growth media containing 1%FBS and cells were treated 
with compound or solvent (final DMSO concentration 0.4) for 24h-48h. Cells (<70% 
confluence!) were harvested by trypsinization (keep media!) and were collected in the kept 
media to include already detached cells. Subsequently cells were centrifuged at 300rpm for 
3min, washed twice in PBS and counted. 1x106 cells per sample were resuspended in 1x 
Annexin V binding buffer and stained with 5µl Annexin-V-FITC (Annexin-V-FITC 
Apoptosis Detection Kit I, BD Biosciences) and 5µl TOPRO-3-iodide (10µM in DMSO, 
Invitrogen) as described in the manufacturer´s instructions for 15min at room temperature. 
Samples were diluted with 400 µl 1x Annexin V binding buffer directly before measurement. 
FACS analysis was performed on a FACS Canto II Flow Cytometer (BD Biosciences) in the 
FITC and 7-AAD setups, analyzing 10.000 cells. Unstained and untreated cells were used for 
live gate settings and TOPRO only stained cells were used to set the gates for FITC and 
TOPRO (TOPRO showed an intensive background staining of live cells, therefore FITC only 
stained cells could not be used to set TOPRO gates). Results were calculated using FlowJo 
Software (Treestar). Apoptotic cells were defined as being TOPRO+/FITC- (late apoptotic), 
TOPRO-/FITC+ (early apoptotic) or TOPRO+/FITC+ (intermediate apoptotic) and all 
three quadrants were summarized. 
 
1x Annexin V binding buffer  
0,1M Hepes/NaOH pH 7,4  
1,4M NaCl  
25mM CaCl2 
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VI.2.6 Cell-cycle analysis  
For cell cycle analysis cells were prepared and harvested as described for the apoptosis assay. 
1x106 cells were resuspended in 300µl PBS and 700µl ice cold methanol was added drop wise 
under constant vortexing. Cells were incubated at least 1 h on ice, diluted with 1ml PBS and 
washed twice in PBS and were finally resuspended in 100µl PBS. DNA was stained with 100 
nM TOPRO-3-iodide and treated with RNAse A (50 µg/ml) for 15 min at 37°C. FACS 
analysis was performed on a FACS Canto II Flow Cytometer (BD Biosciences) in the 7-AAD 
setup, analyzing 10.000 cells. Untreated, unstained cells were used to set up the live gate and 
the laser power/7-AAD gate. Histograms were analyzed using FlowJo Software (Treestar) and 
the percentage of cells in the indicated phases of cell-cycle was calculated based on the 
Watson-model.  
VI.3 Mouse experiments 
VI.3.1 Xenograft models 
VI.3.1.1 H460 cells 
All animal procedures were in accordance with the German Laws for Animal Protection and 
were approved by the local animal protection committee and the local authorities 
(Bezirksregierung Bonn). Tumors were generated by s. c. injections of 5x106 H460 cells into 
nu/nu athymic male mice. After tumor establishment mice were randomized into two groups, 
control (vehicle) and SecinH3-treated mice. Mice were treated by daily i. p. injections (Volume 
100l, dosage 2.5 mM SecinH3 in 50% DMSO/50% isotonic Glucose solution). Tumor 
volume was measured daily and calculated by using the formula π/6 × larger diameter × 
(smaller diameter)2. 
The TUNEL assay was performed according to the manufacturer´s manual (ApopTag Plus 
Peroxidase In Situ Apoptosis Kit, Millipore). 
H460 xenograft studies were performed in cooperation with L.C. Heukamp, University of 
Bonn. 
 
VI.3.1.2 PC9 cells 
All animal procedures were in accordance with the German Laws for Animal Protection and 
were approved by the local animal protection committee and the local authorities 
(Bezirksregierung Köln). Tumors were generated by s. c. injections of 5x106 PC9 cells into 
nu/nu athymic male mice as described previously [195]. After tumor establishment mice were 
Methods  
 
 
 - 140 - 
randomized into two groups, control (vehicle) and SecinH3-treated mice. Mice were treated by 
daily i. p. injections (Volume 100l, dosage 2.5 mM SecinH3 in 25% DMSO/75% isotonic 
Glucose solution). Ki-67 staining was done as described [196-197] and the TUNEL assay was 
performed according to the manufacturer´s manual (ApopTag Plus Peroxidase In Situ 
Apoptosis Kit, Millipore). PC9 xenograft studies were performed by the laboratory of 
R.T.Ullrich, MPI Köln. 
 
VI.3.2 [18F]FLT PET imaging 
Tumor bearing mice were investigated using a FOCUS microPET scanner (Siemens 
Microsystems, Inc., Knoxville, TN). [18F]FLT synthesis was performed as described previously 
[198]. No-carrier-added [18F]FLT (3'-deoxy-3'-[18F]fluorothymidine) was administered i.v. (tail 
vein) into experimental animals with a dose of 200 µCi/mouse. PET images were performed 
60 min after injection. Data evaluation was based on a region of interest (ROI) analysis of 
PET images to determine maximal radioactivity concentration within the tumors. To 
determine the uptake ratio a reference ROI was placed in the mediastinum. Data were decay 
corrected and divided by the total injected dose to represent percentage injected dose per 
gram (%ID/g). PET imaging was performed by the laboratory of R.T.Ullrich, MPI Köln. 
 
VI.4 Analysis of  human tumor samples 
All primary tumor samples stem from the CIO Biobank at the Institute of Pathology, 
University of Bonn, Germany. All tumors were clinically and pathologically identified as being 
the primary and only neoplastic lesion and classified in accordance with WHO guidelines [44]. 
3 µm formalin fixed paraffin embedded sections were stained for pEGFR, pAkt, pStat3, 
pp44/42 and evaluated as previously described [196-197]. The ARNO / cytohesin-1 specific 
antibody (sc-9729, SantaCruz) was used according to the manufacturer´s instructions. Staining 
intensities were individually evaluated as described before [196] by three independent 
observers and the average score was used for statistical analysis. When the individual scores 
differed by more than 1 the results were re-evaluated by the panel of the three pathologists. A 
four-tier scoring system was employed to quantify the respective staining: no or background 
staining (0), weak (1), distinct and of moderate intensity (2), strong (3). Immunofluorescence 
double-staining of cytohesin, pEGFR, pp44, pAkt was performed as described [199].  
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VI.5 Cell-free assays 
VI.5.1 Proteins 
For expression of ARNO and ARNO-Sec7 in E. coli the complete coding sequence of human 
ARNO (GenBank NM_017457) or amino acids 52 – 246 for ARNO-Sec7 were inserted into 
pET-15 vector introducing a N-terminal 6xHis tag. For bacterial expression of MIG6-EBR 
amino acids 325 – 375 were fused to the C-terminus of GST (pGEX-2T, TEV cleavage site). 
For the construction of EGFR-ICD and EGFR-ICD1022 the complete intracellular domain 
of the EGFR (amino acids 669 – 1210) or the intracellular domain truncated after amino acid 
1022 were cloned into pIEx/Bac-1 (Novagen) such that they contained a 6xHis tag (His-
EGFR-ICD) or a StrepTag (ST-EGFR-ICD and ST-EGFR-ICD1022) at the N-terminus. 
Recombinant baculovirus was produced using the BacMagic DNA Kit (Novagen). The coding 
sequences of all constructs were verified by sequencing (GATC Biotech). EGFR-ICD was 
expressed in baculovirus-infected SF9 cells. Purification of His-EGFR-ICD by anion 
exchange and nickel affinity chromatography was performed as described [23]. ST-EGFR-
ICD and ST-EGFR-ICD1022 were purified by StrepTactin affinity chromatography. ARNO 
and its domains and MIG6-EBR were expressed in E. coli and purified by standard nickel or 
glutathion affinity chromatography, respectively.  
N∆17ARF1-CyPET, YPET-GGA3 and ARNO-Sec7 were subcloned into pET15 vectors 
(Novagen) as described previously. N-terminal truncated [∆17]ARF1 (amino acids 18-181), 
lacking the first 17 amino acids and ARNO-Sec7 (amino acids 50-255 of ARNO) were 
expressed in E. coli and purified by Ni-NTA chromatography (Ni-NTA agarose, Quiagen).  
Cloning, expression and purification were performed by Anton Schmitz and Volkmar Fieberg 
(AK Famulok).  
 
VI.5.2 Fluorescence anisotropy  
VI.5.2.1 Labeling of proteins 
Proteins were slowly thawed on ice and centrifuged for 15min at 20000rpm to separate 
protein aggregates. The supernatant was subjected to buffer exchange (1x protein buffer) 
using NAP-5 columns (GE Healthcare Lifescience). Protein concentration of the eluted 
proteins was determined by Bradford or absorption at 280nm. Proteins were labelled with 
fluoresceine isothiocyanate (FITC, dissolved in DMSO, Sigma) using 10-20fold molecular 
excess for 1h at 4°C in the dark. The reaction was stopped by the addition of 75mM Tris-HCl, 
pH 6.8. Free dye was separated by buffer exchange using NAP-5 columns. Concentration and 
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labelling efficiency of the labelled proteins were calculated using the following formulas and 
the absorption at the indicated wavelengths: 
 
 
 
Table 20 Formulas for concentration determination of labeled proteins 
A: absorption, Amax: absorption 495nm, CF: correction factor 0.35, ε’: extinction factor protein 
 
Protein buffer 
25mM HEPES-NaOH pH 7,8  
300mM NaCl  
3mM MgCl2  
10% Glycerin 
 
VI.5.2.2 Anisotropy measurements 
Fluorescein-labelled ARNO, ARNO-Sec7-wt/E156K, MIG6-EBR or lysozyme (Sigma) at a 
final concentration of 1µM was mixed with unlabelled His-EGFR-ICD, ST-EGFR-ICD, ST-
EGFR-ICD1022 or MIG6-EBR (20 nM-3.5 µM) in 1x binding buffer containing 0,05% 
Triton X-100 at room temperature in a 384well Proxiplate (PerkinElmer). Where indicated the 
reactions contained 1 mM ATP. Fluorescence anisotropy was measured after 45min 
incubation in a microplate reader (TecanUltra, Tecan). For comparison, the anisotropy value 
of the labelled protein without ligand was set as 0. 
 
1x binding buffer 
20 mM HEPES-KOH, pH 7.4 
50 mM NaCl 
5 mM MgCl2 
0.2 mM DTT 
 
VI.5.2.3 Aggregation of EGFR-ICD 
To analyze the aggregation of EGFR-ICD an aliquot of the binding reactions was separated 
by centrifugation (20000 rpm, 5 min) into pellet and supernatant. Both fractions were boiled 
in sample buffer and analyzed by SDS-PAGE and immunoblotting.  
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VI.5.3 EGFR-ICD autophosphorylation assays 
For the autophosphorylation assays, His- or ST-EGFR-ICD (100nM) was incubated in 1x 
binding buffer with the indicated protein (200nM) at room temperature for 5min (reaction 
size: 90µl). The reaction was started by addition of 1 mM ATP (10µl). After the indicated time 
aliquots (40µl) were removed, boiled in SDS sample buffer, separated by SDS-PAGE (10µl) 
and analyzed by immunoblotting.  
 
VI.5.4 GDP/GTP-exchange assays 
VI.5.4.1 Tryptophan fluorescence 
GDP/GTP exchange was measured on N∆17ARF1 by tryptophan fluorescence. All 
measurements were performed in PBS pH 7.4, 3 mM MgCl2 at 37°C.  
N∆17ARF1 (2.8 µM) was preincubated with GDP (80 µM) in the presence of EDTA (2 mM) 
for 15 min in PBS pH 7.4 (without MgCl2) at 37°C. The bound GDP was stabilized by 
addition of MgCl2 (final concentration 3 mM) and incubation for further 5 min at 37°C. If not 
otherwise indicated, for each exchange reaction 700 nM of GDP loaded N∆17ARF1 was 
mixed with 15 nM ARNO-Sec7 in the absence or presence of inhibitor or solvent (0,5% 
DMSO) in PBS pH 7.4, 3 mM MgCl2 (total volume 180 µl). The reaction was started by 
injection of 20µl GTP (50 µM). Fluorescence was detected approximately every 5secs, 
depending on sample number for a total of 600sec. The tryptophan fluorescence was 
measured at excitation and emission wavelength of 280 nm and 340 nm, respectively. All 
fluorescent measurements were performed with a Varioskan microplate reader (Thermo 
Scientific), in black 96-well plates. For data analysis the linear increase in fluorescence signal 
(200sec-600sec) was fitted by linear regression using GraphPadPrism software.  
 
VI.5.4.2 FRET 
GDP/GTP exchange was measured on N∆17ARF1-CyPET by FRET. All measurements 
were performed in PBS pH 7.4, 3 mM MgCl2 at 37°C.  
N∆17ARF1-CyPET (2.8 µM) was preincubated with GDP (80 µM) in the presence of EDTA 
(2 mM) for 15 min in PBS pH 7.4 (without MgCl2) at 37°C. The bound GDP was stabilized by 
addition of MgCl2 (final concentration 3 mM) and incubation for further 5 min at 37°C. If not 
otherwise indicated, for each exchange reaction 700 nM of GDP loaded N∆17ARF1-CyPET 
was mixed with 15 nM ARNO-Sec7 in the absence or presence of inhibitor or solvent (1% 
DMSO) in PBS pH 7.4, 3 mM MgCl2 and after 5min incubation at room temperature 500nM 
YPET-GGA3 was added (total volume 180 µl). The reaction was started by injection of 20µl 
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GTP (50 µM). Fluorescence was detected approximately every 10secs, depending on sample 
number for a total of 600sec. The tryptophan fluorescence was measured at excitation and 
emission wavelength of 280 nm and 340 nm, respectively, whereas FRET was measured at 
436nm and 535nm, respectively. To detect possible quenching effects of the compounds 
CyPET and YPET was detected at ex436/em465 nm and ex500/em535, respectively, at the 
beginning of each measurement. All fluorescent measurements were performed with a 
Varioskan microplate reader (Thermo Scientific), in black 96-well plates. For data analysis the 
linear increase in fluorescence signal (200sec-600sec) was fitted by linear regression using 
GraphPadPrism software.  
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GTP Mix 
    for 250Rxn   Stock End 
PBS + 3mM MgCl2 4975 µl   
GTP 25 µl 100mM 200µM 
      
Gesamt   5000 µl     
Prime tubes with GTP-Mix!!! 
ARF Mix 
    for 30Rxn   Stock End 
PBS 1353 µl 1x 1x 
∆17ARF1 16,5 µl 235µM* 2.59µM (final 0.65µM) 
EDTA pH 8,0 6 µl 500mM 2mM 
GDP 120 µl 1000µM 80µM 
    
Gesamt 1495.5 µl   
    
incubate @37°C, shaking (10% speed) for 15min * nach Gel, OD: 650µM 
add   
MgCl2 4.5 µl 1000mM 3mM 
and incubate for 3-5min @37°C       
hCyt2-Sec7 Mix 
dilute hCyt2-Sec7 (80µM) 1:8 in PBS/MgCl2 to get 10µM   
    
PBS + 3mM MgCl2 992.5 µl 1x 1x 
hCyt2-Sec7 7.5 µl 10µM 75nM (final 15nM) 
    
Gesamt   1000 µl     
1. Prepare Mixes 
2. add to plate 89µl  plate buffer PBS + 3mM MgCl2 
1µl Compound/DMSO (200x)
40µl Cyt-Mix (just before addition of ARF) 
and mix thoroughly 
3. add to plate 50µl ARF-Mix 
4. start measurement by injecting 20µl GTP-Mix 
 
Table 21 Exemplary pipet scheme for a GDP/GTP-exchange reaction on N∆17ARF1   
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VI.6 Statistics 
Results are given as the mean +/- SEM (standard error of the mean). Statistical analyses were 
performed with Prism (GraphPad Software) applying the two-tailed t-test or one-way-
ANOVA, as appropriate. All data sets passed the Kolmogorov and Smirnov test for Gaussian 
distribution. For the analysis of the tumor samples the Spearman nonparametric correlation 
test was used. Differences of means were considered significant at a significance level of 0.05 
(Table 22). 
 
p-value meaning symbol
>0.05 non significant
0.01 to 0.05 significant *
0.001 to 0.01 highly significant **
<0.001 extremely significant ***
 
Table 22 Meaning of the p-value 
 
 
VI.7 Materials 
VI.7.1 Instruments 
instrument, type manufacturer 
blotting chamber; semi-dry-blotter PEGASUS Phase 
CCD-Camera; VersaDoc 5000 Bio-Rad 
centrifuge; 5417C Eppendorf 
centrifuge; 5810R Eppendorf 
electronic micro pipette; multidispenser Eppendorf 
fluorescence plate-reader Thermo 
hemocytometer; T728.1 Roth 
incubator, Hera Cell Heraeus 
magnetic stirrer; Combimag IKA 
micoscope; Axiovert25 Zeiss 
micro pipette; research Eppendorf 
Odyssey LICOR 
PAGE-chamber; Mini-Protean 3 Cell Bio-Rad 
PCR-cycler; T3 thermocycler Biometra 
pH-Meter MP220 Mettler Toledo 
pipette controller; Accu-Jet Brand 
power supply: Power Consort E865 Consort 
real-time PCR Cycler; iCycler iQ5 Bio-Rad 
scale; BL 1500S Sartorius 
scale; JL-200 Chyo Balance 
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sterile hood; HeraSafe Heraeus 
thermoblock; Block Heater Stuart-Scientific 
thermomixer; KTM 100RP HLC 
UV-transilluminator; MiniBis Bio-Imaging-Systems 
water purifications system; HP6 UV/UF TKA-Lab 
 
VI.7.2 Materials 
article manufacturer 
cell scraper TPP 
cryo tubes Roth 
culture dishes TPP 
culture flasks  TPP 
culture plates TPP 
filter paper GB005 Whatman 
nitrocellulose membrane; Protran 0,45µM Schleicher&Schuell 
PCR-plate sealer Bio-Rad 
PCR-plates, 96well Bio-Rad 
pipette tipps for micro pipettes Peske, Biozym 
pipette tipps for micro pipettes, multidispenser Eppendorf 
reaction tube (1,5ml und 2ml) Eppendorf or Sarstedt 
reaction tube (PCR 0,2ml und 0,5ml) Eppendorf or Sarstedt 
serological pipettes 2, 5, 10, 25, 50ml TPP 
tubes 15ml, 50ml Falcon 
 
VI.7.3 Cell culture reagents 
article manufacturer 
cell culture media PAA 
EGF; AF-100-15 Peprotech 
Fetal Bovine Serum (FBS), DE14-870F Lonza 
FuGene Roche 
G-418 sulphate solution (50mg/ml) PAA 
HRG-ß-1; AF-100-03 Peprotech 
Lipofectamin Invitrogen 
Lipofectamin LTX + Plus reagent Invitrogen 
Lipofectamin RNAiMax Invitrogen 
Metafecten Biontex 
Metafecten Pro Biontex 
PBS Dulbecco's (1x), pH 7,4 PAA 
Penicillin/Streptomycin (100x) PAA 
Trypsin/EDTA (10x) PAA 
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VI.7.4 Standards for DNA- and protein-gels 
DNA-ladder manufacturer 
peqGOLD 100bp 0,5mg DNA/ml peqLab 
protein-ladder manufacturer 
SeeBluePlus2 Invitrogen 
Page Ruler Prestained Protein Ladder Fermentas 
HiMark Prestained HMW Protein Standard Invitrogen 
 
VI.7.5 Kits 
article manufacturer 
CellTiter96 Non Radioactiv Cell Proliferation Assay (MTT-Assay) Promega  
High Capacity cDNA-Kit AppliedBiosystems 
Platinum Quantitative PCR Supermix Invitrogen 
SV Total RNA Isolation Kit Promega  
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